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ABSTRACT
Conjugated linoleic acid (CLA) refers to a class o f conjugated dienoic isomers o f linoleic 
acid produced by ruminant animals. The predominant dietary sources o f  CLA (cis-9, 
trans-11) are ruminant fat products such as milk, beef and dairy products. CLA has been 
shown to be anti-carcinogenic, anti-atherosclerotic, and anti-catabolic. In this study 
methodology for analysis o f trans fatty acids (TFA) was optimised using a combination 
o f silver-ion chromatography and GLC, and applied to the analysis o f CLA and TFA in  a 
range o f  Irish dairy products. Having established levels o f CLA in Irish dairy products, 
fractionation o f  anhydrous milk fat was investigated as a means o f enriching the levels o f 
this fatty acid within a food ingredient. Dry fractionation with a temperature range 
between 33-10 °C and a cooling rate o f 0.54 °C/h, led to a soft fraction enriched in 
polyunsaturates and low in saturates with a CLA content that was 60.3 % elevated 
compared with the starting material. Its anticarcinogenic effect was dem onstrated in 
mammary and colon cancer cell lines. A synthetic CLA mixture inhibited the growth o f 
mammary MCF-7 and colon SW480 cancer cells in a dose and time dependent manner. 
Superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx) and thiobarbituric 
reactive substances (TBARS) were induced in both cell lines exposed to CLA (20ppm) 
over a period o f 12 days. Similar effects were observed in M CF-7 cells treated w ith the 
pure c9, t 11 CLA isomer and with bovine m ilk fat from animals fed pasture, rapeseed or 
soya. Growth suppression o f these cells was independent o f  the source o f  CLA. 
Equimolar concentrations o f linoleic acid (LA) promoted the growth o f  the MCF-7 cell 
line. CLA and LA exerted differential effects on protein fam esyl transferase (PFTase) 
activity, the rate limiting enzyme in famesylation o f ras oncoproteins in cancer cells, thus 
implicating modulation o f PFTase activity in CLA-mediated growth suppression. 
M ultiple biochemical mechanisms appear to be involved in the growth suppressive 
effects o f CLA isomers in vitro.
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A ck n o w led g em en ts
CHAPTER 1 
Literature Review
M ilk is an im portant source o f  vital nutrients in the human diet. Nevertheless, many 
health-conscious consumers perceive milk and dairy products to contain excessive 
amounts o f  total fat, saturated fat and cholesterol. However, negative consumer 
perception o f  m ilk fat may soon be altered due to an explosion o f  research highlighting 
the potential therapeutic prowess o f a certain class o f  conjugated diene isomers o f  linoleic 
acid (LA) known as conjugated linoleic acid (CLA) present in  m ilk fat. Studies are 
showing that CLA may have potential in the prevention o f  a w ide range o f  human 
medical conditions including cancer, vascular disease, diabetes, obesity and bone 
disorders. Extensive research is underway to determine m echanistic threads that tie these 
multifunctional health benefits together. This has led to efforts to naturally manipulate 
the CLA content o f  milk and animal tissues by dietary intervention. Such research may 
lead to the development o f new  high CLA-containing “functional foods” designed for 
cancer chemoprevention o f  the general population.
The aim o f this chapter is to review the available literature on the role o f  dietary fats, in 
particular CLA, in health and provide a comprehensive background to the research work 
contained in this thesis.
1.1 Milk
M ilk is defined in the M ilk Ordinance and Code recom m ended by the United States 
Public Health Service (Webb and Johnson, 1974) as ‘the lacteal secretion, practically free 
from colostrum, obtained by the complete milking o f  one or m ore healthy cows, which
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contains not less than 8.25 % o f  milk-solids-not-fat (i.e. proteins, lactose, minerals, acids, 
enzymes and vitamins) and not less than 3.25 % o f  milk fat’ (Table 1.1). The distinctive 
feature o f  milk as a food lies in the balanced content o f  essential nutrients which it 
contains. All species o f mammals, from  m an to whales, produce m ilk for the purpose o f 
feeding offspring. Perhaps as early as 6000-8000 BC, ancient m an learned how to 
domesticate species o f  animals for the provision o f  milk. These included cows (genus 
Bos), buffaloes, sheep, goats and camels, all o f  which are still used in various parts o f the 
world for the production o f  m ilk for hum an consumption (M epham, 1987).
T ab le 1.1 Approximate composition o f  bovine milk.
Component Average content (% w/w)
W ater 87.3
Fat 3.9
Protein 3.2
Lactose 4.6
Ash 0.7
Adapted from W alstra and Jenness, 1984
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1.1.1 Milk fa t
M ilk lipids provide a major source o f  energy and essential m em brane structural 
components for the newborn in all mammalian species (Christie, 1994). The content and 
composition o f  lipids from m ilks o f  different species vary w ith such factors as diet, stage 
o f  lactation, number o f  lactations, breed and season (Hawke and Taylor, 1994). More 
than 400 fatty acids have been identified in m ilk fat, although it is generally accepted that 
15 major and 12 minor fatty acids dominate the fatty acid spectrum (M ulder and Walstra, 
1974). The major fatty acids found in m ilk are long chain (C i4:o -  myristic, C i6:o - 
palmitic, C i8:o -  stearic, Cig i -  oleic) and the minor fatty acids are short chain (C^o -  
butyric, Ce$ -  caproic, Cgio -  caprylic, Cio;o -  capric). Butyric acid is specific for m ilk fat 
o f  ruminant animals and is responsible for the rancid flavor produced w hen it is cleaved 
from glycerol by lipase action. Saturated fatty acids, such as Ch:o, C ^ o , and C is:o make 
up two thirds o f  m ilk fatty acids. Cig:i is the m ost abundant unsaturated fatty acid in milk 
with one double bond. W hile the cis form o f geometric isom er is the m ost commonly 
found in nature, approximately 5 % o f  all unsaturated bonds are in the trans position as a 
result o f  rum en hydrogenation.
1.1.1.1 Milk fa t triglycerides
M ilk fat is made up o f  97 -  98 % triglycerides. These are accompanied by  much smaller 
amounts o f  di- and monoglycerides, free cholesterol and cholesteryl esters, free fatty 
acids and phospholipids (Table 1.2). Triglycerides consist o f  a m olecule o f  glycerol to 
which is esterified three fatty acids.
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Table 1.2 Composition of lipids in milks from various species.
Lipid Class Cow Buffalo Human Pig
W t % o f  total lipids
Triglycerides 97.50 98.60 98.20 96.80
Diglycerides 0.36 - 0.70 0.70
Monoglycerides 0.03 - Trace 0 .10
Cholesteryl
esters
Trace 0 .10 Trace 0.06
Cholesterol 0.31 0.3 0.25 0.60
Free fatty acids 0.03 0.5 0.40 0.20
Phospholipids 0.60 0.50 0.26 1.60
A dapted from Christie, 1994.
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Synthesis o f  triglycerides occurs at the cytoplasmic surface o f  the sm ooth endoplasmic 
reticulum (SER) in mammary epithelial cells. The principal pathw ay o f  biosynthesis o f 
triglycerides involves activation o f fatty acids (obtained from the blood or synthesised by 
de novo synthesis) by formation o f  esters with coenzyme A  (CoA), reaction o f  two 
molecules o f  such esters w ith .sw-glycerol-3-phosphate (a-glycerol phosphate) to form 
phosphatidic acid, cleavage o f  phosphate by phosphohydrolase to form  a 1 , 2 -diacyl sn - 
glycerol ( 1 , 2 -diglyceride), and finally, further acylation by another molecule o f  acyl 
CoA to form a triglyceride. Esterification o f  fatty acids on the glycerol molecule does 
not occur in a random order. Fatty acids o f  4, 6 and 8 carbons are almost exclusively 
(95%) positioned on carbon 3 o f  the glycerol molecule, but occasionally do occur on 
carbon 1. Fatty acids o f  10 carbons are primarily positioned on carbons 1 and 3 o f  the 
glycerol molecule in low molecular weight triglycerides (32 to 46 carbons in total) and on 
carbon 3 for higher molecular weight triglycerides. Fatty acids o f  12 to 16 carbons are 
primarily positioned on carbon 2 o f  the glycerol molecule. Fatty acids w ith 18 carbons 
(C i8:o, C i8:i, and C igi) are prim arily found on positions 1 and 3.
1.1.1.2 Minor components o f  milk fa t
Phospholipids account for about 1 % o f total lipid in m ilk fat; these are divided into the 
major classes o f phosphatidylcholine (or lecithin), phosphatidylethanolam ine, 
phosphatidylinositol, phosphatidylserine, sphingomyelin and plasm alogens (Sonntag, 
1979). These phospholipids are located in the m ilk fat globule membrane (Christie, 
1994). The phospholipids act as detergents and are capable o f  covering a  large surface 
area so that their content may be o f  particular relevance during milk processing.
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Cholesterol is the principal sterol present in milk fat, 10 -1 5  %  o f  which is found 
esterified to fatty acids. LA has been reported to am ount to 27 % in  m ilk fat cholesteryl 
esters (Patton and McCarthy, 1963).
1.1.1.3 Origin o f  fatty acids in milk
Fatty acids in milk are derived from two sources, (i) de novo synthesis from acetate and 
P-hydroxybutyrate in the m ammary gland and (ii) m icrobial activity in the rumen 
followed by uptake from circulating lym ph and blood. The com position o f  the fatty acids 
from these two sources is very different e.g. endogenously produced fatty acids are o f  
carbon length C4-C 16, while a proportion o f  C i6, and all o f  the C i8 fatty acids arise from 
blood (Hawke and Taylor, 1994). Synthesis o f short and m edium  chain fatty acids occurs 
by de novo synthesis in the cytoplasm o f the mammary epithelial cell. P-hydroxybutyrate 
provides approximately 8 % o f the total fatty acids in milk, or 16 to 20  % o f  de novo 
synthesised fatty acids and seems to be the major source o f  carbons for short chain fatty 
acids. De novo synthesis also involves the provision o f  acetyl-CoA derived from  acetate 
which acts as a  prim er for the reaction. Acetyl-CoA is a substrate for the synthesis o f 
malonyl-CoA which is required for fatty acid elongation, and for provision o f  p-NADPH 
for the reductive steps o f  the pathway. The first committed step in the synthesis o f  fatty 
acids is the conversion o f  acetyl-CoA to malonyl-CoA by acetyl-CoA carboxylase. The 
enzyme requires biotin, M g/M n as cofactors and its activity is proportional to the 
lipogenic capacity o f  the mammary gland. Elongation o f  the fatty acid requires the 
addition o f more acetyl-CoA molecules which have been activated to malonyl-CoA. The 
reaction is catalyzed by fatty acid synthase. Approximately 30 % o f C i6:o is synthesised
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de novo by the mammary gland (Bishop et al., 1969). M ost o f  the free fatty acids o f 
plants in the diets o f  ruminants are long chain fatty acids and are usually highly 
unsaturated. The rum en microorganisms are capable o f  quickly saturating these 
unsaturated fatty acids which largely explains the high degree o f  saturation o f  the fat in 
m ilk o f  ruminants. Long chain fatty acids are absorbed from  the small intestine into the 
lymph system where they becom e bound to proteins to form  lipoproteins. These 
lipoproteins circulate into the blood stream and are absorbed by the mammary gland 
secretory cell. The uptake o f  very low density lipoproteins (VLDL) and chylomicron 
triglycerides by mammary tissue involves hydrolysis o f  the triglycerides by lipoprotein 
lipase (LPL). The lipase appears to be bound to the luminal surface o f  the endothelium 
o f  the blood capillaries and hydrolysis o f triglycerides is regarded as a pre-requisite to the 
uptake o f lipid by mammary epithelial cells. Estimates o f  the contribution o f  blood lipids 
to milk lipids in the cow vary from about 35 % to as high as 85 % (Annison et al., 1967, 
Bishop et al., 1969). Saturated long chain fatty acids absorbed from  the intestine would 
cause milk fat to be solid i f  excessive amounts were incorporated. M elting point is 
lowered by activity o f  stearoyl Co A desaturase to convert Cigio (m.p. 70 °C) to Cig.i (m.p. 
5-7 °C). There is extensive desaturation o f  C i8:o to C i8:i on entry into the mammary gland 
by a desaturase located in  the microsomes (Annison et al., 1967). Thus, despite the high 
Cig;o to Cis:i ratios in triglycerides circulating in the blood o f  ruminants arising from 
extensive microbial biohydrogenation o f  dietary fat, desaturation o f  C i8:o in mammary 
tissue results in the production o f  milk fat not markedly dissim ilar in Cis.i content to the 
milk fat o f  non ruminants. Figure 1.1 depicts an overview o f  lipid m etabolism in dairy 
cows.
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Figure 1.1 Overview o f lipid metabolism in dairy cows. Babcock Institute 1997
Fresh m ilk contains free fatty acids (FFA) which increase during storage o f  raw  m ilk as a 
result o f hydrolysis o f  the ester linkage by lipase enzymes secreted by psychotropic 
bacteria. Factors affecting free fatty acid levels in m ilk include animal nutrition, stage o f  
lactation, storage temperature, time o f milking and extent o f  foaming or agitation 
occurring during milking and m ilk assembly (Rajeh and Burgess, 1991).
1.2 Discovery o f conjugated linoleic acid in m ilk
The presence o f  conjugated fatty acids in m ilk fat was first established by Booth et al. 
(1935) who reported that when cows were turned out to pasture after winter, the fatty 
acids o f  milk fat showed greatly increased absorption in the ultra-violet (UV) region at 
230 nm. Although the nature o f the fatty acid responsible for absorption at 230 nm  was 
not known at this time, this was the first study to record the seasonal variation in 
conjugated fatty acid (CFA) content in milk fat. A  survey published in 1963, repeatedly 
showed a 2-3 fold increase in  conjugated diene content when cows were turned out to 
pasture (Riel et al., 1963).
By 1939, it was known that absorption o f fatty acids was the result o f  two conjugated 
double bonds and by 1949, it was known that conjugated unsaturation o f  m ilk fat 
fractions was associated with an 18-carbon chain length (Hilditch and Jasperson 1941, 
Mattsson, 1949). During the 1960’s, lipid research was revolutionised by the application 
o f  thin layer chromatography (TLC), silver nitrate-TLC (Ag+-TLC) and gas liquid 
chromatography (GLC). In 1977, Parodi isolated CFAs from  m ilk fat after m ethylation
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with boron trifluoride (BF3) and the use o f  Ag+-TLC. Using benzene and toluene as 
developing solvents CFA where shown to migrate between the cis (c) and tram  (/)- 
monoenes and to possess characteristic infrared (IR) and UV absorption spectra. Partial 
hydrazine reduction followed by preparative Ag+-TLC separation o f  resultant monoenes, 
reductive ozonolysis and GLC analysis o f  the products (aldehydes and aldehyde esters) 
showed that the stereochemistry o f  the major conjugated dienoic acids in m ilk fat was c9, 
/1 1-C i8:2 (Parodi, 1977) (Figure 1.2). Trace amounts o f  conjugated trans/trans dienoic 
acids (/8, ilO -Ci8:2 and i l l ,  f l 3 -C i8:2) were also observed in m ilk fat which were 
attributed to double bond migration during preparative GLC.
Figure 1.2 The structure o f  c9, t\  1 conjugated linoleic acid.
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1.3 Origins of CLA in milk fat
CLA is an intermediate in the biohydrogenation o f  LA, and until recently it was generally 
accepted that CLA in ruminants originated from the incomplete biohydrogenation o f  LA 
by rumen bacteria (Fritsche and Steinhart, 1998). Complete biohydrogenation o f  LA in 
the rumen is a three step process, leading to the production o f  Cig:o (Kepler et al., 1966) 
(Figure 1.3). CLA is formed as the first intermediate o f  this pathway by the action o f  LA 
isomerase, an enzyme o f  the anaerobic rumen bacteria Butyrivibrio fibrisolvens (Kepler 
et al., 1970) and is unusual in the respect that the reaction occurs in the middle o f  a 
hydrocarbon chain away from any activating functional groups and has an absolute 
substrate requirement for a c9, c 12 diene structure and a free carboxyl group. The 
enzyme has been shown to exhibit maximum activity w ith the substrates LA and Cig-3 
(Kepler and Tove, 1967). Lipid biohydrogenation in the rum en is affected by the type 
and amount o f  fatty acid substrate (Nobel et al., 1974), the forage to grain ratio (Gerson 
et al., 1985) and the nitrogen content o f  the diet fed to ruminants (Gerson et al., 1983).
In accepting this explanation for the presence o f  CLA in rum inant lipids, it was assumed 
that the amount o f  CLA escaping rum en biohydrogenation and being absorbed was 
adequate to account for CLA levels in m ilk and body fat. However the absence o f  any 
reported measurements o f  the amount o f  CLA escape and absorption, together with in 
vitro studies showing rapid conversion o f  CLA, formed by LA isomerase, to tram
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vaccenic acid (/11-Cis:i) has cast considerable doubt on the rum en being the sole source 
o f  CLA in tissues and m ilk fat.
Recent work by Griinari et a l  (1997) showed that CLA could be produced endogenously 
from il  1-Cig;i in tissues by A9 desaturase. Figure 1.4 illustrates the tw o pathways o f 
CLA biosynthesis which together may account for the high CLA concentrations observed 
in milk fat even w hen cows are fed diets that are low in LA  e.g. pasture feeding or fish oil 
supplements. It is proposed that ill-C i8 :i accumulates in  the rum en and that a portion 
escapes further biohydrogenation (Griinari and Baumann, 1999). Follow ing absorption 
from the digestive tract, t\  l-C is i is utilised by different tissues where a portion is 
desaturated to CLA and incorporated into tissue and milk lipids. This ‘desaturase 
hypothesis’ has been proposed to explain the relatively constant ratio o f  fll-C is .i and 
CLA in bovine m ilk fat across a range o f  diets. The presence o f  t l  c9 CLA and c9 il3  
Ci 8:2 supports the role o f  an active A9 desaturase, an enzyme that introduces a cis double 
bond between carbons 9 and 10 (Ulberth and Henninger, 1994, Yurawecz et a l, 1998). 
Evidence suggests that A9 desaturation o f  rl 1-Cig:i may be more relevant in the 
production o f CLA than previously thought. Several studies have reported a  strong 
correlation coefficient between t\ l-C is i and CLA concentrations in m ilk fat (Jahreis et 
al, 1997, Jiang et a l, 1996, Lawless et a l, 1998, Precht and M olkentin, 1997). A close 
linear relationship between milk fat ill-Cis.-i and CLA was observed suggesting a 
precursor-product association where /I l-C i8 :i is the precursor and CLA is the product 
(Griinari et a l, 1997). A  slope o f 0.5 suggests approximately one third o f  circulating t l  1- 
Cisii was desaturated by A9 desaturase (Griinari and Baumann, 1999).
13
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Figure 1.3. Biohydrogenation o f LA in the rumen.
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Figure 1.4 Pathways o f  conjugated linoleic acid (CLA) biosynthesis.
A  recent study whereby /11-Cig;i and CLA were fed in equal quantities to m ice reported 
that 1 2  % o f the t \  1 -C i8;i consumed during a  2 -wk feeding period was recovered in the 
carcass as CLA (Santora et al., 2000). O f the proportion o f  t\  1-Cig:i in the tissues that 
was available for bioconversion, 48.8 % was desaturated. CLA was found in the carcass 
only when /1 1 -Cig:i or CLA was fed. CLA was found in both triglyceride and 
phospholipids when CLA was fed, but only in triglyceride w hen fl 1-Ci8:i was fed, 
suggesting that bioconversion occurred in the adipose tissue (Santora et al., 2000).
1.4 CLA in the human diet.
Levels o f  total CLA in various foods range from  as low  as 0.2 mg/g fat in com  and 
peanut oil (Chin et al., 1992) to as high as 17 mg/g in beef (Shantha et al., 1995) and 30 
mg/g in milk fat (Parodi, 1994), w ith c9, t i l  being the predom inant isom er in milk 
amounting to 90 % o f  the total CLA (Table 1.3).
Negligible amounts o f  c9, t\  1 CLA have been observed in seafood and vegetable oils. 
Estimates o f CLA intakes for humans have been based on CLA databases in  conjunction 
with 3 day or 5 week dietary records, national food intake surveys and data from 
biochemical analyses o f  food portions. Using the latter approach, in conjunction with 5 
week dietary records, it was estimated that CLA intake by Finnish m en and women 
ranged between ~  40 and 310 m g /day (Salm inen et al., 1998). Such variation was 
attributed to marked differences in type o f  fat (dairy, trans and stearic acid) in  the diet.
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Herbel et a l  (1998) reported that young m en and w om en living in  the United States 
consumed approximately 127 m g CL A/day. Another US study estim ated that the dietary 
intake o f CLA was lower in women (52 ±  44 mg/day) than in m en (137 ± 84 mg/day) 
(Ritzenthaler et a l, 1998). Dietary intake o f  CLA in Germany was also estimated to be 
lower in women (350 m g CLA/day) than in men (430 m g CLA/day) (Fritsche and 
Steinhart, 1998). The differences between these studies can be accounted for by the fact 
that fat intake is higher in Germany than in the US (A ldolf et a l, 1994). The German 
study was not age-specific, while the US studies were limited to young m en and women, 
suggesting that age may influence CLA intake in humans. A lthough extrapolations from 
animal studies to the human suggest that 3 g/day CLA is necessary to avail o f the 
anticancer effects o f  CLA (Ip et a l, 1994) more information from  hum an feeding trials is 
necessary before such a value can be verified.
Specific intervention studies have shown that increasing the CLA content o f  the diet 
increased the CLA content in human m ilk (Park et a l, 1999a), plasm a (Huang et al.,
1994) and adipose tissue (Jiang et a l, 1999). Feeding a high dairy fat diet containing 291 
± 75 mg CLA /day led to a 1.6 fold increase (13.5 ± 0 .1  (¿mol/ g fat) in CLA content o f 
human m ilk (Park et al., 1999a). Plasm a CLA increased 19-27 % to 9.6 ± 1.1 |a.mol/L 
when men were fed Cheddar cheese containing 178.5 m g CLA each day for 4 weeks 
(Huang et a l, 1994).
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Table 1.3 Total CLA content and % c 9, t\ 1 CL A in food products
Food Total CLA 
(mg g '1 fat)
c 9 ,i l l  CLA 
(% o f  total CLA)
Reference
Butter 9.4-11.9 91 Shantha et al., 1995
N on fat frozen dairy dessert 0.6 90 C h in e / al., 1992
Condensed milk 7 90 Chin et al., 1992
Natural cheeses 0.6-7.1 17-90 H a et a l,  1989, Chin 
et al., 1992
Processed cheeses 3.2-8.9 17-90 H a et a l, 1989, Chin 
et a l, 1992, Garcia- 
Lopez et al., 1994
Cheddar cheese 5.1-5.4 82-88 W erner et al., 1992
Ice cream 3.8-4.9 73-76 Fritsch ee ta l., 1998
Sour cream 7.5 78 Fritsche e ta l.,  1998
Yogurt 5.1-9.0 82 Fritsch e e t a l ,  1998
T-bone (cooked) 4.7-9.9 65 Shantha et al., 1994a
T-bone (raw) 4.4-6.6 59 Shantha et al., 1994a
Round beef 2.9 79 Ip et al., 1991
M ilk fat 2-30 90 Parodi, 1994
Seafood 0.5 ND Chin et al., 1992
Vegetable oils 0.2 45 Chin et al., 1992
ND= not detected
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CLA in human serum has been shown to be derived in part from  the diet and in part by 
conversion o f  dietary TFA (Salminen et a l, 1998). Serum levels o f  CLA varied between 
0.17 - 0.43 %, when healthy subjects were fed a dairy fat diet for 5 weeks, followed by 
either a trans fatty acid (TFA) diet or a Ci8:o diet for 5 weeks (Salm inen et a l, 1998). 
The proportions o f  CLA in the dairy fat, TFA and Ci8:o diets were 0.37, 0.04, and 0.10 % 
o f total fatty acid methyl esters (FAME). The corresponding proportions in serum were 
0.32, 0.43 and 0.17 % (Table 1.4). The difference in the CLA content o f  serum between 
subjects fed the dairy fat and Cig:o diets was explained by different dietary intakes o f  
CLA.
T able 1.4 M ean percentual fatty acid com position o f  total serum from  healthy subjects 
fed a  dairy fat diet followed by a trans fatty acid diet or a stearic acid diet.
Fatty acid Dairy fat diet Trans fatty acid 
diet (n=40)
Stearic acid 
diet (n=40)
Cl 6:0 23.74 20.31 21.42
Ci8:0 7.74 6.68 10.30
Ci 8:i trans fatty acid 0.59 4.47 0.49
C 18:1 23.39 24.39 23.11
Ci8:2 LA 30.03 29.73 29.78
Cig:2 CLA 0.32 0.43 0.17
Adapted from Salminen et al. 1998.
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1.5 Enrichment of CLA by dietary manipulation
There is a wide and natural variation in CLA content o f  raw  milk. Such variation is a 
result o f  many different factors including diet (Dhiman et al., 1996, 1997, 1999a,b, Jiang 
et al., 1996, Kelly and Baumann, 1996, Lawless et al., 1998, M urphy et al., 1990, 1995, 
Parodi, 1977, Riel, 1963, Stanton et al., 1997a, 1997b), age (Lai and Narayanan, 1984, 
Stanton et al., 1997a) and breed (Lawless et al., 1999).
It has been clearly demonstrated that animal diet has a m ajor im pact on the CLA content 
o f  m ilk fat. Several studies have shown that pasture feeding can increase m ilk fat CLA 
concentrations in lactating dairy cows (Dhiman et al., 1996, K elly and Baumann, 1998b, 
Lawless et al., 1998, Stanton et al., 1997a, 1997b). Cows receiving all o f  their daily feed 
as pasture produced milk fat higher in CLA content (22 m g/g fat) than cows receiving 
only one third (8 mg/g fat) or two thirds (14 mg/g fat) o f  their daily feed as pasture 
(Dhiman et al., 1996). In an additional study, CLA concentrations in milk fat were 
doubled when cows consumed pasture only (10.9 mg/g fat) com pared w ith a mixed diet 
(4.6 mg/g fat) (Kelly et al., 1998b). This effect o f pasture has been attributed to the 
provision o f  C i8:3 as a lipid substrate for the formation o f t\  1-Ci8:i in the rumen and its 
subsequent desaturation to CLA in the mammary gland (Griinari and Bauman, 1999). 
Consistent w ith this hypothesis, m ilk fat CLA was reduced in a controlled feeding trial in 
which cows were fed a low  grass diet over a 19 week period (Stanton et al., 1997a).
Dietary supplementation o f  cows at pasture with full-fat rapeseeds (FFR) (Stanton et al., 
1997a) and soybeans (FFS) (Lawless et al., 1998) resulted in substantial increases in
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CLA content o f  milk over unsupplemented controls. A  27 % increase in  CLA levels was 
obtained in m ilk fat following the FFS supplemented diet w hile a  60 % increase in CLA 
levels was obtained in m ilk fat following the FFR diet (Lawless et al., 1998). Rapeseed 
oil is a relatively rich source o f  Cig:3 compared with soybean oil, and the amount o f  LA in 
rapeseeds is relatively low  compared w ith its content in soybeans. This result is 
indicative o f  rumen biohydrogenation o f  Cig:3 in the FFR supplem ent and m ight have 
contributed to increased CLA concentrations observed in m ilk following this dietary 
treatment (Lawless et al., 1998). The relatively lower increase in the CLA concentration 
following supplementation with FFS, which was rich in potential substrates for rumen 
biohydrogenation, suggests that these fatty acids were not readily accessible to the rumen 
microorganisms (Lawless et al., 1998). M ilk fat CLA was found to increase from 3.9 
mg/g fat to 15.9 and 16.3 mg/g fat in cows fed a diet consisting o f  linseed oil at two 
concentrations (2.2 and 4.4 %) respectively, on a dry m atter basis (Dhiman et al., 1996). 
This increase in CLA concentration was attributed to the oils which were rich in C i8:3 
polyunsaturated fatty acids (PUFA) and which were readily accessible to rumen 
microorganisms.
Comparisons between different types o f  plant oils suggest that those high in LA increased 
CLA concentration most effectively (Griinari and Bauman, 1999). Different dietary oil 
treatments (peanut oil, sunflower oil and linseed oil) have been shown to exert substantial 
variations in m ilk fat CLA concentrations (Kelly et al., 1998a). M ilk from cows fed 
sunflower oil (53 g/kg dry weight) for two weeks contained higher CLA content (24.4 
mg/g fat), than milk from cows fed similar amounts o f  linseed oil (16.7 mg/g fat) or
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peanut oil (13.3 mg/g fat) fed cows. Sunflower oil contains the m ost LA (69.4 g/100 g 
oil), compared with peanut (30.2 g/lOOg oil) and linseed oil (15.4 g/lOOg oil), therefore 
increasing the concentration o f  this precursor fatty acid led to the highest concentration o f  
CLA in milk (Kelly et ah, 1998a).
The method o f processing oilseed supplements has been shown to influence the degree 
and extent o f  biohydrogenation (Dhiman et ah, 1997, M urphy et ah, 1990, Lawless et al., 
1998) and therefore m ilk fat CLA content. A recent study showed that feeding dairy 
cows extruded forms o f  soybean and o f  cotton seed, whereby oil is readily available to 
ruminant microorganisms, resulted in higher levels o f  CLA in m ilk compared w ith cows 
fed a control diet containing 13.5 % soybean meal (Dhim an et ah, 1999a). Heat 
processing o f  soybeans produced a similar effect to extrusion (Chouinard et ah, 1998).
Other factors such as the presence o f  fish oil in the diet, the ratio o f  forage to concentrate 
in the diet and restricted feeding increase milk fat CLA by m odifying the rumen 
population o f  bacteria involved in the biohydrogenation o f  unsaturated fatty acids. The 
mechanisms by which dietary supplementation with fish oil (Chouinard et ah, 1998) or 
fish meal (Dhiman et ah, 1996) increase CLA concentration are not known because 
biohydrogenation o f  the long chain polyunsaturated fatty acids in fish oils has not been 
shown to produce CLA or t \  1-Ci8:i- However increased ruminal production o f  111-Cig:i 
has been reported (Chilliard et ah, 1999). It has been proposed that long chain PUFA in 
fish oil may inhibit complete ruminal biohydrogenation o f  Cig:2 fatty acids through
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inhibition o f  the growth o f  bacteria that reduce / 1 1-Cis:i or through inhibition o f  their 
reductase enzymes (Griinari and Bauman, 1999).
A low forage to concentrate ratio in the diet increased CLA concentration significantly 
compared with a high forage to concentrate ratio (Chouinard et al., 1998). A low  forage 
to concentrate ratio reduces the fiber content o f  the diet and as a  consequence reduces the 
ruminal pH (Romo, 1995). The increase in CLA in milk associated w ith a low  ratio has 
been attributed to a low ruminal pH which may have favoured elevated production o f  
trans octadecenoic acids in the rum en (Romo, 1995). Consistent w ith this hypothesis, 
addition o f  buffer to a low fiber diet increased the rum en pH  and decreased production o f  
trans octadecenoic acids (Kalsheur et al., 1997).
As described above, a low  grass intake (16 kg/cow/d) caused a significant reduction in 
the concentration o f  m ilk fat CLA over a 19 w eek period (Stanton et al., 1997a). 
However, dietary restriction in another study led to an increase in the CLA concentration 
o f  the milk (Jiang et a l, 1996). This could be a result o f  dim inished fat synthesis (fewer 
triglycerides increase the proportion o f  CLA). The different results obtained in these 
studies may be explained by the fact that feeding in the former study was restricted when 
the animals were lactating but feeding in the latter was restricted two weeks before 
calving. This may have more severely deprived the animals at a critical time w ith respect 
to energy requirements, resulting in mobilisation o f  body fat stores and direct transfer o f  
tissue CLA to m ilk (Stanton et al., 1997a).
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Feeding patterns differ in certain countries due to variations in  climate. Seasonal pasture 
feeding regimes exist in Ireland, N ew  Zealand and Australia, whereas indoor feeding o f 
forage and concentrates is more common in the US (Hawke and Taylor, 1994). The 
mean c9, t\  1 CLA content in Australian meats (Shantha et a l, 1995) such as lamb, beef, 
veal, pork and chicken was 2 to 3-fold higher than levels reported in equivalent US 
produce (Parodi, 1994). In Ireland a  country with a seasonal m ilk production pattern, 
substantial variation in the CLA content o f  the m ilk supply has been observed (Lawless et 
a l, 2000, Stanton et a l, 1997b), much o f  the variation being attributed to seasonal 
influences on pasture supply and quality.
Lactation number (an index o f  age) is also a factor influencing CLA content o f bovine milk 
fat. A positive correlation between milk fat CLA levels and lactation num ber has been 
reported (Lai and Narayanan, 1984, Stanton et a l, 1997a). Cows with seven or more 
lactations produced significantly more CLA in their milk than cows with one to six 
lactations (Lai and Narayanan, 1984) and cows with lactation numbers greater than four 
produced more CLA than cows with two to four lactation numbers (Stanton et a l, 1997a). 
The stage o f  lactation o f  the animals (i.e. the time elapsed after calving) which ranged from 
12 to 193 days, had no effect on CLA levels in that study (Stanton et a l, 1997a).
A study investigating the effect o f  breed showed that Montbeliardes produced milk 
containing a significantly higher level o f  CLA than Dutch Holstein, Normandes and Irish 
Holstein cows (Lawless et a l, 1999). In a further study milk fat from Friesian herds 
exhibited a significantly higher CLA content than that from Jersey herds (MacGibbon and
23
Hill, 1998). These results suggest that animal breed has some influence over the CLA 
content o f  the milk.
1.6 Enrichm ent o f CLA by non dietary means
M ethods by which the CLA content o f milk fat and oils m ight be enhanced is now the 
focus o f  many studies; such enrichment would be very advantageous in light o f  the many 
scientifically proven beneficial effects o f  this unique fatty acid (described in section 1 .8). 
A  few studies have investigated interesterification, hydrogenation, fractionation and 
microbial activity as means o f  enriching the CLA content o f  food (Garcia et al„ 1998, 
Jiang et a l, 1998, Jung and Ha, 1999, Kim and Liu, 1999, Lin et a l, 1999, 2000).
In one study Garcia et al. (1998) examined the possibility o f  increasing the CLA content 
o f  butter oil via a lipase mediated interesterification reaction. M icrobial lipases from 
Candida cylindracea, Pseudomonas sp., Mucor miehei and Candida antartica were 
screened for their ability to incorporate CLA into butter oil triglycerides by 
interesterification (acidolysis) whereby free CLA is incorporated into the glycerides o f 
milk fat. CLA was produced by isomerisation o f  LA  using the m ethod o f  Chin et al. 
(1992) and added to butter oil with each lipase and subsequently the butter oil was 
analysed for CLA content. The lipase from Candida antartica increased the CLA content 
o f  the acylglycerides from 0.6 to 15 g/100 g fat. A solvent free approach was chosen for 
this study to minimise product bleaching, deodorisation and hydrolysis. However, the
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observed reaction rates were slow in comparison w ith those in organic solvents (Oba and 
Witholt, 1994).
Microbial synthesis o f  CLA by food grade strains m ay also provide a m eans o f  enriching 
the CLA content o f  food products. The formation o f  CLA by certain rum en bacteria e.g. 
Butyrivibrio fibrisolvens, in the biohydrogenation o f  LA has been known for m any years 
(Kepler and Tove, 1967). More recently, the intestinal flora o f  rats has been shown to be 
capable o f  converting free LA to c9, / I I  CLA (Chin et al., 1994). One hundred and 
eighty strains o f  common bacterial lung pathogens were studied to determine i f  they 
could produce a conjugated diene isomer o f  LA in vitro (Jack et al., 1994). It was found 
that 12.8 % o f the strains were capable o f  producing elevated levels o f  c9, t\  1 CLA from 
free LA. A  study by Jiang et al. (1998) investigated the production o f  CLA by dairy 
starter cultures. N ineteen different strains o f  lactobacilli, lactococci, streptococci and 
propioni bacteria which are commonly used as dairy starter cultures w ere screened for 
their ability to produce CLA from LA in vitro. Three strains o f  propioni bacteria, 
including Propionibacterium freudenreichii ssp. freudenreichii and one strain o f  P. 
freudenreichii ssp. sheramnii were shown to convert free LA to extracellular CLA. The 
highest level o f  CLA formed in the m edia was 265 p.g/ml by the strain 
Propionibacterium freudenreichii ssp. freudenreichii. This represented a 2-3-fold 
increase in CLA formation compared with the other strains examined. O f the different 
isomers, c9, t\ 1 CLA represented more than 70 % o f  the total CLA formed. In a  separate 
study, six lactic acid cultures including Lactobacillus acidophilus (C CRC14079), L. 
delbrueckii subsp. Bulgaricus (CCRC14009), L. delbrueckii subsp. lactis (CCRC14078),
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Lactococcus lactis subsp. cremoris (CCRC12586), Lactococcus. lactis subsp. lactis 
(CCRC10791), and Streptococcus salivarius subsp. thermophlius (CCRC12257) were 
tested for their ability to convert free LA to extracellular CLA (Lin et al., 1999). A sharp 
increase in CLA levels was observed following addition o f  LA to cultures o f  each o f  the 
six strains tested. Incubation o f  L. acidophilus in skim m ilk m edium  containing LA for 
24 h was most effective in promoting CLA formation. The effects o f  additions o f 
sucrose, lactose, fructose, and sodium chloride to these strains on CLA form ation were 
also tested (Lin et al„ 2000). A significant decrease in c9, /II-C L A  level was observed 
in all but one culture Lactococcus. lactis subsp. cremoris when sucrose, lactose, fructose, 
and sodium chloride were added. Inoculation o f  Lactobacillus acidophilus into 
sweeteners and sodium chloride-treated skim m ilk m edium  under aerobic conditions for 
24 h incubation was m ost effective in promoting c9, /II-C L A  form ation (Lin et al., 
2000).
The effect o f  hydrogenation o f  soybean oil on CLA content has been examined. Two 
types o f  process exist: selective and nonselective hydrogenation. Selective 
hydrogenation involves the conversion o f  a  diene to a monoene fatty acid and is more 
discriminating than the conversion o f  a  monoene to a saturated fatty acid. By contrast, 
nonselective hydrogenation, being a random process does not specify desirable 
hydrogenation and isomerization reactions. Both are performed in the edible oils and fats 
industry with commercially available nonselective and selective catalysts. M ost known 
selective hydrogenation catalysts contain one o f  the expensive metals rhodium , palladium 
or platinum. The fatty acid composition o f  oil is greatly dependent on the duration and
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type o f  hydrogenation process. Selective hydrogenation o f  soybean oil was found to be 
more favorable for the production o f CL A (98.27 m g total CLA/g oil) than nonselective 
hydrogenation (9.06 mg total CLA/g oil) (Jung and Ha, 1999).
Milk fat consists o f  a mixture o f  triglycerides that exhibit a broad and variable melting 
range, from approximately -4 0  °C to +40 °C. This allows the crystallising out o f  a series 
o f triglycerides at temperatures below their melting points by controlled cooling o f  the 
melt. U rea crystallisation allows fractionation o f  fatty acids by the degree o f 
unsaturation; saturated fatty acids form complexes with urea to a  greater extent than 
polyunsaturated fatty acids and as a consequence these can be separated from  each other. 
The process yields two fractions: a soft fraction which contains fats w ith low  melting 
points and is therefore liquid and a hard fraction which contains fats with high melting 
points and therefore is solid. This approach was investigated for production o f  milk fat 
enriched in CLA, which resulted in a 250 % increase in the CLA content, to 12.7 mg/g fat 
(Kim and Liu, 1999). The CLA-enriched soft fraction was similar in  saturated fatty acid 
content and higher in unsaturated fatty acids compared with the parent m ilk fat.
1.7 Factors influencing CLA content o f food products
1.7.1 Beef
The initial data from Pariza’s laboratory demonstrated that the CLA content o f  ground 
beef could be increased four-fold after heating as a  result o f  free radical mediated 
oxidation o f  LA (Ha et al., 1987). The proposed model for CLA form ation by heating is
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shown in Figure 1.5. W hen heated in the presence o f  moisture LA undergoes thermal 
oxidation, which involves abstraction o f  a hydrogen from the double bond system, 
resulting in a shift in the double bond structure to form a conjugated diene. The highly 
reactive radical formed may be converted to CLA via proteins functioning as H  donors. 
Different cooking methods (frying, broiling, baking and m icrowaving) did not greatly 
influence CLA content o f  ground beef (Shantha et al., 1994a).
Dietary manipulation o f  cattle prior to slaughter was shown to influence the CLA 
concentration o f  beef (French et al., 2000). Decreasing the proportion o f  concentrate in 
the diet o f  steers, which effectively increased grass intake, led to a linear increase in the 
intra-muscular CLA concentration (P < 0.001) and the PUFA to saturated fat ratio (P < 
0.01). Furthermore, a linear decrease in  the concentration o f  intra-m uscular saturated 
fatty acids (P < .01) and in the n -6  to n-3 PUFA ratio (P< 0.001) was observed as a result 
o f increased pasture intake over concentrate.
1.7.2 Dairy products
The CLA concentration in raw milk fat is a m ajor determinant o f  CLA concentration in 
dairy products. Levels o f  CLA in a  range o f  dairy products such as low  fat yoghurt, 
whole fat yoghurt, whole fat and regular ice cream, sour cream  or cheese such as 
Mozzarella, Gouda, and Cheddar were the same as in the starting m ilk (Shanta et al.,
1995). This would suggest that the effect o f  processing was negligible. As cheese is 
generally the richest dietary source o f  CLA this product has received the m ost attention in 
relation to the effects o f  processing on CLA (Garcia-Lopez et al., 1994, Jiang et al., 
1998, Lin et al., 1995, Shantha et al., 1994a, 1994b, W erner et al., 1992).
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High heat treatment o f  Cheddar cheese increased CLA content com pared w ith low heat 
treatment. This was attributed to heat-induced formation o f  LA radicals which, in the 
presence o f  proteins functioning as H donors can be converted to CLA (Shantha et a l, 
1992). Air is also important in the formation o f  CLA through the free radical 
mechanism. The CLA content o f  cheese processed under atmospheric conditions was 
significantly higher than that o f  cheese processed under nitrogen (Shantha et a l, 1992). 
Incorporation o f  air into butter also increased CLA content (Shantha et a l, 1995). While 
free radical oxidation mechanisms are proposed to be the m ajor mechanism for CLA 
formation in cheese prior to aging, biohydrogenation o f linoleic or linolenic acids to CLA 
is proposed to predominate during aging (Ha et a l, 1989). Addition o f  hydrogen donor 
supplements to the intermediates o f  free radical oxidation and biohydrogenation reactions 
may increase CLA by conversion o f  LA radicals to CLA, but may also decrease CLA by 
enhancing hydrogenation o f  CLA to stearic acid. A ddition o f  supplements (BHA, 
tyrosine, lysine) yielded cheeses with lower CLA contents after 6 months com pared with 
a control additive- free cheese (Lin et a l, 1998). Addition o f  supplem ents allowed the 
reduction o f  CLA to monoenoic or saturated fatty acids and thereby led to a  decreased 
CLA content. Cheese that was m illed at pH  5.5 and 5.9 had lower CLA than cheese 
milled at pH  5.7 (Lin et al., 1998). M illing at pH 5.5 and 5.9 m ay retard the production 
o f lactic acid, and the development o f  hydrogen donors therefore reducing enzymatic 
activities o f  the starter culture. High CLA cheeses had higher titratable acidity than low 
CLA cheeses; thus indicating that higher enzyme activity o f  cultures during aging may
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lead to enhanced CLA formation via isomerisation and biohydrogenation (Lin et a l, 
1998).
1.7.3 Stability o f  CLA during storage
While free radical mediated oxidation o f  linoleic acid has been shown to increase the 
CLA content o f  beef and cheese, CLA itself is not prone to oxidation during storage. 
Oxidative reactions measured during 7-day refrigerated storage o f  cooked beef did not 
alter CLA content suggesting that CLA was stable during storage (Shanta et al., 1994a). 
Another study in which dairy products were examined during refrigerated storage also 
demonstrated that CLA is a stable food component (Shanta et al., 1995).
1.8 Health benefits o f CLA
The c9, t\ 1 isomer o f  CLA acid is the m ost abundant isomer am ounting to as m uch as 90 
% o f the total CLA content o f  dairy products (Chin et al., 1992). A  num ber o f reports 
show an association between this isomer and protection against cancer (Belury et al.,
1996, 1997, Belury and Kempa-Steczko, 1997, Brodie et al., 1999, Cunningham et al.,
1997, Durgham and Fernandes, 1997, H a et al., 1990, Ip et al., 1991, 1994, 1995, 1996, 
1997, 1999a, 1999b, Ip, 1997, Ip and Scimeca, 1997, Liu and Belury 1997, 1998, Liew et 
al, 1995, Scimeca et al., 1994, Schut et a l, 1997, Shultz et a l, 1992), atherosclerosis 
(Doyle, 1998, Lee et al., 1994, N icolosi et a l, 1997) and diabetes (Houseknecht et a l, 
1998). The rlO, c l 2 isomer o f  CLA has also been implicated in many biological 
activities, particularly in relation to alteration o f body mass (Park and Pariza, 1998).
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Additionally, CLA has been shown to regulate production o f  cytokines acting as growth 
factors to increase bone (Li and W atkins, 1998) and muscle m ass (M iller et al., 1994, 
Park et al., 1997) while reducing subcutaneous fat (Dugan et al., 1997).
The m ost studied bioactivity o f  CLA is its anticancer effect. The following sections 
describe the biological events involved in the development o f  cancer, the modulation o f  
these events by specific dietary fat components and the particular studies that have been 
conducted to elucidate mechanism(s) o f  chemoprotection by CLA.
1.9 Development o f cancer
Cancer is synonymous w ith malignant tumour; the Latin term  ‘cancer’ is actually a  literal 
translation o f  the Greek ‘karkinos ’ for crab, and refers to claws reaching out to grasp 
surrounding tissues (invasion). The key ingredient in order to produce a  tumour is a cell 
type capable o f  dividing. The birth o f  a tum our cell requires at least 2 successive events. 
Firstly, an initiator must strike the DNA o f a cell and introduce a “suitable” defect (i.e. a 
mutation); at this point the cell is potentially a  cancer cell but is held in  check by DNA 
repair enzymes. Secondly, a promoter must cause the cell to m ultiply and to generate a 
tumour, thus revealing the latent curse o f  the initiated cell. Initiation is conceived as a 
quick, almost instantaneous process; i f  it is repeated, the effect on the tissue is additive. 
Initiators can be chemical, physical or biological. 7,12 -dim ethyl-benz[a]anthracene 
(DMBA), a polycyclic hydrocarbon was one o f  the first specific carcinogens isolated 
from tar in the 1930’s and is still used today as an initiator in experimental animal models 
o f  carcinogenesis. It is metabolised stepwise by the enzym es o f  the endoplasmic 
reticulum such as P-450 cytochromes to yield the ultimate carcinogen, an electrophilic
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species capable o f  covalent bonding w ith nucleophilic sites on DNA. Prom otion is 
viewed as a  slow process, its effect is reversible and non-additive. M any promoters cause 
cells to multiply and inhibit cell-cell communication. Promoters m ay be chemical (e.g. 
tetradecanoylphorbol-13-acetate (TPA)) or biological (e.g. estrogen). TPA activates 
protein kinase C (PKC), for which the physiological activators are diacylglycerols. In 
this way TPA inserts itself as a link in the transduction o f  signals from  the cell surface to 
effectors in the cytoplasm. Once malignant tumours have started to grow, they acquire a 
genetic instability which favours such accidents as chromosom al breaks and 
translocations that result in the appearance o f  new clones (tum our progression). The 
overall result is clinically apparent; there is an increase in tum our grow th rate, an increase 
in invasiveness and metastasis. The latter is the most lethal expression o f  malignancy 
and poses the most important concern for the treating physician by virtue that tumours 
have spread to other parts o f  the body usually via the blood stream  or lymph. In addition, 
malignant tumours show a  reduced sensitivity to drugs and hormones, decreased 
antigenicity and decreased radiosensitivity. M olecular genetic studies o f  cancer have 
shown that carcinogenesis is a continuous evolving process involving the accumulation 
o f  a series o f  genetic alterations, particularly in genes controlling cellular proliferation 
and the integrity o f  the genome (Ames et al„ 1995). Some tum ours are driven by normal 
genes that are expressed inappropriately (dominant oncogenes). Other tumours are 
triggered by the loss o f  normal genes (suppressor oncogenes). To date, well over 60 
dominant and suppressor oncogenes have been identified (Baserga, 1994). Because each 
gene is best defined by its product m uch effort is concentrated in finding out what 
proteins are coded by these oncogenes. Despite many loose ends a  picture is emerging: 
gene products o f  oncogenes are either growth factors, growth factor receptors or links in 
an intracellular network through which external stimuli induce cell proliferation (Figure 
1.6).
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One o f the best understood dominant oncogenes is ras; ras genes code for 2 1 -kilodalton 
proteins called p21, which are located in cell membranes, bind guanine nucleotides (GTP 
and GDP) and function as GTPases (Ames et al„ 1995). Ras acts positively to stimulate 
a cascade o f  kinase-driven phosphorylation events that culm inate in the activation o f  
nuclear transcription factors (Downward, 1990). Figure 1.7 shows that the active form o f 
Ras has a molecule o f  GTP bound in the nucleotide binding site whereas the inactive 
form contains a GDP in that site. The intrinsic GTPase activity o f  Ras therefore converts 
the active Ras-GTP form into the inactive Ras-GDP moiety (Downward, 1990). Two 
types o f  proteins, GAPs (GTPase activating proteins) and GNRFs (guanine nucleotide 
releasing factors) control the activity o f  Ras such that GAPs are negative regulators and 
GNRFs are positive regulators o f  Ras (M ilbum et al., 1990). A bout 15 % o f  hum an solid 
tumours contain one or more ras genes with single-base alterations. Activated ras genes 
have also been found in premalignant and malignant lesions induced experimentally with 
carcinogenesis. The most prevalent dominant mutations in ras occur on codons 12, 13 
and 61 and cause a defect in the Ras GTPase activity such that it is always in the active 
ras-GTP form (M ilbum et al., 1990). Under these circumstances, the cell receives a 
‘false’ signal to activate growth-promoting genes, even in the absence o f  growth factors 
(M ilbum  et al., 1990). Figure 1.8 depicts a  proposed phosphorylation -signalling cascade 
showing how Ras connects the epidermal growth-factor m em brane receptor to fos and 
jun  through a sequential series o f kinase-activated steps. Fos and ju n  are nuclear 
trancription regulators and when activated signal growth stim ulation in the cell (Baserga, 
1994). The role o f  Ras in signalling is known to involve localisation o f  Ras to the 
membrane which occurs via the famesylation pathway (M arshall, 1996).
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The fameslyation pathway involves the addition o f  a fam esyl m oiety to the GTP-bound 
Ras oncoprotein enabling it to bind to the cell membrane (Singh et al., 1997a). Several 
Ras inhibitors are being developed to target the enzyme protein fam esyl transferase 
responsible for Ras fam esylation and thereby disrupt the dom inant activity o f  mutated 
Ras in cancer cells (Singh et al., 1998).
1.9.1 Dietary Chemoprotective agents
Cancer chemoprotection is defined as the use o f  chem ical agents or dietary components 
either to protect against the initiation o f  carcinogenesis or to retard the progression o f 
neoplastic disease once it has begun. Compounds that reduce the rate at which mutations 
arise can be broadly classified into two groups (bioantimutagens and desmutagens), 
according to their mechanism o f action. Bioantimutagens act m ainly on DNA replication 
and repair processes, reducing the extent o f  DNA damage that has been induced by 
mutagens (Clark and Shankel, 1975). They also act as ‘suppressing agents’ by promoting 
expression o f special features o f  the normal cell (i.e. differentiation), inhibiting oncogene 
activation, inhibiting proliferation o f  initiated cells and enhancing cell death via apoptosis 
(Ferguson, 1994). Desmutagens are considered blocking agents (i.e. they block mutagen 
activation) because they induce proteins involved in detoxification o f  carcinogens, inhibit 
the activation o f  carcinogens or prevent the uptake o f  carcinogens by the cell. 
Carcinogen activation may induce free radicals that initiate a series o f  reactions that have 
irreparable effects on lipid, protein, carbohydrate and DNA molecules. Lipids are prime
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molecular targets for free radical mediated attacks and polyunsaturated fatty acids present 
in cell membranes are especially at risk. The hydrogens on carbons between two double 
bonds o f  a  polyunsaturated fatty acid are easily abstracted by free radicals leading to a 
rearrangement o f  the double bonds. This rearrangement changes the shape o f  fatty acids 
and under aerobic conditions they are more likely to combine w ith oxygen to form a 
peroxyl radical. This peroxyl radical is capable o f  initiating the same process with 
another fatty acid, so propagating a  chain reaction. Cells have two lines o f  defense, 
antioxidant vitamins (e.g. a-tocopherol, ascorbic acid and P-carotene) and antioxidant 
enzymes that scavenge free radicals induced by carcinogen activation and are important 
desmutagens. Antioxidant enzymes are the first line o f  defense eliminating superoxide 
radicals and hydrogen peroxides responsible for the production o f  dangerous hydroxyl 
radicals. Superoxide dismutase (SOD) eliminates superoxide radicals and occurs in 
several different compartments o f  the cell. The cytosolic enzym e is com posed o f  two 
similar subunits, each one containing one equivalent o f  Cu2+ and Zn2+, whereas the 
mitochondrial enzyme contains Mn2+ (Halliwell and Gutteridge, 1989). True to its 
important function SOD is very stable and one o f  the m ost active enzymes known. 
Catalase and glutathione peroxidase (GPx) eliminate hydrogen peroxide. Catalase acts 
specifically on hydrogen peroxide converting it to w ater and oxygen. GPx requires 
cosubstrates glutathione and NADPH and acts on all hydroperoxides. Antioxidants are 
an important component o f  the desmutagen artillery found in the diet (Table 1.5). The 
following section contains a synopsis o f  research showing that particular components o f 
dietary fat can influence the development o f  cancer during prom otion and metastasis.
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Table 1.5 Selected dietary anticarcinogens and their postulated m echanism  o f  action.
Compound Bioantimutagen Desmutagen
Binding
scavenger
Direct
chemical
inactivator
Enzyme
m odulator
Antioxidant
w
Tumour
growth
suppressor
Ascorbic acid X X X
BHA - X X - X -
Calcium - - - - - X
Carotenoids - - - - X X
CLA - - - - - X
Coumarins - - X - - -
Dithiolthiones - - X - - -
Dietary fiber - - - - - -
Flavonoids - - X X X X
Folic acid - - - - - X
Genistein - - X - X X
Indoles - - X - - X
Isothiocyanates - - - - X -
Lignins - - X - - -
Omega 3 Fatty Acids - - - - X X
Organosulphur - - - - X X
compounds
Phenolics X - X - X X
Phytates - - X - X -
Phytoestrogens - - - - ? X
Porphyrins - - ? - X X
Protease inhibitors - - - X - X
Retinoids - - - - - X
Saponins - - - - - X
Selenium - - - - X X
Terpenoids - - X - - -
Tocopherol - X - - X -
Vanillin X * “ ■*
'
- represents no effect.
X  represents an effect.
? represents conflicting results. Adapted from Ferguson, 1994.
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Evidence that dietary fat can exert both non-specific and specific effects on 
carcinogenesis has come from experimentation in animal cancer m odels and from 
epidemiological data on human populations. Non-specific effects relate to dietary fat as a 
whole and specific effects relate to particular components o f  dietary fat (Guthrie and 
Carroll, 1999). Non-specific effects o f dietary fat on carcinogenesis are deleterious, 
being primarily related to its high energy density (38 kJ/g) relative to carbohydrates and 
proteins (17 kJ/g) and the low energy cost required for its m etabolism  and deposition into 
adipose tissue (Pariza and Boutwell, 1987). Accumulation o f  fat in adipose tissue over a 
long period o f  time is conducive to obesity. Obesity has been associated w ith an 
increased risk o f  cancer at a number o f  different sites, including endom etrium , breast and 
kidney (Goodman, 1997). It could be postulated that the grow th o f  a  cancer requires 
energy, and an excess o f  energy from the diet m ight serve as a growth stimulant, whereas 
a deficit o f  energy from under-nutrition could help inhibit cancer grow th (Guthrie and 
Carroll, 1999).
1.9.2.1 Monounsaturated fatty acids
C i8;i is the most abundant dietary monounsaturated fatty acid and is a major constituent 
o f  many fats and oils, including olive oil, high-oleic safflower oil, canola oil and palm 
oil. The role o f  Cig:i on mammary carcinogenesis is controversial and m any conflicting 
results have been published. A  carcinogenic effect was observed in rats fed Cig;i - 
enriched safflower oil and treated with DM BA (Carroll and Khorr, 1975, Carroll, 1977). 
However, little effect on tumourigenesis was observed when methylnitrosourea (MNU)
1.9.2 Dietary fa t and cancer
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treated animals were fed olive oil (a rich source o f C i8;i) (Cohen et al., 1986a). The 
seeming inconsistency may be related to the amount o f  LA in the olive (5 %) and 
safflower oils (17 %). In a further study when the LA content o f  the two oils were equal 
the differential effects o f  safflower and olive oil in DM BA treated rats w ere not evident 
(Laeskan et al., 1990). This argues against any specific effect o f  Cig:i on mammary 
carcinogenesis (Guthrie and Carroll, 1999).
1.9.2.2 Saturated fatty acids
Saturated fats seem to have little effect on cancer unless com bined w ith small amounts o f  
polyunsaturated fats (Carroll and Khor, 1971, Carroll et al., 1981). C i6:o is the most 
abundant dietary saturated fatty acid derived mostly from  m ilk fat but diets contain 
smaller amounts o f other saturated fatty acids o f  varying chain lengths. Little is known 
about the effects o f  individual saturated fatty acids on cancer, but a study on medium 
chain saturated fats C 10-C 14 present in large amounts in coconut oil, showed little 
evidence that they had any promoting effect on mammary cancer (Cohen, 1986b).
1.9.2.3 Polyunsaturated fatty acids
Particular components o f dietary fat have been shown to exert specific effects on the 
development o f  cancer in animals. Whereas n -6  (double bond positioned six carbons 
from the methyl terminal end o f  the fatty acid chain) fatty acids (e.g. LA) have been 
associated w ith enhancement o f  the promotional phase o f  experim ental rat mammary 
carcinogenesis (Ip et al., 1987), long chain n-3 (double bond positioned three carbons 
from the methyl terminal end o f  the fatty acid chain) fatty acids present in fish oils have
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been associated with inhibition o f  this spectrum o f the cancer process (Appel et al., 
1994). Dietary fish oil supplementation is associated with reduction o f  both mammary 
and colon tumourigenesis in rodent models (Rose and Connolly, 1993, Singh et al., 
1998). Docosohexaenoic acid (DHA) (C22:6) is an n-3 fatty acid present in fish oil. DHA 
has been shown to reduce the onset o f  colon cancer by inhibiting the famesylation 
pathway, responsible for membrane localisation o f ras oncoproteins (Singh et al., 1998). 
W hen mixtures o f  n-3 and n-6 PUFA were fed to rodents, it appeared that a relatively 
high proportion o f  n-3 fatty acids was required to overcome the prom otional effect o f  the 
n-6 fatty acid, LA (Cave, 1991a, 1991b, 1997, Rose and Connoly, 1997).
LA undergoes desaturation and elongation to yield arachidonic acid (C20:4)5 (AA) a 
substrate for the biosynthesis o f  eicosanoids. Eicosanoids are potent bioregulatory 
compounds involved in a  wide variety o f  cell signalling processes. Upon stimulation by 
inflammatory stimuli or tum our prom oter agents, AA is released from cell membranes by 
the action o f  phopholipase A2 (PLA2). Eicosanoids derived from AA which may 
modulate carcinogenesis include those formed as a result o f  cyclooxygenase (COX) 
pathways (prostaglandin E2 (PGE2), prostaglandin p 2a (PGF2a,), prostaglandin D2 
(PGD2)) and o f  lipoxygenase pathways (hydroxyeicosatetraenoic acids (HETEs) and 
leukotrienes (LTs)). Eicosanoids have been linked to cancer by the findings that human 
tumours synthesise elevated levels o f  prostaglandins w hen com pared w ith normal tissue 
(Karim, 1976). M uch o f  the subsequent research has concentrated on the COX products 
o f AA metabolism with particular emphasis on prostaglandin PGE2, which has been 
shown to promote growth and metastasis in many experimental tum ours (Fulton, 1998).
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It is not yet clear how PGE2 levels are regulated in tum our cells but it has been suggested 
that the overexpression o f  COX 2, one o f  the two isoforms o f  COX, leads to elevated 
PGE2 production (Sano et ah, 1995). A  simple pathway outlining eicosanoid synthesis is 
shown in Figure 1.9.
The release o f  AA from membrane phospholipids is the rate-lim iting step for the 
production o f  eicosanoids. PLA2 catalyses the hydrolysis o f  the sn 2 fatty acyl bond o f 
membrane phospholipids to liberate AA and lysophospholipids. Though the major 
pathway o f  AA release is via PLA2, AA can also be released from  sequential cleavage o f 
phospholipids by phospholipase C (PLC) to generate diacylglycerol (DAG) that is 
subsequently acted on by DAG lipase to liberate AA. Because PLA 2 preferentially 
hydrolyses phosphatidycholine (PC) (Hanel et al., 1993), the pattern o f  AA  incorporation 
into phospholipid classes may have an effect on the release o f  AA and so effect 
eicosanoid production.
The growth-enhancing effect o f  LA on mouse mammary epithelial cells was inhibited by 
indomethacin, a  COX inhibitor, and was partially reproduced by the COX product PGE2 
(Rose and Connolly, 1997). However the growth response to PGE2 was less than that to 
LA. For full stimulation, both PGE2 and one o f  the three HETE acids formed from AA 
under the influence o f  the lipoxygenase activity were required. Thus the optimal growth 
response o f  mouse mammary epithelial cells to LA appears to represent a synergism 
between HETE and PGE2, which occurs under the added influence o f  epidermal growth 
factor (EGF) (Rose and Connolly, 1997) (Figure 1.10).
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EGF when bound to its membrane bound receptor stimulates the proliferation o f  cells. 
Connolly and Rose, (1993) demonstrated a metastatic effect due to LA in  the M DA-M B- 
435 human breast cancer cell line and provided evidence that local invasion o f  tum our 
cells through the extracellular matrix was associated w ith induction o f  HETE mediated 
expression o f  matrix metalloproteinases.
Similar effects o f  polyunsaturated fatty acids have been reported in  the development o f  
colon cancer. High fat dietary com  oil (HFCO) rich in n -6  fatty acids was shown to 
enhance COX-2 expression, while a  high fat fish oil (HFFO) diet reduced COX-2 
expression in colonic mucosa and in tum ours (Singh et al., 1997). These studies suggest 
that HFCO may promote colon tumourigenesis by up-regulating PGE2 production and 
that moderation o f PGE2 production by HFFO m ay exert an antitum our effect in  colon.
As in human breast cancer, mouse mammary tum ours develop through a multi-step 
process (Medina, 1976). An intermediate pathologically defined stage is the formation o f 
hyperplastic alveolar nodules, which appear with increasing frequency over time in mice 
expressing the mouse mammary tum our vim s (MMTV). Telang et al. (1984, 1988) 
investigated the effects o f  fatty acids on the hyperplastic nodule-like m ammary alveolar 
lesions that develop in explants cultured from the m ammary tissue o f  m ice expressing 
MMTV. They found that both LA and AA enhanced replicative D NA synthesis in these 
lesions, whereas both Cis.o and the long chain C20:5 n-3 fatty acids w ere inhibitory. These 
alterations in proliferation were associated with changes in c -rasH p21 expression. The 
oncogene c-ras11 p2 1  signals an initiation event in carcinogenesis.
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The demonstration that fatty acids affect events associated w ith cancer initiation, such as 
expression o f  MMTV and c-rasH p21, in nontransformed tissue has important 
implications for breast cancer prevention. Growth modulatory effects o f  fatty acids have 
also been demonstrated in a number o f in vitro studies involving hum an cells. A 
neoplastic, spontaneously immortalised, M CF-10A hum an mam m ary epithelial cell line 
and the same line expressing the c-Ha-ras protooncogene showed growth stimulatory 
responses to LA and inhibitory responses to n-3 fatty acids (Grammatikos et al., 1994).
Despite the large number o f  experimental studies in animals showing that 
polyunsaturated fats enhance tumourigenesis more effectively than saturated fats 
(Connolly and Rose, 1993, Rose and Connolly, 1997), the involvem ent o f  dietary fatty 
acids in the etiology o f  human breast cancer remains controversial. M ost available data 
on polyunsaturated fat and breast cancer risk was assem bled by Howe et al. (1990) in 
their pooled analysis o f  12 case control studies. The overall association o f  breast cancer 
with total dietary fat was due only to the saturated fat. In pooled prospective studies 
neither saturated nor monounsaturated fat intake was related to breast cancer (Hunter et 
al., 1996). Case control studies o f  diet are based on contrasts between reports o f  recalled 
diets o f  people with and without cancer. A m ajor problem  with case control studies is 
their dependence on recall o f  past dietary habits, w hich m ay be inaccurate. This problem  
is not evident in cohort studies as subjects are asked to provide inform ation on their 
present diet. In cohort studies a database o f  current diets is established; because this 
assessment o f diet is made before diagnosis it is unbiased by the cancer experience. 
However these studies are lim ited because they only cover part o f  the life span. Due to
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the presumed long latent period for some types o f  cancer, such as breast cancer, 
assessment o f  dietary fat intake during adolescence, when initiation m ay have occurred 
may be more important than assessment in later life (Hill, 1995).
1.9.2.4 Trans fatty acids
A comparison o f  the effects o f  cis and trans fatty acid diets on the growth and metastasis 
o f  mammary tum our cells in female BALB/c mice showed no differences in either the 
length o f  the latency period, tumour growth or the final tum our size at the local 
transplantation site (Erickson et al., 1984). M ore viable tum our cells w ere found in the 
liver and spleen o f  mice fed the cis diet compared with those fed the trans fat diet. Thus, 
the trans fatty acid diet appeared to behave similarly to the cis fatty acid diet regarding 
growth o f  the prim ary mammary tumour. However, trans fatty acids m ight be less 
effective than cis fatty acids in promoting blood borne homing and survival o f  tumour 
cells at distant organ sites (Ip et al., 1997).
A study in which DM BA-treated rats were fed either a  diet enriched in trans fatty acids 
(35 % trans monoene and 22.5 % cis monoene), or a  non-hydrogenated fat diet 
(containing 55 % cis monoene) also showed a lower tum our incidence in  the trans-fatty 
acid fed group (Selenkas et al., 1984). Using the same experimental model rats fed 
hydrogenated soybean oil had a  lower incidence and yield o f  mam m ary tum ours than 
those fed unhydrogenated soybean oil (Kritchevsky et al., 1992). These studies suggest 
that a  trans fatty acid diet may be less carcinogenic than a  diet containing predominantly 
cis fatty acids.
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Epidemiological data showing an association between high intake o f  trans fatty acids and 
an increased risk o f  breast cancer, suggests that further studies in  this area are waranted 
(Kohlmeier and M endez, 1997). Trans fatty acid levels in gluteal fat biopsy samples 
from 698 post menopausal incident cases o f  primary breast cancer and controls showed a 
positive association with breast cancer. W omen containing the highest level o f  trans 
fatty acid stores had a breast cancer risk 40 % greater than w om en w ith low  trans fatty 
acid stores (Kohlmeier and M endez, 1997).
1.9.3 Milk fa t and cancer
M ost o f the studies reviewing the effect o f  m ilk fat on carcinogenesis present problems 
associated with insufficient adjustment for other confounding dietary and nutrient 
variables such as total energy, fat, protein, fiber and vitam in A. It is difficult to clearly 
separate the effects o f  fat from those o f  calories, and o f  fat from  dairy foods from  other 
dietary fats. The presence o f  substantial correlations in caloric intake among dairy foods 
and meats complicates the assessment o f  individual nutrient or food effects (Jain, 1998).
Milk fat contains many anticarcinogenic components: butyric acid, ether lipids, 
sphingomyelin and CLA. About one third o f  all m ilk triglycerides contains one molecule 
o f  butyric acid C4, a potent inhibitor o f  proliferation and inducer o f  differentiation and 
apoptosis in a wide range o f  neoplastic cell lines (Hague and Paraskeva 1995, Lupton, 
1995, Mandal and Kumar 1996). A t the molecular level, butyrate causes histone 
acetylation that may benefit DNA repair and suppress the expression o f  various
50
oncogenes (Parodi, 1996). Interest in butyric acid as a chem opreventive agent stems 
from its role in the colon where it is produced during bacterial ferm entation o f  dietary 
fiber and starch. A lthough butyrate produced by colonic ferm entation is considered 
important for colon cancer protection, an animal study suggests that dietary butyrate may 
also inhibit mammary tumourigenesis (Yianagi et a l, 1993). M ilk fat contains small 
quantities (0.17 %) o f ether lipids com prising o f  alkylglycerols,
alkylglycerophospholipids and their derivatives are potent antineoplastic agents, which 
inhibit growth, show antimetastatic activity and induce differentiation and apoptosis in 
cancer cells (Berdel, 1991, Diomede et al., 1993). These are present in neutral lipids and 
to a greater extent in the phospholipids o f  m ilk fat (Hallgren et al., 1974).
In vitro studies have shown that sphingomyelin (0.1-1.0 % o f  m ilk fat), through its 
biologically active metabolites, ceramide and sphingosine, participates in  three major 
antiproliferative pathways influencing carcinogenesis, namely, inhibition o f  cell growth 
(Hannun, 1994, Hannun and Linardic 1993) and induction o f  differentiation (M errill et 
al., 1993) and apoptosis (Jarvis et a l, 1996). M ice fed sphingomyelin after initiation 
with DM BA had fewer colon tumours and aberrant crypt foci (ACF) than control fed 
animals (Dillehay et al., 1994). These results obtained with a lim ited supply o f 
sphingomyelin, short feeding time (28 wk) and limited numbers o f  mice, offer exciting 
prospects for future research.
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1.10 Chemopreventive action ofCLA
1.10.1 in vivo studies
The tide o f  anticancer research involving CLA began when H a et al. (1987) topically 
applied a  synthetic mixture o f CLA isomers (prepared using the m ethod o f  the AOCS, 
1973) to the dorsal area o f  mouse skin prior to initiation o f  cancer w ith the carcinogen, 
DMBA and its prom otion with TP A. CLA inhibited the in vivo initiation o f  mouse 
epidermal tumours (Figure 1.11). Sixteen weeks after promotion, CLA-treated mice 
consistently exhibited fewer papillomas and a lower tumour incidence than control or 
LA-treated mice.
In the knowledge that CLA was present in a wide range o f  food products these 
researchers began to investigate how oral CLA treatment m ight act in other tum our 
models. Figure 1.12 demonstrates the design o f  an in vivo experiment showing that CLA 
reduced forestomach neoplasia induced by the carcinogen, benzo(a)pyrene in m ice by up 
to 50 % (Ha et al., 1990). CLA or LA was administered by gavage w ith olive oil twice 
weekly for 4 weeks. Control mice were treated with olive oil. All m ice were 
administered 2.0 mg o f  benzo(a)pyrene once weekly for 4 weeks. CLA-treated mice 
(total dose 800 mg/mouse) developed ha lf as many neoplasm s/anim al as mice in the 
control groups. Body weight and food intakes were not affected by CLA; therefore 
calorie restriction, known to reduce tum our risk (Ip et al., 1985, Pariza, 1988) was not a 
factor in the reduction o f  forestomach neoplasia by CLA.
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Shave
dorsal
skin
DMBA
(50 nmol)
TPA twice-
weekly (6ng/0.2 
ml acetone')
Observe change 
in tumour
1
Days prior to DMBA treatment 
r i r i r
nuniber
1 1 1
Day 7 Day 3 5 min
20 mg CLA 20 mg CLA 10 mg CLA
(control groups received LA or 0.2 ml acetone)
° tmie W eek 1 W eek 2 W eek 3 W eek 4 W eek 5 W eek 16
Figure 1.11 Design o f  2-stage mouse skin cancer chem oprevention m odel (H a et al., 
1987).
6 week old female CD-I mice, 20 mice per treatment (topically applied CLA or LA) and 30 mice in the 
control group. DMBA : 7,12-dimethyl-benz[a]anthracene, TPA :12-0-tetradecanoylphorbal-13-acetate.
0.1 ml CLA or LA 0.1 ml CLA or LA 0.1 ml CLA or LA 0.1 ml CLA or LA
+ olive oil + olive oil + olive oil + olive oil
Days 12 19 26
8 10 15 17 24
BP 2 mg/ml BP 2mg/ml BP 2mg/ml BP 2mg/ml.
• Sacrifice
• Remove forestomach
• Count tumours
• Examine histology
W eek 30
Figure 1.12 Design o f mouse forestomach chem oprevention m odel (H a et al., 1990).
6-7 week old female ICR mice, 25 mice per treatment (0.1 ml CLA or LA + olive oil). BP: 
benzo(a)pyrene.
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M ammary cancer is usually detected w hen a  primary tum our o f  m alignant cells, which is 
clinically silent becomes a visible painless lump which the patient notices. Each breast 
has 15 to 20 sections called lobes, which have many smaller sections called lobules. The 
lobes and lobules are connected by thin tubes called ducts. The m ost com m on type o f 
mammary cancer is found in the cells o f  the ducts and is called ductal cancer. Cancer 
that begins in the lobes or lobules is called lobular cancer. Lobular cancer is more often 
found in both breasts than other types o f  breast cancer.
The effects o f  CLA on the rat mammary gland are the m ost extensively studied o f all 
effects on cells and tissues to date. In over ten separate studies Ip and coworkers (1999a, 
1999b, 1997, 1997, 1997, 1996, 1995, 1994, 1991, 1985) have shown that dietary 
administration o f  CLA was an effective w ay o f  achieving cancer protection. CLA was 
effective at various doses, at various stages o f  carcinogenesis and for varying durations 
corresponding to particular stages o f  gland maturation, regardless o f  the level or type o f 
fat in the diet. M orphological remodeling occurs during m aturation o f  m ammary gland in 
the rat. At birth and in the first week o f  postnatal life, the mam m ary gland is made up o f 
a single primary duct, which branches into several secondary ducts, w hich end in club -  
shaped structures referred to as terminal epithelial buds. During the second and third 
weeks, additional sprouting o f  ducts occurs leading to a sharp increase in the number o f 
terminal epithelial buds (Ip et a l, 1994). After reaching a peak at weaning (21 days o f 
age for a rat) terminal epithelial buds begin to differentiate into alveolar buds and lobules.
1.10.2 Mammary carcinogenesis.
54
After 40 days o f  age their population density has reached a level approxim ate to that o f  
the mature gland (56 days).
Figure 1.13 shows the design o f  the rat mammary gland tum our m odel in which cancer 
was induced in adult female rats with a single dose o f  DM BA (10 mg). Feeding a basal 
diet supplemented with CLA (0.5, 1.0, 1.5 %) two weeks before DM BA treatment and 
for up to 24 weeks afterwards led to a dose responsive reduction in tum our number by 32 
-  60 %. The maximum effect was observed at 1 % CLA (Ip et al., 1991).
A subsequent study determined the sensitivity o f dietary CLA treatm ent in rats treated 
with a lower dose o f  DM BA (5 mg) (Ip et al., 1994). Feeding a  low er dietary level o f  
CLA (0.05 -  0.5 % o f the diet) for a longer period o f  tim e (36 weeks) showed that as 
little as 0.1 % CLA in the diet was sufficient to cause a reduction in total tum our number 
(Ip et al., 1994) (Figure 1.14). Total mammary tumour yield was reduced by 22, 36, 50 
and 58 % in the 0.05, 0 .1 ,0 .25 and 0.5 % CLA diets, respectively.
Studies in which timing o f CLA feeding was carefully controlled have helped to delineate 
the role o f  CLA in modulating the kinetics o f  mammary gland development. Significant 
protection against tumour occurrence was offered (Table 1.6) when CLA feeding was 
initiated at weaning (i.e. 2 1  days) and limited only to 1 week after chemical carcinogen 
treatment (49 days) (Figure 1.15), such that it coincided w ith differentiation o f  terminal 
end buds and maturation o f  the rat mammary gland to the adult stage morphology. It is 
apparent from Table 1.6 that CLA exposure during m ammary gland m aturation caused a 
significant reduction in tumourigenesis in both DMBA (61 %) and M NU (65 %) treated 
animal models (Ip et al., 1994).
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Rats fed the AIN-76A basal 
diet or AIN-76A basal diet 
+ 0.5, 1 or 1.5 % CLA for 
duration.
DMBA (10 mg) oral 
intubation
Week 26
experimant
terminated
• Sacrifice
• Expose mammary gland
• Observe microscopic tumo
Figure 1.13 Design o f  rat mammary DM BA tumour model (Ip et al., 1991).
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< -------------------------------------------------------------------------►
l
Time
k *
2 weeks
i  A
36 weeks
i
^  W
Basal diet + 0.05, 
0.1, 0.25 and 0.5% 
CLA for duration
P.O.intubation 
DMBA (5 mg) oral 
intubation
• Sacrifice
• Expose mammary gland
• Observe microscopic tumours
Figure 1.14 Design o f  rat mammary DM BA tumour model (Ip et ah, 1994).
56
Table 1.6 M am m ary cancer prevention  b y  short term  feed in g  o f  C L A  from  w eaning until 
1 w eek  p ost carcinogen treatment for a total period o f  5 w eek s.
Carcinogen % dietary CLA 
supplementation
Tum our incidence Total number o f 
m am m ary tumours
DMBA ( 10 mg) 0 80 62
1 52 38
MNU (6 mg) 0 88 76
1 60 50
(Ip et al., 1994).
Tumour 
initiation MNU
Differentiation of TEB Tumour progression/promotion
49 days CLA-free diet
weaning
21 days
I % CLA
56 days
F ig u re  1 .15 D esig n  o f  rat m am m ary tum our m odel (Ip et al„ 1995).
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W hen CLA was fed immediately after MNU treatment (i.e. in  the post initiation phase 
only) for 1 or 2 months it was relatively ineffective in cancer protection. It was only 
when CLA was continued in the diet for 5 months that any significant inhibition occurred 
(Figure 1.16). This clearly showed that in the post initiation stage o f  mammary 
carcinogenesis a continuous supply o f CLA was necessary for m aximum tumour 
inhibition (Ip et al„ 1995).
M N U
administration
mg
56 days 1 month 2 months 5 months
(mature) post M N U  p ost M N U  p ost M N U
1 % CLA
for 1 month
 <-------------------- r-
1 % CLA for 2 months
 < ►
1 % CLA for 5 months
Figure 1.16 Design o f  mammary gland chemoprevention model (Ip et ah, 1995).
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Subsequent work using the M NU-induced mammary gland tum our m odel showed that 
the tumour protective effect o f  the triglyceride form  o f  CLA was similar to that o f  the 
free fatty acid and thus ruled out the probability o f  a non specific free fatty acid effect (Ip 
etal., 1995).
The chemoprotective effect o f  dietary CLA present at 1 % in a  basal diet containing 5 %  
com  oil (3 mg LA) was shown to be independent o f  the level or type o f  fat consumed (Ip 
et al„ 1996). Increasing the level o f  fat to 20 % by weight o f  the diet did not adversely 
affect the magnitude o f  tum our inhibition by 1 % CLA (Table 1.7). Switching to a 
predominantly saturated fat (lard) diet containing 1 % CLA did not affect the magnitude 
o f  tum our inhibition. Dose responses to CLA when the am ount o f  com  oil was increased 
from 5 % to 20 % in the diet suggests that the effects o f  CLA were mediated via 
mechanisms separate and distinct from LA.
The hypothesis that CLA and LA were distinctive m odulators o f  m am m ary 
carcinogenesis was tested by examining the dose response to CLA (at 0.5, 1.0, 1.5 and 2 
%) in rats fed a 2 % or a 12 % LA diet (Ip and Scimeca, 1997). End points o f  
investigation included measurement o f  tumour incidence and tum our num ber in addition 
to the incorporation o f  CLA, LA and AA in mammary glands.
As seen previously, the efficiency o f  tumour suppression by CLA was not affected by LA 
and no further protection was evident with CLA levels greater than 1 % o f  the diet.
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Table 1.7 Mammary cancer prevention by CLA in rats fed different levels of fat.
Dietary fat level
%
CLA % Tumour incidence
%
Total no. of
tumours
Inhibition (%)
10 0 68.8 71
10 1 40.6 31 56
13.3 0 81.3 74
13.3 1 46.9 40 46
16.7 0 87.5 94
16.7 1 59.4 46 51
20 0 90.6 98
20 1 59.4 49 50
(Ip e ta l ,  1996).
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GLC analysis o f  fatty acids in neutral and phospholipids o f  the m am m ary tissue indicated 
that the accumulation o f  CLA was dose dependent from 0.5 % to 2 % and that CLA 
concentration was 10  times higher in neutral lipids than in phospholipids regardless o f  the 
LA content o f  the diets (Table 1.8). CLA did not appear to displace either LA or A  A in 
the mammary tissue phospholipids (Table 1.8) (Ip and Scimeca, 1997b).
A plausible explanation to address why no further protection was detected at CLA 
concentrations > 1 % while target tissue continued to accumulate CLA w ith dietary 
intakes > 1 %  may be that CLA was converted to some active metabolite(s). A limited 
capacity o f  a biochemical pathway would explain m axim isation o f  the protective effect at 
1 % CLA, despite increasing accumulation o f  CLA in neutral lipids at dietary levels > 1 
%. Studies by Banni et al. (1995) have provided evidence that desaturation and 
elongation o f  CLA m ay be one such pathway. Conjugated diene Cig:3 and C20:3 were 
recovered in the liver o f  rats fed only 0.04 % CLA in the diet (Banni et al., 1995).
CLA accumulated rapidly in neutral lipids following supplem entation w ith CLA. W hen 
supplementation ceased there was a rapid disappearance o f  CLA from the neutral lipid 
with a  return to basal levels (0.2 %) in 6 weeks. The rate o f  disappearance o f  neutral 
lipid CLA paralleled more closely the rate o f  occurrence o f  new  tum ours in  the mammary 
gland. By contrast, the rate o f  change o f  phospholipid CLA during either exposure or 
withdrawal was slower. M axim um levels o f  phospholipid CLA (0.5 %) were not attained 
until 6 - 8  weeks. However a similar detectable amount o f  CLA (0.2 %) was present 6 
weeks subsequent to removal o f  CLA from the diet (Figure 1.17). This suggests that a
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continuous supply o f  CLA is necessary for m axim um  tum our inhibition in  the post 
initiation phase o f  mammary carcinogenesis.
Table 1.8 Incorporation o f  CLA, LA and AA in neutral and phospholipids o f  mammary
gland.
Dietary treatment Neutral lipids 
% o f total fatty acids
Phospholipids 
%  o f  total fatty acids
LA CLA CLA LA AA CLA LA AA
2 0 0.2 14.8 0.4 0.1 12.6 23.2
0.5 1 .1 15.2 0.3 0.1 11.4 24.7
1 2.8 14.5 0.5 0.3 13.1 21.3
1.5 3.9 14.3 0.4 0.3 12 .2 21.5
2 5.2 13.9 0.3 0.4 11 .8 22.8
12 0 0.2 45.1 0.6 0.1 13.0 24.6
0.5 0.9 43.6 0.5 0.1 12.8 21.4
1 2.7 46.5 0.7 0.3 13.5 23.9
1.5 3.6 42.4 0.6 0.4 11.7 22.4
2 5.0 42.7 0.5 0.4 12.4 23.3
Ip and Scimeca (1997).
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F igure  1.17 The kinetics o f  CLA retention in a) neutral lipids and b) phospholipids o f 
mammary gland following CLA supplementation and withdrawal (Ip et al., 1997).
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Digitised image analysis o f  mammary gland mounts suggested that there was diminished 
epithelial branching as a result o f  CLA treatm ent (Thom pson et al., 1997). In particular, 
a  20  % reduction in the density o f  the ductal lobular tree was accom panied by a 
suppression o f bromodeoxyuridine labeling (a thym idine analogue incorporated during 
DNA synthesis) in  the terminal epithelial buds and lobuloalveolar buds. This change in 
morphology could account in part for the reduced susceptibility to chem ical induction o f 
carcinogenesis. Studies by Banni et al. (1999) related these m orphological changes to 
particular biochemical profiles o f CLA and LA metabolites. Specifically, there was a 
dose-dependent increase in desaturated and elongated products o f  CLA m etabolism  and a 
decrease in LA metabolites. Other biochemical changes were an increase in the vitamin 
A contents o f  mammary tissue and liver (Banni et al., 1999). Retinoids related to vitamin 
A have become the focus o f  intense interest as potential anticancer agents. For example, 
it has been possible to obtain terminal differentiation o f  mouse teratocarcinom a cells in 
vitro and even in vivo by injecting a  vitam in A analog directly into the tumour. In 
vitamin A treated experimental animals, inhibition has been obtained against cancers o f 
the bladder, breast and skin (M cCormick et al., 1981).
Feeding butter fat (4 % CLA) to rats during the time o f  pubescent m am m ary gland 
development reduced mammary epithelial mass by 2 2  %, decreased the size o f  the 
terminal end bud population by 30 %, suppressed the proliferation o f  term inal end bud 
cells by 30 % and inhibited mammary tum our yield by 53 % (Ip et al., 1999a). 
Furthermore, rats consuming CLA enriched butter fat consistently accumulated more
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total CLA in the mammary gland and other tissues compared w ith those consuming free 
fatty acid CLA.
1.10.3 Skin carcinogenesis
Studies showing that CLA inhibited the prom otion o f  tum ours in skin in a  m anner that 
was independent o f  its anti-initiation activity have expanded knowledge o f  the role o f  
dietary CLA in carcinogenesis (Belury et al., 1996). Using the m ouse skin multistage 
carcinogenesis model, female SENCAR mice were fed control diets during initiation and 
then fed diets containing various levels o f  CLA (0-1.5 % w/w) during skin tumour 
promotion with TPA (Figure 1.18). Twenty five weeks after TPA treatm ent was 
initiated, an inverse relationship was observed between tum our yield and level o f  dietary 
CLA; the average number o f  tumours per mouse was 39 % low er (P < 0.05) in mice 
receiving 1.5 % dietary CLA compared w ith mice fed the control diet (Beluiy et a l,
1996). There was a m odest reduction in skin tum our incidence o f  approxim ately 15 % 
for mice fed the 1.5 % diet. It is apparent that the biological potency o f  CLA against 
mouse skin carcinogenesis (Belury et al., 1996) was lower than had been observed in the 
mammary cancer model as described by Ip et al. (1994).
1.10.4 Colon carcinogenesis
Other evidence that CLA has anti cancer activity arose when CLA treatm ent reduced a 
number o f  early preneoplastic markers o f  carcinogenesis in rat colon (Liew et al., 1995). 
Introduction o f  CLA by gavage prior to and during a 4 week exposure o f  rats to 2-amino-
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3-methy 1 -im idazo[4,5-f]-quinoline (IQ) (Figure 1.19), a heterocyclic am ine known to 
cause tumours at several sites, caused a  74 % decrease in the num ber o f  colonic aberrant 
crypt foci compared with control animals given IQ without any dietary treatment. In 
addition, CLA treatm ent was associated with a significant reduction in the num ber o f  IQ- 
DNA adducts formed in the colon as determined by 32P -postlabeling analysis. These 
results were consistent with an earlier report (Zu and Schut, 1992) showing that CLA 
inhibited IQ-DNA adduct formation in liver, lungs, kidney and large intestine o f CDF1 
mice.
TPA induction o f
carcinogenesis 
twice weekly
4 weeks 
Jnitiation  stage
25 weeks 
Promotion stage
Mice fed basal Mice fed basal
diet. 1 application d ie t+0.5, 1.0,
w ithDM BA 1.5%  CLA
Figure 1.18 Design o f  2-stage mouse skin chemoprevention model (Belury et al., 1996).
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a ' '
Remove colon and score ACF
F igu re  1.19 Design o f  rat colon tumour m odel (Lie w  e ia /., 1995).
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1.10.5 Prostate cancer
An inhibitory effect on growth o f  prostate tumours was reported by Cesano et al. (1998) 
in a study where DU145 human prostate cells were subcutaneously im planted into 1 % 
CLA-fed severe combined im munodeficient (SCID) mice. Control animals fed a non 
CLA diet showed tumours o f  -1500  mm 3 by 12 weeks; CLA- fed m ice showed 
significantly smaller sized tumours and reduced tumour growth.
1.10.6 Inhibition o f progression (metastasis)
Mice fed 1 % CLA for two weeks prior to subcutaneous inoculation o f  107 MDA-M B468 
cells had 73 and 30 % less tum our growth at 9 and 14 weeks post inoculation, 
respectively (Visonneau et al., 1997). M oreover, CLA com pletely abrogated the spread 
o f  breast cancer cells to the lungs, peripheral blood and bone marrow. These results 
indicate the ability o f  dietary CLA to block both local growth and systemic spread 
(metastasis) o f  human breast cancer (Visonneau et al., 1997).
1.10.7 In vitro studies
The chemopreventive potential o f  CLA as seen in vivo has been verified in a number o f 
in vitro studies wherein physiological concentrations o f  CLA (1.78-7.14 x 10'5 M) 
inhibited growth o f  various types o f  cultured cells especially tum our cell lines in a dose 
and time-dependent manner (Cunningham et al., 1997, DesBordes and Lea, 1995, 
Durgam and Fernandes, 1997, Schonberg and Krokan, 1995, Shultz et al., 1992a). A 
dose and time dependent decrease in cell proliferation was seen on hum an cancer cells
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(M21-HPB, malignant melanoma; HT-29, colorectal; M CF-7, breast) incubated with 
CLA compared w ith control cultures. CLA also inhibited the growth o f  three human 
lung adenocarcinoma cell lines (A-427, SK-LU-1, A-549) in  a  dose and time dependent 
manner, but had no effect on a human glioblastoma cell line (A-172) (Schonberg and 
Krokan, 1995).
CLA was found to selectively inhibit proliferation o f  estrogen receptor positive MCF-7 
cells compared with estrogen responsive negative M DA-M B-231 cells (Durgam and 
Fernandes, 1997). A  higher percentage o f  the CLA treated M CF-7 cells remained in the 
G0/G1 phase (i.e. the resting and prereplication stage) com pared to control cells or those 
treated w ith LA and thus did not progress to S (replication), G2 (post replication), and M 
(mitotic) stages o f  the cell cycle. CLA also inhibited c-myc, a transcriptional factor 
known to play a key role in biochemical pathways controlling cellular proliferation, in 
these cells. These authors concluded that CLA may inhibit M CF-7 cell growth by 
interfering with hormone regulated mitogenic pathway due to decreased expression o f  c- 
myc.
Both a mixture o f  CLA isomers and pure c9, t i l  CLA inhibited the growth o f  rat 
mammary epithelial cell organoids (MEO) in primary culture (Ip et al., 1999b), and this 
growth inhibition was mediated both by a reduction in DNA synthesis and stimulation o f 
apoptosis. MEO number was reduced with increasing concentration o f  CLA (0 -128  
jaM). Table 1.9 demonstrates that the CLA mixture o f  isomers was (14 -  30 %) more 
potent than the individual c9, t\ 1 CLA isomer. The effects o f  CLA did not appear to be
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mediated by changes in epithelial PKC since neither total activity, expression nor 
localisation o f  PKC isozymes a, p il, 8, e, rj, or £, w ere altered in the epithelium o f CLA 
fed rats. In contrast adipocyte PKCs 8, s, and r| were specifically upregulated in CLA fed 
rats. PKC isozymes phosphorylate serine and threonine residues on a diverse group o f 
proteins including growth factor receptor kinases associated with signal transduction. 
Taken together these observations demonstrate that CLA can act directly to inhibit 
growth and induce apoptosis o f  normal MEO and m ay thus prevent breast cancer by its 
ability to reduce mammary epithelial density and to inhibit the out growth o f initiated 
MEO. The changes in mammary adipocyte PKC expression and lipid composition 
suggest that the adipose stroma may play an important in vivo role in mediating the 
ability o f  CLA to inhibit mammary carcinogenesis (Ip et al., 1999b).
Table 1.9 Comparison o f  growth inhibitory effect o f  m ixed isomers o f  CLA with pure c9, 
i l l  CLA.
MEO number at day 12 (x 10'*)
Concentration (|aM) CLA isomers c9, i l l  CLA
0 21.0 ± 2 .4 21.0 ± 2 .4
16 17.5 ± 1 .2 20 .2  ± 0.2
32 15.5 ± 0 .5 19.8 ± 2 .1
64 11.8 ± 0 .4 17.1 ± 1.4
128 5.9 ± 3 .4 8.5 ± 0.7
(Ip et al., 1999b).
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1.11 Mechanistic studies
CLA has been associated w ith a variety o f  biological events that are involved in three 
broad stages o f  carcinogenesis, initiation, promotion and progression. A num ber o f  
studies have investigated the mechanism o f action o f  CLA. This is an evolving area o f  
research that has identified to date a  few pieces o f  the puzzle, although the picture is far 
from complete. In the following sections the various biological events will be treated 
separately as it is as yet impossible to present a unified mechanistic theory.
1.11.1 Oxidative effect
As described in section 1.9.1 antioxidant vitamins and enzym es that protect against 
damaging effects o f free radicals are important aspects o f  chemoprevention. An 
investigation o f  the potential antioxidant activity o f  CLA arose following the discovery 
that CLA reduced iron thiocyanate-induced peroxide and thiobarbituric reactive 
substance (TBARS) formation in vitro (H a et al., 1990). TBARS is a  m arker o f  lipid 
peroxidation. This led to the initial assumption that CLA may prevent carcinogenesis by 
its ability to act as an antioxidant and scavenge free radicals generated from carcinogen 
exposure. Ip et al. (1991) reported that feeding CLA resulted in lower levels o f 
malondialdehyde (MDA) in the mammary gland, an end product o f  lipid peroxidation. 
However, this activity did not correlate with dietary concentrations o f  CLA producing 
maximum suppression o f  tumourigenesis. CLA also failed to change the levels o f  8- 
hydroxyguanosine, a marker o f  oxidatively damaged DNA in m ammary tissue. Taken
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together, the available evidence suggests that antioxidant m echanism s do not account for 
the inhibitory activity o f  CLA.
M any studies have since reinvestigated the antioxidant potential o f  CLA. Experiments 
employing synthetic l-palm itoyl-2-linoleoyl phosphatidylcholine (PLPC) membrane 
vesicles and precise analytical methods have shown that CLA (1-50 jjM / 0.28-14.08 
ppm) did not have a clear protective effect under a variety o f  experimental oxidative 
stress conditions (Van den Berg et al., 1995). Chen et al. (1997) showed that two forms 
o f  CLA, the free fatty acid form and its methyl ester form induced oxidation o f  heated 
canola oil in a dose dependent manner. Triglyceride bound CLA had no protective effect 
against oxidation in the same model (Chen et al., 1997). Analysis o f  conjugated diene 
hydroperoxy fatty acids using HPLC with a diode-array detector showed that conjugated 
diene fatty acids were more susceptible to oxidation than their parent non-conjugated 
fatty acids (Banni et al., 1998). Another study has dem onstrated that CLA may be 
oxidised by singlet oxygen yielding furan fatty acids upon decom position (Yurawecz et 
al., 1995). A significant increase in lipid peroxidation as m easured by MDA was 
observed after treatment o f three lung adenocarcinoma cell lines (A-427, SK-LU-1, A- 
549) w ith CLA (Schonberg and Krokan, 1995). LA did not exert the prooxidant effect 
shown by CLA (Schonberg and Krokan, 1995). Hence oxidation o f  CLA may play an 
im portant role in influencing cancer cell death.
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1.11.2 Anti-mutagenic mechanism
Inhibition o f IQ activation was proposed as the mechanism o f  chem oprevention by CLA 
in colon tissue (Liew et al., 1995). IQ must be activated to an aryl nitrenium  ion by 
various enzymes which include cytochrome P4501A2, prostaglandin H  synthase, 
acetyltransferase and sulfotransferase before it reacts w ith guanine residues o f  DNA 
forming an adduct at the C -8  position leading to tum our production. Liew et al. (1995) 
showed that hepatic microsomes from CLA-treated rats exhibited lower 
methoxyresorufin O-deethylase (MROD) activity, an enzyme indicative o f  cytochrome 
P4501A2. Furthermore, their demonstration that CLA was antimutagenic in the presence 
o f ram seminal vesicle microsomes, a rich source o f  prostaglandin H synthase (enzyme 
responsible for the production o f  prostaglandin H) is additional evidence that CLA might 
also inhibit prostaglandin-mediated activation o f heterocyclic amines in extrahepatic 
tissues.
1.11.3 Modulation o f  eicosanoidproduction
Given the well established association between n -6  PUFA, o f  which LA is a 
representative, and prom otion o f  carcinogenesis together w ith the requirement o f  LA for 
the metabolic pathways o f  eicosanoid biosynthesis, an obvious avenue to investigate a 
possible mechanism for the anticarcinogenic effect o f  CLA is the determination o f  its 
effect on eicosanoid production. Tables 1.8 and 1.10 present data that shows 
incorporation o f  CLA into membrane phospholipids and neutral lipids in a num ber o f 
tissues (Belury and Kempa-Steczko, 1997, Ip and Scimeca, 1997). It is therefore 
plausible that CLA through its incorporation into membrane phospholipids m ay modulate
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the fatty acid com position o f  membranes and subsequently alter eicosanoid synthesis (Liu 
andB elury, 1998).
Table 1.10 Fatty acid com position in neutral and phospholipids o f  m ice as a result o f  a 
CLA diet (0-1.5 % CLA). Values are expressed as percentages o f  total fatty acids.
Fatty acids Neutral lipids Phospholipids
g/100g FAME g/100g FAME
% dietary 
CLA
0 0.05 1 1.5 0 0.05 1 1.5
Ci8:i;9 42.85 44.28 44.50 47.63 22.03 20.48 20.09 21.95
C1S:1;11 4.82 4.56 4.45 4.96 3.86 3.44 3.62 3.26
Cj8:2>9,12 10.63 9.55 8.20 5.97 11.94 11.32 10.64 8.59
c ,8!2;9,i i
CLA
0.06 0.47 0.67 0.65 0 0.13 0.28 0.38
C18:2;10,12
CLA
0 0.17 0.35 0.38 0 0.14 0.20 0.10
C20:4 4.29 4.58 3.02 2.87 20.15 22.08 21.72 19.14
(Belury and V an den Heuval, 1997)
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A murine epidermal cell line (HEL 30) was used to show that CL A did influence the 
cellular content o f  AA. Pre-treatment o f  cells w ith CLA reduced by 50 % (p < 0.05) the 
AA content compared with pre-treatment with LA (Liu and Belury, 1997). Levels o f 
cellular AA decreased as increasing amounts o f  CLA were added to cells. Additionally, 
CLA decreased both uptake o f  14C AA into cellular phosphatidycholine and the release o f 
14C AA compared with LA. TPA-induced 14C PGE2 production was also significantly 
reduced in cultures pre-treated w ith CLA compared with equimolar concentrations o f  LA 
(Liu and Belury, 1997). CLA was incorporated into phospholipids and neutral lipids in a 
dose dependent fashion in an in vivo study in which mice were fed increasing amounts o f 
CLA (0-1.5 %) in the diet (Kavanaugh et al., 1999). PGE2 synthesis was 50 % lower in 
mice fed 1.5 % CLA compared with mice fed a control diet (Kavanaugh et al., 1999). 
These data suggest that the chemoprotective effect o f  CLA in skin carcinogenesis is 
mediated by a change in the composition o f  the lipid pool o f  the plasm a m em brane which 
alters the availability o f  AA for eicosanoid synthesis during tum our promotion. The 
involvement o f  the eicosanoid pathway in the growth m odulatory influence o f  CLA and 
LA has also been demonstrated in human cancer cells (Cunningham et al., 1997). LA 
stimulated growth and [3H]-thymidine incorporation into normal hum an m am m ary cells 
(HMEC) and MCF-7 cells, while CLA was inhibitory. Incubation w ith LA and 
eicosanoid inhibitors (indomethacin; INDO or nordihydroguaiaretic acid; NDGA), 
resulted in growth inhibition in both cell lines. Incubation o f  normal HM EC w ith CLA 
and eicosanoid inhibitors stimulated growth. Incubation o f  M CF-7 cells w ith CLA and 
an inhibitor o f  the leukotriene pathway caused growth suppression suggesting that CLA
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effects were mediated through inhibition o f  leukotriene synthesis (Cunningham et al., 
1997).
CLA was shown to be a  substrate for liver microsomal A6 desaturase, an enzyme that 
catalyses conversion o f  LA to AA, in an in vitro model (Belury and Kempa-Steczko 
(1997). This suggests that CLA may compete w ith LA for this enzyme and thereby 
ultimately reduce levels o f  AA that would be incorporated into tissue phospholipids. 
Uptake o f  CLA into liver lipids was associated w ith an alteration in fatty acid 
composition: amounts o f  C i8 i were increased at the expense o f  LA  and AA. In support 
o f a hypothesis that CLA may exert a general chem oprotective effect via a mechanism 
that modulates eicosanoid metabolism was the finding that the CLA-dose response effect 
on cancer protection in the mammary gland corresponded with dose-dependent increases 
in conjugated CLA metabolites in mammary tissue and dose-dependent decreases in LA 
metabolites (Banni et al., 1999). A  number o f  conjugated C20 m etabolites o f  CLA have 
recently been identified in tissues from rats fed increasing amounts o f  N u Chek CLA in 
the range 0.5 to 2 % (Banni et al., 1995, 1999, Banni and Contini, 1996, Sebedio et al., 
1997). Conjugated metabolites included c8, t\2 , c l4  C20:3 and c5, c8 , t\2, c l4  C20:4both 
o f  which undoubtedly arose from the ¿10, c l2  CLA isomer and c5, c8, e l l ,  /13 C20:4 
which arose from the c9, t\  1 isomer (Sebedio et al., 1997).
1.11.4 Peroxisomal-proliferator actived receptor- mediated effects
It was hypothesised that the w idespread chem oprotective actions o f  dietary CLA in
extrahepatic tissues may be dependent upon its role in modulating lipid m etabolism in
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liver (Belury and Kempa-Steczko, 1997). Feeding 1.5 % CLA in the diet caused a 
decrease in body weight and an enhancement o f  lipid accum ulation in  livers o f  female 
SENCAR mice. Additional findings also suggest that CLA alters lipid homeostasis. 
Diets containing 1.0 % and 1.5 % CLA were associated w ith the induction o f  genes 
encoding acyl Co A oxidase, the first and rate limiting enzyme in peroxisom al P- 
oxidation, liver fatty acid binding protein and cytochrome P450IVA1, a lipid 
metabolising enzyme involved in hydroxylation o f  fatty acids (Belury and V an den 
Heuvel, 1997). Diets containing 0.5 %, 1.0 % and 1.5 % CLA w ere associated with 
approximately six to nine-fold increases in hepatic acyl Co A  oxidase mRNA, compared 
with mRNA levels in livers from mice fed the control diet (0 % CLA). Quantification o f 
acyl Co A oxidase protein by W estern blot analysis revealed that the hepatic acyl Co A 
oxidase protein o f  mice fed 0.5 %, 1.0 % and 1.5 % CLA were 2.5 to 3.0 times the level 
o f  acyl Co A oxidase protein o f  mice fed the control diet (0 % CLA). All o f  these 
proteins and enzymes are regulated to some extent by a PPAR, an intracellular receptor 
that belongs to the steroid hormone receptor superfamily. Because several isomers o f 
CLA are known to be high affinity ligands and activators o f  PP A R a (M oya-Cam arena et 
al., 1999b) it is believed that CLA isomers (in the order o f  c9, t\  1 > /10, c l2  > t9, t\  1) 
exert a modulatory influence on lipid metabolism and liver cell growth through activation 
o f the PPA R a receptor subtype predominantly expressed in liver. Once bound, the 
PPAR-CLA complex is expected to form a heterodimer with another nuclear hormone 
receptor, a 9-cw-retinoic acid receptor (RXR) and the PPAR-RXR heterodim er interacts 
with specific DNA response elements known as peroxisom al proliferator response 
elements (PPREs) located upstream o f responsive genes (M oya-Camarena et al., 1999b).
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Such genes include those encoding lipid metabolising enzymes m entioned already and 
several growth regulatory genes (i.e. c-myc, c-jun and COX 2).
These PPAR-mediated effects o f  CLA on lipid m etabolism and gene expression appear 
however to be species specific. Incremental levels o f  CLA were associated with 
enhanced hepatic ornithine decarboxylase activity, a m arker o f  tum our prom otion and 
cell proliferation in mice (Belury et a l, 1997). A lthough CLA also activated PPAR a  
and p subtypes in Sprague Dawley rats, it did not induce hepatic peroxisom e proliferation 
(M oya-Camarena et a l, 1999a). In three strains o f  rats studied (Sprague Dawley, lean 
and obese Zucker diabetic and Fisher 344 rats) dietary CLA did not have a significant 
effect on the content o f  lipid in liver (M oya-Camarena et a l, 1999a). By contrast in two 
strains o f mice (CD-I and SENCAR) 1.5 % CLA increased the lipid content in liver by 
approximately 2-3 fold in both strains. Species-specific differences in absorption, 
metabolism, optimal dose as well as sex o f  the animal are potential factors that may affect 
the ability o f  a PPAR ligand such as CLA to exert biological responses (M oya-Camarena 
et al., 1999a).
The alteration o f  lipid homeostasis, being m uch greater in mice than in rats is therefore 
not a unifying hypothesis to explain the ubiquitous widespread chem oprotective actions 
o f dietary CLA in extrahepatic tissues in rodent models. Studies on the short and long 
term effects o f  consuming CLA on lipid metabolism in hum ans are warranted to 
determine if  CLA decreases the risk o f  cancer in extrahepatic tissues at the expense o f
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increased risk for liver cancer. Table 1.11 is a  summary o f  the reported effects to date o f 
CLA on events associated with carcinogenesis.
1.12 Effect of CLA on atherosclerosis
Atherosclerosis, an underlying cause o f  myocardial infarction, stroke and other 
cardiovascular diseases is responsible for 50 % o f all mortality in Europe, USA and Japan 
(Ross, 1993). The earliest recognisable lesion o f  atherosclerosis is the so-called ‘fatty 
streak’, an aggregation o f  lipid-rich macrophages, T lymphocytes and lipoproteins within 
the innermost layer o f  the artery wall, the intima. M uch evidence has accumulated to 
suggest that oxidised low density lipoprotein (oxLDL) is a key com ponent in  endothelial 
cell injury (Ross, 1993). Once formed by the endothelium, oxLDL m ay directly injure 
the endothelium and play an initial role in the increased adherence and m igration o f 
monocytes and T lymphocytes into the subendothelial space. It can induce formation o f 
adhesive cell glycoproteins, such as vascular cell adhesion molecules by the endothelium. 
During the subsequent progression o f  the lesion, macrophages are transform ed into lipid­
laden foam cells, presumably by uptake o f  ox LDL and sm ooth m uscle cells migrate into 
the lesion to form a fibrous cap around the lipid rich core (Ross, 1993). By projecting 
into the arterial lumen these fibrous caps m ay impede the flow  o f  blood. Studies showing 
that vitamin E and other lipophilic antioxidants e.g. probucol inhibited lipoprotein 
oxidation as well as the macrophage component o f atherosclerotic lesions indicate that 
antiatherogenic effects o f  antioxidants may in part be m ediated by interference with 
oxidation-dependent expression o f adherence molecules, cytokines and chemotactic 
factors (Fruebis et al., 1999, O ’Brien et al., 1991, Reaven et al., 1993).
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Table 1.11 CLA effect on events associated with carcinogenesis.
Event Species/cell
type
Experimental model Route o f 
administration
M ajor finding
Tumourigenesis Mouse DMBA skin tumours Dermal Inhibition o f incidence and 
multiplicity
Mouse BP forestomach 
tumours
Gavage Inhibition o f incidence and 
multiplicity
Rat DMBA breast 
tumours
Diet Dose response Inhibition o f 
incidence and multiplicity
Rat AOM intestinal 
tumours
Diet Inhibition w/short term 
feeding
Rat DMBA and MNU 
breast tumours
Diet N o effect
Promotion
biomarker
Mouse Forestomach ODC Gavage Inhibition o f  TPA-induced 
ODC activity
Mitogenesis Rat BrdU labelling o f
mammary gland
Diet Inhibition o f lobulo- 
alveolar proliferation
M21-HPB
HT-29
MCF-7
Cell growth curves In vitro Cytostatic and cytotoxic 
effects at micromolar 
concentrations
Mutagenesis Salmonella Ames assay Gavage CLA incorporated into S-9 
inhibits IQ activation, but 
not BP or DMBA 
activation
Carcinogen 
activation &
Mouse IQ-DNA adducts Gavage Inhibition in certain target 
and non target organs
detoxification
Rat Mammary and liver 
phase 11 enzymes
Diet No effect on liver and 
mammary GST
Signal
Transduction
Mouse Forestomach extracts Gavage PKC like activity refractory 
to activation
3T3 Phospholipid In vitro Modulation o f  TPA- 
stimulated phospholipase C 
activity
Antioxidant
capacity
Rat Ex vivo TBARS Diet Inhibition in mammary 
gland but not in liver
Eicosanoid Mouse TPA skin tumours Diet Decreased PGE2 synthesis
modulation
Expression o f Mouse Liver tissue Diet Activation o f PPARa
genes for lipid 
metabolism
Adapted from Scimeca et al., 1994.
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A small number o f  studies have demonstrated that CLA reduces aortic plaque formation 
in experimental animals (Lee et a l ,  1994, N icolosi et a l, 1997). Lee et al. (1994) 
reported that dietary CLA (0.5 g CLA/ rabbit/ day) fed in conjunction w ith an 
atherogenic diet (containing 0.1 % cholesterol for 2 2  weeks) reduced the severity o f 
atherosclerotic lesions developing in the aorta o f  rabbits. Figure 1.20 shows that the ratio 
o f LDL cholesterol to HDL (high density lipoprotein) cholesterol was significantly 
reduced in CLA fed rabbits compared with the control group (Lee et al., 1994). The 
percentage o f total aortic surface covered by fatty lesions was significantly lower in the 
CLA-fed group (43 ± 11 %) compared with the control group (55 ±  14 %). Other 
histological evidence o f  a  less severe form o f atherogenesis was the reduction in the 
plaque to wall volume ratio and a 30 % reduction in cholesterol deposition in the CLA- 
fed group.
Nicolosi et al. (1997) reported that dietary CLA (0.025-0.5 % ) reduced fatty streak area 
in arteries o f hamsters fed an atherogenic diet. Total plasm a cholesterol, non-HDL 
cholesterol and triglyceride levels were significantly reduced in these animals w ith no 
effect on HDL cholesterol compared to controls. Plasm a tocopherol /total cholesterol 
ratios were markedly higher in CLA-fed animals (48-86 %) com pared w ith LA-fed 
animals (29 %) (Table 1.12) suggesting that CLA treatment caused a tocopherol sparing 
effect. However, the antiatherosclerotic effects o f  CLA in rabbits were not associated 
with a reduction in TBARS (Lee et al., 1994).
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Figure 1.20 LDL cholesterol /HDL cholesterol ratio in rabbits fed experimental diet with 
or without 0.5 g CLA/ rabbit/ day (Lee et al., 1994).
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Table 1.12 Effect of dietary CLA and LA on plasma lipids, plasma tocopherol and aortic
fatty streak area in hamsters.
Control Low CLA M ed CLA High CLA LA
Total
Cholesterol
(mmol/L)
17.85 ± 0.62 13.19 ±2.56* 14.12 ±  1.06* 13.71 ± 1 .56* 15.25 ± 1 .09
N onH D L-C
(mmol/L)
16.5 ± 0 .6 12.08 ±2.38* 12.73 ±  1.14* 12.39 ±  1.56* 13.91 ± 1.08
HDL-C
(mmol/L)
1.35 ± 0 .0 6 1.3 ± 0.11 1.4 ± 0 .13 1.32 ± 0 .08 1.34 ±0.16
Triglycerides
(mmol/L)
12.41 ± 2 .4 8.97 ±2.35* 7.93 ±  2* 11.33 ± 1 .7 9 8.93 ±2 .25*
a-tocopherol
(mmol/L)
0.036 ± 0.001 0.0359 ± 0.004 0.04 ±  0.004 0.051 ±  0.005 0.0379 ± 0.004
Fatty streak 
area
(|rni2/mm2 x 
100)
53 ± 1 4 43 ± 18 39 ± 1 1 37 ± 15 40 ± 18
(Nicolosi et al., 1997)
* significantly different from control (p < 0.05)
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Clearly, further studies are warranted to determine if  CLA  inhibits early aortic 
atherosclerosis via specific inhibition o f  LDL oxidation and/or via reduction o f  the 
macrophage component o f  the lesions. A lthough the evidence indicates that dietary CLA 
can modify plasm a lipids and lipoprotein cholesterol levels, the m echanism  for this action 
remains to be elucidated.
Recently a study has shown that short term  feeding o f  the pure c9, t\  1 CLA isomer 
(Matreya CLA), thought to be the active component in CLA did not produce the same 
lipid lowering effects as a  mixture o f  CLA isomers (Nu-Chek CLA) in hamsters fed an 
atherogenic diet (Gavino et al., 2000). In addition, the CLA-fed group had significantly 
lower weight gain but greater food intake than either c9, t\ 1 CLA- or LA- fed animals. 
The data suggested that CLA may disrupt assimilation and/or transport o f  fat as 
lipoprotein triglyceride and that c9, t\ 1 CLA m ay need to act synergistically w ith another 
CLA isomer to exert its biological effects. A  clue to the identity o f  which isom er m ay be 
responsible for lower weight gain has come from a study by Park el al. (1999c) in which 
it was reported that CLA-induced body com position changes in mice were associated 
with the ¿10, c 12 CLA isomer and not c9, t\  1 CLA. This isom er has also been shown to 
suppress triglyceride and cholesteryl ester synthesis in a human liver cell line while also 
reducing apolipoprotein B (apo B) secretion (Yotsumoto et al., 1999). The latter is 
essential for the accumulation and secretion o f  VLDL by liver which w hen secreted into 
blood are metabolised to LDL with apo B in LDL acting as a ligand for the LDL receptor 
(Brown and Goldstein, 1986). Clearly, more studies are needed to investigate the effects
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o f other individual CLA isomers on the level o f  apo B in blood as this is an independent 
risk factor for coronary heart disease and atherosclerosis (H uff and Burnett, 1997).
1.13 Effect of CLA on immunity
Considerable evidence exists that stimulation o f  the immune system either by vaccination 
or exposure to environmental lipopolysaccharides (LPS) partitions energy away from 
growth and causes catabolism o f body protein stores (Klasing el a l, 1987). The resultant 
cachexia (immune-induced weight loss) is mediated by cytokines released from 
stimulated macrophages or other immune cells. Two cytokines o f  central im portance in 
this process are interleukin 1 (IL-1) and tum our necrosis factor a  (TNF). These 
cytokines induce antibody synthesis and an inflammatory response in im m une cells and 
induce catabolism and changes in cell surface proteins in skeletal m uscle cells. Figure 
1.21a depicts the stimulatory effect o f  IL-1 released from antigen-stimulated 
macrophages on muscle catabolism and lymphocyte proliferation (Cook et al., 1999).
A n increase in PGE2 production upon induction o f  skeletal muscle degradation by 
cytokines indicates a metabolic basis for immune-induced catabolism (Goldberg et a l, 
1984). During cytokine mediated signalling events in skeletal muscle, AA  is cleaved 
from phospholipids by the action o f  a phospholipase (Figure 1.21b). U pon the action o f 
COX, AA can be converted to PGE2 or other eicosanoids depending on the cell type and 
signal received. Since AA is a desaturated and elongated product o f  the dietary fatty 
acid, LA, dietary manipulation o f  membrane phospholipid com position and hence
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eicosanoid synthesis may modulate cytokine-induced catabolism. Figure 1.21b shows a 
proposed mechanism for interplay o f eicosanoids in im mune function and muscle 
catabolism.
CLA was first shown to prevent immune-induced weight loss in chickens (Cook et a l, 
1993). CLA-fed chickens had significantly less growth suppression w hen injected with 
LPS compared with control -fed chickens. Subsequent studies in m ice and rats showing 
reduced cachexia confirmed that CLA was protective against immune-induced 
catabolism despite enhancement o f  a  select immunological function (spleen lymphocyte 
blastogenesis). The antibody response in rats or chickens to bovine serum albumin and 
sheep red blood cells was not adversely affected by feeding CLA (Cook et a l, 1993). 
Other measures o f  immune function enhanced in CLA-fed animals include phagocytic 
activity o f  peritoneal macrophages, lymphocyte blastogenesis and proliferation in 
response to mitogens (Cook et a l, 1993, M ichal et a l, 1992, W ong et a l, 1997). CLA 
feeding significantly raised the levels o f immunoglobulins in serum such as IgA, IgM  and 
IgG but decreased levels o f  IgE, particularly in rats fed 1 % CLA (Sugano et a l, 1998). 
Age-related depression o f  mitogen-induced splenocyte blastogenesis appeared to be 
slightly alleviated by feeding CLA (Hayek et a l, 1999). A  study w ith the macrophage 
cell line RAW 264.7 showing that CLA prevented LPS-induced increases in  PGE2 
production is further evidence o f  the potential o f  CLA as a unique immunostimulatory 
and anticachectic nutrient. An elongated and desaturated product o f  ¿10, c l2 CLA isomer 
(c5, c8 ¿12, c l4  C20:4) has been known to inhibit COX activity (Nugteren, 1970). This 
suggests that ¿10, c l 2 CLA could be the biologically relevant isomer capable o f  
enhancing select immunological responses while protecting against adverse effects o f 
immune cytokines (Cook et a l, 1999).
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Figure 1.21 (a) IL-1 stimulates muscle catabolism, (b) PGE2 induced muscle catabolism 
(Cook and Pariza, 1998).
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1.14 Effect of CLA on growth
The growth performance o f  young rats was significantly im proved (8.6 %) w hen the 
maternal diet was supplemented during gestation and lactation w ith 0.5 % CLA in the 
diet (Chin et al., 1994). A 0.25 % dietary CLA dose was inefficient, as was a 0.5 %  dose 
during lactation only. These observations suggest that a  threshold level o f  CLA 
supplementation during foetal life is necessary for optimal grow th preformance. After 
weaning, dietary supplementation with 0.25 % CLA (in the diet) allowed detection o f  a 
small but significant enhancement in body weight (5.6 g for m ale pups after 5 weeks and
7.1 g for female pups after 7 weeks) and better feed efficiency. Increasing the 
concentration o f  CLA in the supplemented diet to 0.5 % (o f the diet) enhanced body 
weight gain and feed efficiency further.
Supplementation with 0.5 % CLA by weight o f  the diet for 4 to 8 weeks reduced body fat 
mass by 57-70 % in young mice, by 23 % in rats and by 22 % in chickens (Pariza et al.,
1996). Such an effect was not limited to young animals but was also noticed in adult 
mice fed for 4 weeks with a diet containing 20 % o f  lipids com prising 0.5 % CLA. The 
CLA group exhibited a 46 % lowering o f  the body fat mass and a 9 % increase in the lean 
body mass, leading to a decrease o f  body weight for a similar food intake to control 
group. Albright et al. (1996) reported that a continuous supply o f  CLA was required to 
maintain this effect. CLA withdrawal led to a  19 % decrease in whole body protein. 
Park et al. (1997) showed that feeding mice CLA (0.5 % by weight o f  the diet) caused a
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60 % lower body fat and 14 % increase in lean body mass relative to  control. This 
physiological effect was associated w ith an increase in carnitine palmitoyltransferase, a 
key regulatory enzyme controlling fatty acid p-oxidation in fat pad and skeketal muscle. 
Taken together these studies suggest that effects on body com position may be due to 
reduced fat deposition and increased lipolysis in adipocytes, possibly coupled with 
enhanced fatty acid oxidation in both muscle cells and adipocytes.
A study o f  the effects o f  high and low  fat diets with and without CL A (1.2 and 1.0 % in 
high and low fat diets, respectively) on rodent metabolism showed that CLA significantly 
reduced energy intake, growth rate, adipose depot weight, and carcass lipid and protein 
content independent o f  diet com position (W est et al., 1998). A  reduction o f  43 to 88 % 
in adipose depot weight was observed, w ith the retroperitoneal (abdominal) depot being 
the m ost sensitive to CLA. CLA significantly increased m etabolic rate and decreased 
night-time respiratory quotient (the m olar ratio o f  CO2 production to O2 consumption). 
These findings demonstrate that CLA m ay reduce body fat by several mechanisms, 
including a reduced energy intake, increased metabolic rate and a shift in the nocturnal 
fuel m ix (W est et al., 1998).
A recent study has attributed CLA-associated body compositional changes to the ¿10, c l2  
CLA isomer (Park et al., 1999c). Feeding mice CLA preparations enriched in either c9, 
¿11 or ¿10, c l2  isomers o f  CLA led to reduced body fat and enhanced body water, body 
protein and body ash contents in ¿10, c l2  CLA fed mice com pared to controls. By 
contrast, the c9, ¿11 CLA isomer had no effect on these biochemical parameters.
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1.15 Effect of CLA on bone metabolism
Long bones in children increase in length and diameter by a process called bone 
modeling (Watkins and Seifert, 1996). Bone modeling represents an adaptive process o f  
generalised and continuous growth and reshaping o f  bone, governed by the activities o f  
osteoblasts and osteoclasts until the adult bone structure is attained. Osteoblasts produce 
and mineralise bone matrix, whereas osteoclasts are responsible for bone matrix 
resorption (Baron, 1993). Osteoblasts have receptors for horm ones (parathyroid 
hormone, Vitamin D and oestrogen), cytokines and growth factors which regulate 
differentiation, growth and metabolism o f bone cells. Osteoclasts are associated with 
bone resorption via creation o f  a secondary lysosomal space for solubilisation o f 
hydroxyapatite and digestion o f  matrix proteins. A bnormal bone modeling has 
implications in a  number o f adult pathologies such as osteoporosis or arthritis, which can 
be avoided if  bone modeling is optimised early in life or i f  diets are supplemented with 
nutrients that reduce tissue concentrations o f factors that underm ine skeletal health 
(W atkins et al., 1999). Recent investigations suggest that dietary lipids influence bone 
formation by modulating PGE2 synthesis (W atkins et al., 1996, 1997). Dietary lipids, in 
particular n -6  fatty acids which increase production o f  PGE2 by bone, stimulated an 
increase in bone resorptive activity and thus reduced bone volum e in chickens. By 
contrast, the rate o f  bone formation was significantly greater in chickens fed n-3 fatty 
acids. This increase in bone formation was associated w ith a 50 % decrease in AA  and a
3.5 fold decrease in ex vivo PGE2 production in tibia. This suggests that the role o f  PGE2
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on bone formation may be biphasic, stimulating bone form ation at a low  concentration 
but inhibiting it at higher concentrations.
PGE2 has been shown to be a  stimulator o f  IGF-1 (insulin like growth factor 1) 
production in osteoblast-enriched cell cultures (Baylink et al., 1993). CLA like n-3 fatty 
acids has also been reported to lower PGE2 production while n -6  fatty acids stimulated 
PGE2 production and increased serum IGF levels in chickens and rats (Li et al., 1999). 
Recent data suggests that inclusion o f  butter fat containing CLA in  chicken diets can 
modulate PGE2 and IGF-1 production to support higher bone formation (W atkins et al., 
1997).
Several reports have revealed that CLA may affect bone density (Cook et al., 1997, Lee 
et al., 1994, W atkins and Seifert, 1996). Cook et al. (1997) found that whole body ash 
content was higher in CLA-fed animals across a num ber o f  animal species suggesting 
that CLA enhanced bone mineralisation. Tibia from chickens fed CLA were ashed and 
found to have a higher dry, fat-free bone ash than control fed chickens (Cook et al.,
1997). This prompted a study to see if  CLA would inhibit post menopausal bone loss. 
Adult ovariectomised rats, however, did not appear to be protected from  bone loss due to 
oestrogen depletion. Another study showed that CLA prevented a  skeletal disease known 
as valgus and varus leg deformity in chickens. Valgus and varus leg deformities have 
been related to a number o f  nutrient deficiencies, which have affected the poultry 
industry for some time (Cook et al., 1997).
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1.16 Effect of CLA on diabetes
Non insulin-dependent diabetes mellitus (NIDDM) is characterised by a resistance to 
insulin and a relative elevation o f  postprandial blood glucose levels (Belury and V an den 
Heuval, 1999). Currently available therapies for the treatm ent o f  NIDDM , e.g. 
exogenous insulin and sulphonylureas largely address the insulin secretary defects o f  this 
disease but do not improve the response o f  peripheral tissues such as adipose tissue and 
muscle to insulin. While the exact causes o f  insulin resistance are unknown, it has been 
speculated that insulin resistance may be mediated in part by an increase in  free fatty 
acids (Belury and Van den Heuval, 1999). Thiazolidinedione analogs are a new  class o f  
drugs that act by improving insulin action, thereby lowering blood sugar levels in patients 
with diabetes. They block release o f  free fatty acids and reduce insulin resistance in 
adipose tissue via activation o f  the adipose enriched novel nuclear receptor PPARy. 
Activation o f PPARy is a pivotal event in the adipocyte differentiation program, and is 
important in the transcriptional regulation o f  many genes that characterise the adipocyte, 
for example aP2 (Hollenberg et al., 1997, Loftus and Lane, 1997, Torontoz et al., 1994). 
aP2 is an adipocyte lipid-binding protein which plays a  central role in facilitating the 
trafficking o f  fatty acids w ithin adipocytes. Like thiazolidinediones, CLA has been 
shown to significantly increase the steady state level o f  aP2 m RN A  in adipose tissue from 
fatty Zucker diabetic rats consistent with stimulation o f  adipocyte differentiation (Vanden 
Heuval et ah, 1994). This m ay be due to the ability o f  CLA to activate PPARy, since 
increasing levels o f  CLA induced a dose-dependent transactivation o f  PPARy in CV-1
cells cotransfected with PPARy and a PPRE X  3-luciferase reporter construct. As CL A 
may share a common mechanism o f action with thiazolidinediones via activation o f 
PPARy, a study on the effects o f  1.5 % dietary CL A (by weight) on diabetic rats was 
undertaken. CLA normalised glucose intolerance and im proved hyperinsulinem a in the 
pre diabetic rat (Houseknecht et al., 1998). The enhancing effects o f  CLA on glucose 
tolerance and glucose homeostasis indicate that dietary CLA m ay be an im portant therapy 
for the prevention and treatm ent o f  NIDDM  (Houseknecht et al., 1998).
1.17 Antithrombotic effect of CLA
The control o f  bleeding is a system o f fine tuned checks and balances. In the formation 
o f  a thrombus (blood clot), platelets must undergo three processes; adhesion to exposed 
collagen in blood vessels, release o f  their contents and aggregation. Throm bin formed 
from the blood coagulation cascade interacts w ith its receptor on the platelet plasm a 
membrane to initiate aggregation and release o f  the contents o f  the various types o f  
platelet granules. Collagen-induced activation o f  a platelet PLA 2 by increased levels o f 
cytosolic calcium results in liberation o f AA from platelet phospholipids, leading to the 
formation o f  thromboxane A 2 (TXA2), which in turn can further activate PLC, promoting 
platelet aggregation. Drugs (e.g. aspirin) that m odify the behavior o f  platelets by 
inhibiting production o f  TXA2 are important in m anagem ent o f  angina, myocardial 
infarction and also in prevention o f  stroke and death in patients w ith transient cerebral 
ischemic attacks. M any studies have shown that Cis PUF As inhibit hum an platelet 
aggregation caused by thrombin, collagen and the calcium ionophore A23187 (MacIntyre
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et al„ 1984). A recent study has shown that CLA also possesses antithrombotic 
properties (Truitt et al., 1999). It was found that c9, ¿11 CLA, ¿10, c \2  CLA and the 
CLA isomer m ix inhibited AA- and collagen-induced platelet aggregation and that LA 
was a less potent inhibitor. The c9, ¿11 CLA and ¿10, c l 2 CLA and the mixture o f  
isomers o f CLA inhibited formation o f  TxA2. No significant differences in the inhibitory 
potencies between the c9, ¿11- and the ¿10, c l2-C L A  were observed. The inhibitory 
effect o f  CLA on platelets was reversible and dependent on the tim e o f  addition o f the 
aggregating agent.
1.18 Bacteriostatic effect of CLA
A  bacteriostatic activity o f  CLA against Listeria monocytogenes, a  hum an food-borne 
pathogen, that can grow even at refrigeration temperatures w as demonstrated in a brain 
and heart infusion broth and in m ilk (Wang and Johnson, 1992). A lthough 5 to 10 fold 
less potent than lauric acid, monolaurin or LA, CLA as a potassium  salt was bacteriocidal 
in brain and heart infusion broth at 50 to 200(j.g/  mL for up to six days. Potassium CLA 
was potent in inhibiting bacterial growth in whole and skim m ilk at 4 °C. A t 25 °C, 
potassium CLA (300 (xg/ml) prolonged the bacteriostatic lag-phase by 3 Oh. This 
antibacterial activity o f  CLA in foodstuff requires further investigation with other 
microorganisms.
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1.19 Analysis of conjugated linoleic acid isomers
The term CLA refers to mixtures o f  positional and geom etric isomers o f  LA. 
Commercial production o f  CLA by the base catalysed isomerisation o f LA yields a 
mixture o f isomers (M ounts et a l, 1970, Sturve, 1983). The two double bonds in CLA 
are in positions 7 and 9, 8 and 10, 9 and 11, 10 and 12 or 11 and 13 along the carbon 
chain (Parodi, 1994, Yurawecz et al., 1998). Each o f  the bonds can be in the cis (c) or 
trans (/) configuration. Pure samples o f  CLA have been prepared com mercially by the 
dehydration o f  ricinoleic acid and by the microbial conversion o f  LA (Aldolf, 2000).
Accurate analysis o f  CLA mixtures is imperative as specific effects o f  CLA in nutritional 
studies may be attributed to specific isomers. The CLA found in dietary supplements and 
used in all, but one in vivo study to date has been shown to be com posed o f  a complex 
mixture o f positional (8, 10-, 9, 11-, 10, 12- and 11, 13) and geometric isomers (Nu Chek 
Prep CLA) (Ip et al., 1999a). Analysis o f  this com plex mixture by a single 
chromatographic method has proven difficult. GLC utilising 100 m  capillary columns 
can separate (as fatty acid methyl esters (FAME)) the major cis/trans isomers but the 
cis/cis isomers overlap and the 8, 10  through 10 , 12  trans!trans isomers remain 
unresolved. Separation o f 12 positional and geometric isomers o f  CLA as their methyl 
esters is possible using Ag+ HPLC with 0.1 % acetonitrile in hexane as the mobile phase, 
operated isocratically and using UV detection at 233nm. Figure 1.22 shows a separation 
using one Ag+ HPLC column. The mixture is dominated by four trans/trans, cis/trans
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and cis/cis positional isomers as follows: 8, 10 -, 9, 1 1 -, 10 , 1 2 - and 1 1 , 13-Ci8:2- 
Geometric pairs could not be separated w ith the use o f  only one column, however 
resolution was improved when two or more Ag+ HPLC columns were used in  series 
(Figure 1.23). The identities o f  the CLA isomers can be determ ined by gas 
chromatography- electron impact mass spectrometry (GC-EIM S) o f  their 4,4- 
dimethyloxazoline (DMOX) derivatives. This method was successfully used to separate 
and identify numerous minor new CLA isomers (t l , c9, c8, ¿10 and c l, t9) in milk, 
cheese, beef, human m ilk and adipose tissue (Rickert et al., 1999, Sehat et al., 1998, 
Yurawecz et a l, 1998).
GLC and Ag+ HPLC are complementary techniques in the total analysis o f  CLA isomers. 
The analysis o f  CLA isomers by GLC and Ag+ HPLC requires their conversion to 
derivatives that can be separated from other fatty acids by using GLC. The procedure for 
conversion o f  CLA to methyl ester derivatives (methylation) depends on the type and 
chemical composition o f  the material to be methylated. In early studies, acid catalysed 
methanolysis was used at high temperatures (100 °C) which resulted in  excessive 
formation o f  trans/trans CLA isomers (Ha et al., 1990, Ip et al., 1991), how ever this 
isomerisation was greatly reduced by lowering the temperature and duration o f 
methylation. A  4 % (v/v) HCL-catalysed m ethylation for 20 m in at 60 °C resulted in only 
~ 5 % trans/trans isomerised CLA product (Chin et al., 1992). Under these conditions 
test samples consisting m ainly o f  triglycerides (such as m ilk fat) were completely 
methylated but phospholipids were not (Kramer et al., 1997).
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Figure 1.22 Ag+HPLC separation o f  twelve CLA isomers using a single colum n (Sehat et 
al„ 1998).
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Figure 1.23 Separation o f  CLA geometric isomers by Ag+HPLC columns used in series 
(Kramer et a l, 1999)
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However this methylation procedure, while suitable for samples com posed o f 
triglycerides such as milk fat, poses a problem when determining the CLA content in 
animal tissues and biological samples, due to their high content o f  phospholipids. The 
use o f  tetramethylguanidine (TMG) as a base catalyst in the methylation o f  CLA- 
containing lipids has been extensively studied by Shantha et al. (1993) and appears to be 
the method o f  choice for biological samples as it does not isomerise conjugated double 
bonds (Yurawecz et al., 1999). However free fatty acids are not methylated under these 
conditions. Therefore choice o f  methylation procedure depends largely on the lipid 
composition o f  the sample. GLC resolves pairs o f  geom etric isomers (c, t from t, c) 
whereas Ag+ HPLC separates only those with odd A (9,11- and 11, 13-Cis:2) but not even 
(8,10- and 10,12-Cig:2) A values. Ag+ HPLC resolves all o f  the t, t and c, c CLA isomers. 
In GLC the dominant c9, t\  1 peak in dairy products and m eat from ruminants severely 
overlaps with a  number o f  CLA isomers such as t l ,  c9 and t8, clO whereas three Ag+ 
HPLC columns in series clearly resolve these isomers. Both methods helped identify and 
quantitate the isomeric distribution o f  CLA isomers in tissues o f  pigs fed a commercial 
CLA mixture containing four positional CLA isomers (18.9 % c l  1, ¿13 Cig:2, 26.3 %  ¿10, 
c l2  Cig;2, 20.4 %  c9, ¿11 C i8:2 and 16.1 % ¿8, clO Cig:2) at 2 % o f  basal diet (Kramer et 
al., 1998). Analysis o f  omental fat, liver triglycerides and heart triglycerides showed that 
the distribution o f  CLA isomers was similar to that o f  the diet. The liver phospholipids, 
particularly phosphatidylcholine and phosphatidylethanolamine selectively accumulated 
c9, ¿11 —Cig;2, except diphosphatidylglycerol (DPG) which showed a  preference to 
accumulate e l l ,  ¿13-Cig.2* Heart phospholipids, particularly D PG  also showed a 
preference for incorporating e l l ,  ¿13-Ci8.2. The remaining isomers w ere distributed
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evenly across liver, heart, backfat and omental fat (Kramer et al., 1998). The health 
benefits associated with the CLA content in m ilk may be countered by the metabolic 
effects o f  tram  fatty acids, high levels o f  which are generally accepted as unhealthy. 
Therefore the accurate analysis o f  tram  fatty acids is essential when analysing CLA 
levels in food products.
1.20 Trans fatty acid analysis
Previously, to separate methyl esters o f  the same carbon chain length, a  packed or fused- 
silica capillary column coated with polar stationary phases such as SP-2340 was 
necessary. This was based on the assum ption that C i8:i cis and trans isomers are 
completely separable on the high polar column. However, because o f  the multiplicity o f 
positional and geometric isomers present in partially hydrogenated vegetable oil (PHVO), 
these columns can give overlapping results for trans and cis monoenes o f  the same chain 
length (Ratnayake et al., 1998). To quantify the fatty acids, the analyst m ust use his/her 
judgem ent as to where the point o f  division between each group lies (Christie, 1991). On 
capillary columns coated w ith cyano-alkyl-siloxane (highly substituted cyano-propyl 
phase that has been stabilised) stationary phases (e.g. SP 2560 or CP Sil 88), Cig:2 tram  
and Cis :3 trans fatty acids (TFA) are separated as distinct groups w ithout any interference 
or overlaps and levels o f  these trans polyunsaturated fatty acids can be obtained directly 
by GLC analysis.
The combination o f  GLC with Ag+-TLC is a more effective m ethod o f  separating TFA 
than GLC alone. Argentation chromatography can separate fatty acids according to the
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configuration and number o f  their double bonds and also according to the position o f  the 
double bonds. A complex is formed between the silver ions and the double bonds by 
interaction o f  p i  electrons o f  carbon-carbon double bonds, and separation is based on 
position and geometry o f  the bond (Ratnayake et a l, 1998). Because o f  steric hindrance, 
trans double bonds form weaker complexes compared with cis double bonds (Nickolova- 
Damyanova, 1992), thus Ag+-TLC is an effective means o f  fractionation o f  either 
triglycerides or FAME.
Pre-coated plastic backed sheets w ith 0.2 mm  layer o f  silica gel im pregnated with 10 % 
(w/v) silver nitrate in acetonitrile allow equally good separation o f  TFA com pared with 
the glass plates used previously (Ulberth and Henninger, 1992). The first step in Ag+- 
TLC involves the preparation o f  the TLC plate in a  solution o f  10 %  silver nitrate in 
acetonitrile, prior to application o f  FAM E which are dissolved in non-polar organic 
solvents. Common TLC solvent systems include hexanerdiethyl ether, toluene-hexane 
and hexane-cholorform in different proportions. The separated bonds are visualised 
under UV light at 254 nm  by spraying the TLC plates with fat binding dyes such as 2 ’, T  
-dichloroflourescein or rhodamin B, (Rao et al., 1995). A TLC band corresponding to 
the trans fatty acids can then be scraped o ff and extracted w ith diethyl ether or any 
suitable solvent and analysed by GLC. A  limitation o f  A g+-TLC is that complex 
mixtures o f  FAM E containing a range o f  chain lengths and higher degrees o f  
unsaturation, such as are encountered in fish oils, produce very complex chromatograms 
(Sebedio et al., 1981). In partially hydrogenated fish oils, num erous m ixed bands are 
expected due to separation according to chain length, and are superim posed on the
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separation o f  geometric and positional isomers. The cross overlap occurs especially in 
FAME isomers containing more than three double bonds.
The same principal o f separation by Ag-TLC can be applied as a HPLC technique in 
which silver ions are bound to an ion exchange support. However, the m ain disadvantage 
o f  this method is reproducibility as a result o f  rapid loss o f  resolution. This can occur 
after a short time o f daily use (4 weeks) in contrast to capillary GC colum n which can be 
used daily for up to a year w ithout loss o f  resolution (Ratnayake et ah, 1998). Ag+- 
HPLC may be a  good alternative to Ag+-TLC for preliminary isom er fractionation before 
GLC analysis and was recommended by the American Oil C hem ists’ Society (AOCS,
1997) for TFA analysis. The combination o f  GLC w ith reverse phase HPLC is an 
additional means o f  analysing TFA (Christie, 1991). Reverse phase HPLC separates on 
the position as well as on the configuration o f  the bond. Epoxidation o f the double bonds 
o f  TFA prior to GLC analysis is also beneficial for TFA analysis as trans epoxides elute 
clearly ahead o f  the corresponding cis derivatives, but it seems that conjugated isomers 
cannot be epoxidised quantitatively (Christie, 1991).
By selecting the proper operating param eters and a polar cyanopolysiloxane capillary 
column, detailed fatty acid com position including trans isomers and other isomeric fatty 
acids in partially hydrogenated vegetable oils can be obtained by GLC analysis alone. 
For applications requiring more precise trans fatty acid data and detailed information on 
individual isomers, it is necessary to couple GLC with either Ag-TLC or Ag-HPLC 
(Ratnayake et al., 1998).
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1.21 Aims
The aims o f  this study were to validate methodology for trans fatty acid analysis, and to 
investigate dry fractionation as a means o f  enriching m ilk fat CLA. The resulting m ilk 
fat fraction was then compared with a range o f  food products w ith respect to levels o f  
CLA and trans fatty acid. The second stage o f  this work was to investigate specific 
mechanisms o f  action that may be responsible for the anticarcinogenic effect o f  synthetic 
CLA in human cancer cell lines and to compare these effects w ith those induced by m ilk 
fat triglyceride bound CLA.
1.22 Specific objectives
• To investigate dry fractionation as a means o f  enriching m ilk fat CLA, and to
compare CLA levels as a result o f  dry fractionation w ith CLA and trans fatty acid
contents o f  a range o f food products. In parallel, to establish and validate Ag-TLC 
and GLC methodologies for the accurate detection and quantification o f  trans fatty 
acids in edible oils.
•  To evaluate the relative growth effects o f  a synthetic m ixture o f  CLA isomers, pure
c9, / l l -  and ¿10, c 12- CLA on hum an cancer cell lines by exam ination o f  viability,
protein, RNA and DNA synthesis in the cells.
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•  To compare the cytotoxic effects o f  the synthetic isomers c9, t \  1 CLA, ¿10, c 12 CLA 
and N u-Chek CLA w ith CLA-enriched m ilk fat, consisting prim arily o f  the c9, t\  1 
isomer, present in triglyceride bound form on the growth o f  m am m ary cancer cells.
•  To investigate if  the growth suppressive effects o f  CLA are m ediated by specific 
effects on lipid peroxidation, the enzymes o f  the antioxidant defence system and on 
famesylation o f  Ras oncoprotein.
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CHAPTER 2
Validation of methodology for trans fatty acid analysis
2.1 Introduction
As described in chapter 1 trans fatty acids (TFA) are formed during biohydrogenation o f  
unsaturated fatty acids in the rum en and consequently are present in m ilk and meat o f 
ruminant animals (Craig-Schmidt, 1998). Non-natural TFA  are formed in industry 
during partial hydrogenation o f  vegetable and marine oils. There are highly unsaturated 
oils and as such are generally unsuitable for food fats because o f  their low melting points 
and ready susceptibility to oxidative deterioration. Industrially produced TFA differ in 
many respects from TFA formed in the ruminant animal during biohydrogenation; some 
o f these differences are related to isomer distribution. The small amounts o f  TFA in 
butter and other ruminant fats are mostly /l l-C ig :i, w hile TFA in vegetable oils, 
margarine and shortenings are mostly Cig:i fatty acids w ith double bonds distributed in a 
Gaussian fashion around A 9, A 10, A 11 and A 12. O ther differences relate to their 
amounts (1 -  2 % o f total fat in dairy products such as butter, versus 35 -  50 % o f total 
fat in  edible oils) and their speed o f  metabolism (t\  1-Cig:i is metabolised much faster than 
TFA in partially hydrogenated vegetable oil (PHVO)).
Epidemiological data has suggested an association between TFA  consumption and the 
incidence o f  coronary heart disease (CHD) (Ascherio et al., 1994). However, due to the 
nature o f  epidemiological studies it is difficult to assess the effects due to TFA because o f 
the different amounts o f  TFA consumed and the different combinations o f  TFA with 
saturated and cis unsaturated fatty acids in foods. A survey o f  the literature carried out 
by Aro (1998) suggested that when consumed in large amounts, the effects o f  TFA on
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CHD are expected to be comparable with those o f  saturated fatty acids in the diet. 
Ultimately the effects o f  dietary TFA depend on how they affect the balance between the 
hypercholesterolaemic saturated C 12 to C i6 fatty acids and the hypocholesterolaemic cis 
unsaturated fatty acids in food (Aro, 1998). Several experimental studies have now 
indicated that substitution o f  a  cis fatty acid diet w ith a  TFA diet resulted in  increased 
total LDL-cholesterol concentrations and decreased HDL-cholesterol concentrations in 
blood. Changes in blood concentration o f apolipoprotein B and apolipoprotein A -l in 
response to TFA intake have been reported for the m ost part to m irror changes in LDL 
and HDL cholesterol, respectively. TFA intake has also been reported to increase blood 
lipoprotein (a) (Lp[a]) concentration, although this observation has not been consistent 
(Aro et a l, 1997, Almendingen et a l, 1995, Judd et a l, 1994, M ensink and Katan, 1990, 
Zock and Mensink, 1996).
In view  o f the possible harmful effects o f dietary TFA, accurate analysis o f  these fatty 
acids is necessary to monitor their levels in foods. Owing to the com plexity o f  
hydrogenated fat mixtures, a  simple definitive method for simultaneous determination o f  
both total TFA content and fatty acid composition does not exist (Ratnayake et a l, 1998). 
GLC in combination with other techniques, particularly Ag+-TLC, IR  or mass 
spectrophotometry (MS) allows for a complete analysis o f  fatty acids and these are now 
the most commonly used methods for analysing TFA composition.
Current analytical tools are still, however, inadequate for complete analysis o f  TFA, 
mainly due to the unavailability o f  suitable reference materials particularly for minor,
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unusual cis and tram  isomers (Ratnayake and Beare-Rodgers, 1990). Certified reference 
materials (CRM) are defined as reference material whose properties are certified by a 
technically valid procedure accompanied by or traceable to other docum entation which is 
issued by a certifying body (Laboratory o f  Government Chem ists (LCG)). These 
reference materials are then used for the following four m ain purposes; calibration and 
verification o f measurement processes under routine conditions, internal quality control 
and quality assurance schemes, verification o f  the correct application o f  standardised 
methods and development and validation o f  new methods o f  analysis.
2 .2  Objectives
Due to the lack o f a certified reference material and the wide variation in methodologies 
used in TFA analysis, this study was undertaken to validate com bined Ag+-TLC and GLC 
methodology for the accurate quantification o f  TFA in vegetable oils, provided by F. 
Ulberth (Department o f  Dairy Research & Bacteriology, Agricultural University, Gregor 
Mendel-Str. 33, A-1180 Vienna). This study was undertaken in parallel w ith 11 other 
analysing laboratories with a view to making a com parison o f  data obtained by a variety 
o f  analytical methodologies including GLC, using CP SIL88 and BPX70 columns and IR 
spectrometry, ultimately with a view to harmonisation o f  m ethodology for TFA analysis. 
Only the data obtained by analysis o f  a variety o f  TFA-containing samples, by Ag+-TLC 
and GLC as performed in our laboratory are reported in this chapter. Results were 
compared with data obtained from the other laboratories. This perm itted intercomparison 
o f  results and a critical assessment o f  methodology for TFA analysis, and where 
appropriate, alterations to the Ag+-TLC and GLC m ethodology were made to improve 
accuracy.
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2.3 Materials and Methods
2.3.1 Materials
Solvents: n-hexane, n-heptane and acetonitrile (HPLC grade) were purchased from 
Labscan (Stillorgan Industrial Park, Dublin). Free fatty acids, standard FAM E and 0.25 
mm silica gel plates were purchased from Sigma (Sigma Chemical Co., St. Louis, USA). 
CRM 162 soya-maize oil blend was purchased from the Laboratory o f  the Government 
Chemist (LCG, Queens Road, Teddington, M iddelsex, UK). Trans polyene FAM E 
standards were purchased from Supelco (Supelco Inc, Bellefonte, PA). Oil and FAM E 
samples containing known levels o f  TFA where provided by F. U lberth (Department o f  
Dairy Research & Bacteriology, Agricultural University, Gregor M endel-Str. 33, A -1180 
Vienna). These included elaidinised linseed oil FAM E, a mixture o f  FAM E standards 
(Ci4;o, C i6:o, C i8:o and C i8:i), 3 soya oil samples spiked w ith approxim ately 1 %, 5 % and 
30 % methyl elaidate and trieladin, and 4 vegetable oil (soya, palm, linseed) samples 
containing varying levels o f  TFA (1 ,1 .5 , 5 and 25 % TFA).
2.3.2 Sample preparation and methylation.
FAM E standard mixtures o f  known composition were prepared freshly on each day o f 
analysis. Standards were prepared gravimetrically, approxim ately 10 m g o f  each 
standard was weighed, pooled and dissolved in n-heptane to a concentration o f  0.1 mg/ml 
each in the solvent for GLC analysis. Vegetable oils (soya, palm, linseed) o f  unknown 
composition were also analysed. On each working day, a  fresh ampoule o f  each sample 
was melted by immersion in a water bath at 45-50 °C. W hen a  clear oil was obtained, the
109
contents were mixed by repeated inversion for 30 sec, and the free fatty acids were 
converted to FAM E using base-catalysed methanolysis as described previously (ISO, 
1978). An aliquot (100 mg) o f the triglyceride mix was dissolved in 5 m l o f  n-heptane 
and added to 0.4 ml o f  2 M  methanolic KOH. This was m ixed for 1 min and allowed to 
stand for 5 min at room  temperature. Sodium sulphate (0.5 g) was then added and the 
sample was mixed for 1 min. The sample was centrifuged (Sanyo M SC M istral 2000R, 
Gallencamp PLC, Leicester, UK) at 280 x g for 5 min, and 1 fj.1 o f  the supernatant was 
used for GLC analysis.
2.3.3 Silver ion thin layer chromatography (Ag -TLC)
Prior to GLC analysis, the FAM E were separated using Ag+-TLC, according to the 
method o f Ulberth and Henninger (1992) described as follows. Initially, 0.25 m m  silica 
gel plates (Sigma) were placed in a solvent tank with 10 % (w/v) A gN 03 in  acetonitrile 
(stationary phase) for approximately 2 h to im pregnate the plates with A gN 0 3 . The 
FAME samples (100 fj.1) were applied to the plates manually using a pipette and allowed 
to develop in a mobile phase o f  hexane : diethyl ether (9:1 v/v) for approximately 3 h. 
The plates were allowed to dry at room temperature and were stained by spraying with 
0.05 % (w/v) rhodam in B in ethanol. The trans and saturated fatty acid tracks, visible 
under UV light, were scraped from the plates individually and dissolved in diethyl ether 
by frequent agitating for 30 min. The resulting extracts were dried in a stream o f N 2 and 
redissolved in hexane prior to GLC analysis. The calculation o f  the trans-monoene 
content was based on the concentration o f  C 18.0 in the pre-TLC sample and in the 
fractionated sample, using the following equation:
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mass o f  the pre-TLC C i8^  peak area o f  trans Cig:i post-TLC
_________________________  X ________________________________
total sample mass peak area o f  Cig:o post-TLC Equation 1
2.3.4 GLC analysis
Separation o f  FAM Es was performed using a Varian 3400 GLC (Varian, W alnut Creek, 
CA, USA) fitted w ith a flame ionisation detector (FID). Samples (1 (4.1) were injected 
onto the column using a splitless injector and a Varian 8035 auto-sam pler (Varian). 
Separations were performed on a Chrompack CP Sil 88 column (60 mm  x 0.25 mm  i.d., 
0.02 (am film thickness) (Chrompack, M iddleburg, The Netherlands). The N 2 carrier gas 
and H2 flow rates were 20 ml/min, and the airflow rate was 300 ml/min. The injector and 
detector temperatures were 140 °C and 250 °C, respectively. The colum n temperature 
was programmed from 140 °C with an initial delay o f  8 min followed by an increase o f
8.5 °C/min to a  final temperature o f 200 °C, which was held for 15 min. Fatty acids were 
identified by retention times with reference to standard FAME. Collected data were 
analysed on a M inichrom PC system (VG, D ata Systems, M anchester, UK).
2.3.5 Accuracy assessment
The accuracy o f  the GLC system was evaluated by performing a series o f  tests to verify 
the levels o f  decomposition (deterioration o f  sample) and degree o f  irreversible 
adsorption (sample remaining on the column) o f  saturated and m onounsaturated fatty 
acids that occurred during chromatography. Thus analysis o f  samples o f  known 
composition allowed determination o f  the degree o f  decom position and irreversible
Trans monoene content =
adsorption that occurred: composition o f  the sample following GLC was com pared with 
known data relating to that sample. This involved preparation o f  three identical test 
mixtures as described in 2.3.2 composed o f approxim ately equal quantities (10 mg) o f 
C i4:o, C 16:0s C i8:0 and Ci8:i FAM E standards and analysis was perform ed in triplicate by 
GLC. In addition, a  mixture o f  FAM E (C i4;o, C i6:o, Cig:o and Cigii) in unknown quantities 
(provided by F. Ulberth), which was prepared as described in 2.3.2 w as also analysed in 
triplicate.
Response factors
Response factors (RF), i.e. correction factors w hich compensate for the variable response 
o f the flame ionisation detector (FID) to individual fatty acids were calculated relative to 
Ci8:o and were used to convert the peak areas to mass percentages, using the following 
equation :
RF = (mj %) / (Aj %) = mj x 2Aj / Smj x Aj Equation 2
where mj is the mass o f  the individual fatty acid,
Enii is the sum o f  the masses o f  all fatty acids,
Aj is the individual area o f  the fatty acid and 
SA; is the sum o f  total areas.
Individual RFs were standardised with respect to the RF o f Ci8:o- To m aintain specified 
limits o f  accuracy, it was established that these response factors should not deviate by 
more than 0.05 from 1.0.
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2.3.6 Validation o f  méthylation procedure
The effect o f derivative formation on glyceride bound unsaturated fatty acids was 
assessed as follows. Three triglyceride samples o f  known com position (Ci6:o, Ci8;o, Ci8:i, 
C i8;2 and C i8:3) (provided by F. Ulberth) were methylated prior to GLC analysis as 
described in 2.3.2. A  further FAME sample (provided by F. Ulberth) w ith identical fatty 
acid compositions (Ciô.o, Cis.o, C 18.2 and C 18.3) to the triglyceride samples above was also 
analysed in triplicate as described in 2.3.4. It was established that the average FAME 
composition (area %) o f  the triglyceride sample should not differ by more than 0.2 % 
(absolute) from those o f  the FAM E mix.
2.3.7 Separation power
The chromatographic parameters leading to an effective separation o f  cis/trans fatty acids 
were optimised using specific mixtures o f  cis and trans fatty acids that are difficult to 
separate with conventional methods. Sample mixtures o f  equal quantities o f  13-trans 
Ci8:i, 9-cis C 18:is C20:0, all cis Cig:3 and 11 -cis C20:1 (Sigma) w ere prepared for analysis by 
GLC as described in 2.3.2. The parameters o f  the GLC program  were modified (i.e. 
ramping temperature (rate o f  temperature increase o f  the colum n and injector), detector 
temperature, flow rate, flow rate temperature and injector temperature) until 
chromatographic resolution (R) (baseline resolution) between com ponents was ns 1.
Chromatographic resolution was calculated using the following equation;
R = 2d /  (wi + w2) Equation 3
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where wi and W2 are the widths, (mm) o f the peaks for C i8:o and C i8:i, respectively, 
measured between the points o f  intersection o f  the tangents at the inflexion points o f  the 
curve with the baseline,
d is the distance (mm), between the respective peak m axim a for methyl C i8:o and methyl 
C i8:l.
To verify that these adjustments to the GLC programs were accurate for separation o f  cis 
and trans isomers, a vegetable oil containing trans was analysed to achieve similar 
resolution A sample o f  nitrous acid isomerised linseed oil (provided by F. Ulberth) was 
analysed by GLC and the R  value between 13-trans C i8:i, and 9-cis C i8:i components was 
determined. Equal quantities o f  methyl esters o f  trans-9 and cis-9 Cis:i, (Sigma) were 
also prepared as described in 2.3.2 and separated by Ag+-TLC as described in 2.3.3. The 
efficiency o f  separation by TLC was validated by analysis o f  the samples post-TLC by 
GLC.
2.3.8 Proficiency testing
The precision o f  the methodology for TFA analysis was established by verifying the 
repeatability and reproducibility o f  the A g+-TLC and GLC methodologies. Repeatability 
was assessed by examining the difference between two single results found on an 
identical test material using the same method o f  analysis w ithin a short time frame. 
Reproducibility was assessed by examining the difference between tw o operators 
working in different laboratories on an identical test material. Three oil samples and 
three FAM E samples (provided by F. Ulberth) were analysed by GLC, both before and 
after separation by A g+-TLC as described in section 2.3.2. The oil samples consisted o f
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fatty acids from soya oil in fatty acid methyl ester and triglyceride form. They had been 
spiked with approximately 1 %, 5 % and 30 % methyl elaidate and trielaidin. The 3 oil 
samples in triglyceride form were methylated prior to analysis by GLC and the 3 FAM E 
samples were analysed directly by GLC. GLC analysis prior to TLC gave the 
composition o f the samples and in particular the C i8:o content which was necessary to 
calculate the TFA content o f  the post-TLC fraction as described in section 2.3.3. All 6 
samples were then separated by Ag+-TLC to enable separation o f  the trans isomers as 
described in 2.3.3, and analysed again post TLC by GLC to quantify the TFA content.
2.3.9 Intercomparison testing
Four test materials (provided by F. Ulberth) containing different TFA levels (1, 1.5, 5 and 
25 % w/w TFA) were analysed using the combined Ag+-TLC and GLC methods for 
quantification o f  TFA content and the results were com pared w ith those from other 
laboratories involved in similar analyses, which allowed the intercom parison o f  results 
and critical assessm ent o f  the methodology employed. The sample containing 1 % TFA 
was a physically refined soya oil, the sample containing 1.5 % TFA was a physically 
refined rapeseed oil, the sample containing 5 % TFA was an oil as used for 
manufacturing margarine (primarily palm  oil) and the oil containing approxim ately 25 % 
TFA was a partially hydrogenated sunflower oil, all o f  which had previously undergone 
homogenicity and stability testing based on BCR guidelines (ISO Guide 30, 1981). The 
oils were methylated and analysed by GLC both pre- and post-TLC to determine the TFA 
content o f  the oils.
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A set o f  performance criteria, described below were established and had to be 
successfully achieved daily, prior to analysis o f  samples. Initially the perform ance o f  the 
GLC system was examined by injecting a  solution containing equal am ounts o f  the 
critical pairs trans-13/cis-9 Cig:i and cis-\ 1 C20:i/all-c/s to achieve a resolution (R) 
o f critical pairs > 1 .0 . A solution containing elaidinised linseed oil FAM E (provided by 
F. Ulberth) was analysed to determine retention times o f  /ra«.s-containing 
polyunsaturated fatty acids (single analysis) to achieve separation o f  the geometrical 
isomers o f  Cig:2 into 4 components (tt, ct, tc, cc) and Cig:3 into 6 com ponents (ttt, ctt+tct, 
ttc+cct, ctc, tcc, ccc). These trans polyenes were identified using trans polyene FAME 
standards. A  FAM E solution obtained by methylation o f  CRM 162 (LCG) was analysed 
to determine accuracy o f quantification. The average concentration o f  individual FAME 
(y) in CRM 162 following analysis m ust be within the range outlined in  BCR guidelines 
(Table 2.1) for sufficient accuracy o f the GLC system. Composition o f  the sample must 
be within the following range for the GLC system to be accurate,
(certified value - 2 SD) < y < (certified value +  2 SD) 
where y is the individual fatty acid following analysis by GLC,
the certified value is the concentration o f  that fatty acid present according to the BCR 
guidelines.
SD is the standard deviation (Table 2.1).
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Table 2.1 BCR guidelines for quantification of CRM 162.
(soya/maize oil blend)
FAME Certified mean 
% total lipids
Standard deviation Range
% total lipids
C l 6:0 10.65 0.279 10.09-11 .21
C l 8:0 2.87 0.123 2 .6 3 -3 .1 1
Ci8:i 24.14 0.392 23.36 - 24.92
C i8:2 56.66 0.760 55 .1 4 -5 8 .1 8
Cl8:3 4.68 0.309 4.06 - 5.30
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2.4 Results
2.4.1 Assessment o f  accuracy o f  GLC methodology for FAME analysis 
Mixtures o f  FAM E o f  known concentrations were analysed by GLC to determine i f  
decomposition or irreversible adsorption onto the GLC colum n occurred which would 
lead to inaccurate results. Three identical test mixtures were prepared, as described in 
section 2.3.2, composed o f  approximately equal quantities (10 mg) o f  C i4:o, C i6:o, C i8:o 
and C i8:i FAM E standards and analysis was performed in triplicate by GLC. The 
performance criteria for this analysis recommended that response factors (relative to 
C i8;o) should not differ by more than 0.05 from 1.0 as described in section 2.3.5. The 
FAME mixture contained between 22 and 28 % o f the fatty acids C i4:o, C i6:o, Cis:o and 
C i8:i (Table 2.2) which, when analysed by GLC, produced peak areas corresponding to 
the concentration o f  the individual FAME in the samples. The % peak areas for 
individual FAME (Table 2.2) corresponded closely to the known %  mass o f  the fatty 
acids suggesting that decomposition and irreversible adsorption did not occur. This 
conclusion was supported by calculation o f  the relative RF values as described in section 
2.3.5. The RF values for each o f  the individual fatty acids were between 0.95 and 1.05 
(Table 2 .2 ) and therefore fulfilled the required performance criteria, which required that 
this value should not deviate from unity by ± 0.05.
The FAME sample o f  unknown com position was also analysed by GLC, and the 
composition by area is reported in Table 2.3.
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Table 2.2 GLC compositional analysis of a FAME standard mixture (Ci4:o, Ci6:o, Ci8:oand Cig;i )*.
FAME Mass (g) M ass (%) A rea (counts) Area (%) RF Relative RF
Ci4:0 0.010 ± 0.003 26.54 ± 3.79 7035694 ±  136567 25.32 ±  4.04 1.05 ± 0 .02 1.05 ± 0 .02
C l 6:0 0.009 ± 0.001 22.87 ± 2.74 6669243 ± 899979 24.03 ±  2.68 0.95 ± 0.01 0.95 ±  0.00
C l 8:0 0 .0 11  ± 0.002 28.24 ±  0.64 7827426 ±490155 28.23 ± 0.57 1.00  ± 0.00 1.00  ± 0.00
C i8:l(*9) 0.009 ± 0.002 22.35 ± 0.80 6224554 ± 578919 22.43 ±1.13 1.00  ± 0.02 1.00 ± 0 .03
*(Data represent the mean ± SD o f triplicate analyses)
Table 2.3 Quantification of FAME in an unknown mixture (provided by F. Ulberth)*.
FAM E Area (counts) A rea (%)
Cl4:0 4 78 1 1 9 8  +  139428 2 2 .7 6  ± 1 .0 2
C l 6:0 5 6 4 6 7 2 4  +  247213 26 .89  ± 2 .7 1
Ci8:0 5207 3 1 6  +  401251 2 4 .80  ± 1 .5 0
C i8 :i(f9 ) 5 3 6 5 5 5 9  ± 99802 25.55  ± 0 .1 3
*(D ata represent the m ean ±  SD  o f  triplicate analyses)
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A s the % m ass o f  the individual fatty acids in th is sam ple w as unknow n, RF values could  
not be calculated. T he com position  by area o f  the F A M E  sam ple w as sim ilar to that o f  
the previous standard m ixture suggesting that the RF va lues m ay a lso  be sim ilar.
2.4.2 Val idation of méthylation procedure
Three triglyceride sam ples o f  know n com position  (Ci6.o, C i8:o, C i8:i, C i8:2 and Cis:3) w ere  
m ethylated and analysed by GLC using the procedures outlined  in sections 2 .3 .2  and
2 .3 .4  and the results presented in Table 2.4. A  further preform ed F A M E  sam ple w ith  
identical fatty acid  com position  (Ci6:o, Ci8:o, C i8:i, C is:2 and C is s )  to  the triglyceride  
sam ples above w as also  analysed by GLC and the results presented in  T able 2 .5 . The 
perform ance criteria for this analysis recom m ended that the average FA M E  com position  
(area %) o f  the triglyceride sam ples (Table 2 .4 ) should not d iffer by m ore than 0.2 % 
(absolute) from those o f  the preform ed FAM E m ix  (Table 2 .5 ). T ables 2 .4  and 2 .5  report 
the com position  by w eigh t o f  the individual fatty acids in  each  sam ple and the 
com position  by area as determ ined by GLC. U sin g  these data, the RF and relative RF 
values w ere calculated (as described in section  2 .3 .5 ) for the triglycerides m ethylated in 
the laboratory and the pre-form ed FA M E. It w as clear that the acceptance criteria w ere  
not fu lfilled  in th is section, as the difference betw een  the % area va lues obtained for Ci6:o, 
for preform ed F A M E  (Table 2 .5 ) and the sam ples m ethylated  in  the laboratory (Table 
2 .4 ) w as greater than 0.2 %. H ow ever, criteria w ere fu lfilled  for the other fatty acids 
analysed Cis:o, C i8:i, C is:2 and C i8:3 as values obtained for the % area for preform ed  
FAM E (Table 2 .5 ) and the sam ples m ethylated in the laboratory did not differ by  m ore 
than 0 .2  % (Table 2 .4).
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Table 2.4 GLC compositional analysis of a triglyceride sample (Ci6:o, Ci8:o, Ci8:i, Ci8:2
and Ci8:3) (provided by F. Ulberth)*.
FAM E Area (counts) A rea (%) RF R elative RF
C i 6:0 3 6 2 7 1 4 6 +  103980 2 1 .26  ± 0 .0 6 0 .94  ±  0 .00 0 .95  ±  0.01
Cl 8:0 335 4 7 0 6  ± 4 8 5 2 4 19.67 ± 0 .2 3 1.02 ± 0 .0 1 1.03 ± 0 .0 2
Ci8:l 3 4 3 9 4 6 6  ±  124501 20 .16  ± 0 .2 3 0 .9 9  ± 0 .0 1 1.00 ± 0 .0 0
Ci 8:2 3 3 6 5 1 7 9 ± 112612 19.72 ± 0 .1 7 1.01 ± 0 .0 1 1.02 ± 0 .0 1
C i8 :3 3272151  ± 5 7 5 5 4 19.18 ± 0 .1 7 1.04 ± 0 .0 1 1.05 ± 0 .0 2
*(Data represent the m ean ±  SD  o f  triplicate analyses)
Table 2.5 GLC com positional analysis o f  a preform ed F A M E  standard sam ple (C i6:o, 
C 18.0, Ci8:i, C i8.2and Ci8:3) (provided by F. U lberth)*.
FAM E Area (counts) Area (%) RF R elative RF
Ci6:0 5375 1 5 9  ± 2 3 0 4 7 1 20.93 ±  0.02 0 .9 6  ± 0 .0 1 0 .97  ± 0 .0 1
O OO O 5 034423  ± 2 1 1 0 8 7 19.60 ± 0 .1 6 1.02 ± 0 .0 2 1.04 ± 0 .0 0
C i 8:l 5 22 9 8 2 4  ±  143775 2 0 .37  ± 0 .4 1 0 .9 9  ± 0 .0 1 1.00 ± 0 .0 2
Cl8:2 5099931 ± 2 1 3 1 5 1 19.86 ± 0 .2 2 1.00 ± 0 .0 0 1.03 ± 0 .0 1
C i8 :3 494 0 4 8 5  ± 5 1 4 8 3 2 19.24 ± 0 .1 1 1.04 ± 0 .0 0 1.06 ± 0 .0 1
*(D ata represent the m ean ±  SD  o f  triplicate analyses)
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The chrom atographic parameters leading to an effec tive  separation o f  cis/trans fatty acids 
w ere optim ised. Sam ple m ixtures o f  equal quantities o f  13-trans C i8:i, 9 -cis C i8:i, C20.0, 
all cis Ci 8:3 and 11 -cis C20:i (S igm a) w ere analysed b y  GLC and the results presented in  
Table 2.6 . The com position  b y  w eigh t o f  these isom ers ranged from  18.43 % to 21.61 %. 
The retention tim es and peak base w idth o f  the individual FA M E  in  the sam ples w ere  
obtained from the chrom atograph (Figure 2 .1 ) and are reported in Table 2 .6 . T hese  
values w ere required for calculation  o f  chrom atographic reso lu tion  (R) b etw een  the pairs 
13-trans C\%,\l9-cis C i8:i and all cis C i8:3/ l l - c w  C2o:i as described  in  section  2 .3 .7 . The 
predefined criteria for this separation w as a chrom atographic resolution  b etw een  the pairs 
o f  at least 1.00. The chrom atographic resolution w as acceptable, b eing  2 .2 6  for 13-trans 
Ci8:i/9-cw C 18:1 and 4 .7 0  for all cis C ¡8:3/ 11 C2o.i-
A  sam ple o f  nitrous acid isom erised  linseed  o il w as analysed  b y  G LC and the resolution  
o f  the pairs 13-trans C\%-\/9-cis Cig:i w ith in  the o il w as calculated from  the 
chromatograph (Figure 2 .2 ). T his value (2 .14 ) b eing  >  1.00, dem onstrated that effic ien t  
separation w as ach ieved  for these pairs in  the presence o f  other fatty acids in the o il 
sam ple. The effic ien cy  o f  separation by A g +-TLC w as exam ined  by separation o f  equal 
quantities o f  m ethyl esters o f  trans-9 and cis-9 C i8:i (S igm a) by  A g +-TLC and subsequent 
analysis o f  the cis and trans fractions by GLC. The cis and trans isom ers w ere effic ien tly  
separated as seen  from the chrom atograph (Figure 2.3 a, b), as there w as no cross 
contam ination in  either fraction (i.e . no cis peak in the trans fraction or vice versa).
2.4.3 Separation power
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T a b le  2 .6  Data from  chrom atograph (Figure 2 .1 ) representing GLC an alysis o f  a FA M E  
sam ple ( 13-trans Ci8:i, 9-cis Cig.-i, C20:0> all cis C 18.3 and 11 -cis C20.1) w h ich  is  used  to  
calculate the separation power.*
FAM E M ass (g) M ass (%) R etention  tim e  
(m in)
Peak base  
w id th  (m in)
13-trans Ci8;i 0.009 + 0.01 18.43 ±2.12 19.48 ±0.002 0.17 ±0.00
9-cis Cl8:1 0.001 ±0.01 19.99 ±1.02 19.70 ±0.001 0.14 ±0.01
C20:0 0.010 ±0.06 19.68 ±0.021 22.00 ± 0.002 0.19 ±0.02
all-CW’ Cl8:3 0.011 ±0.02 21.61 ±1.79 22.69 ±0.001 0.19 ±0.01
ll-CiS C20:l 0.010±0.11 20.25 ±1.22 23.20 ±0.010 0.19 ±0.00
*(Data represent the m ean ±  SD  o f  triplicate analyses)
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Figure 2.1 Separation o f  critical pairs 13-trans/9-cis Cig:i, a ll cis Cwz/ll-cis  C20:i 
R esolution  o f  13-tram Cu.i/9-cis Cig.i =  2 .26 . R esolu tion  o f  a ll-cw  C is:3 / l  1 -cis C20:i =  
4.70.
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Figure 2.2  Separation o f  isom erised  linseed  o il by GLC. R eso lu tion  o f  13-trans Ci8:i/9- 
Cis Ci8:l = 2.14.
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F igu re 2.3 Separation Power o f  A g +-TLC. GLC analysis fo llo w in g  A g +-TLC (a) cis-9 
Ci8:i and (b) trans-9  C is i-
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The precision  o f  the m ethodology for TFA  analysis w as established  b y  ver ify ing  the 
repeatability and reproducibility o f  the A g +-TLC and GLC m ethods. Three o il sam ples 
spiked w ith  trielaidin and three FA M E  sam ples spiked w ith  m ethyl elaidate containing  
variable T FA  contents w ere analysed by GLC, both prior to and fo llo w in g  separation by  
A g+-TLC and the results presented in  Tables 2 .7 - 2 .1 2 .  T he criteria established  to assess  
precision o f  the m eth odology  w as a recovery rate o f  T FA  in e x c ess  o f  90  % fo llow in g  
separation by  A g +-TLC; repeatability and reproducibility w ere assessed  by  fu lfillin g  the 
precision  criteria for triplicate analysis o f  sam ples on  three separate days. T he fatty acid  
com position  o f  the soya  o il sam ple spiked w ith  approxim ately 1 % m ethyl elaidate as 
m easured by  GLC, pre- and p ost-A g+-TLC are presented in  T able 2 .7 . U sin g  these data 
the quantity o f  T FA  present in the o il w as calculated relative to  C i8:o (using  equation 1 in  
section  2 .3 .3 ) and w as found to be 1.16 % and 1.1 % for pre and p o st A g +-TLC analysis, 
respectively. This represented a 95 % recovery o f  TFA , (post A g +-TLC com pared w ith  
pre A g +-TLC) and therefore m et the perform ance criteria for precision  analysis o f  this 
sample.
The fatty acid com position  o f  the soya o il sam ple spiked w ith  approxim ately 5 % m ethyl 
elaidate as m easured by  GLC, pre- and p ost-A g+-TLC are presented in T able 2 .8 . U sin g  
these data the quantity o f  TFA  present in the o il w as calculated  relative to  C is:o (using  
equation 1 in section  2 .3 .3 ) and w as found to  be 4.91 % and 4 .65  % for pre- and post- 
A g+-TLC analyses, respectively. T his also represented a  95 % recovery o f  TFA  and 
therefore m et the perform ance criteria for precision  analysis o f  th is sam ple. Figure 2 .4  
represents a chrom atogram  o f  the sam ple (a) pre TLC and (b) p ost TLC.
2.4.4 Proficiency testing
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Table 2.7 Determination o f  TFA content o f  FAM E sample containing ca. 1 % methyl
elaidate by GLC analysis pre and post Ag+-TLC.*
FA M E A rea (counts) 
Pre-TLC
Area (%) 
Pre-TLC
A rea (counts) 
Post-TL C
A rea (%) 
Post-TLC
pvO
U
3 7 4 0 0 6 +  10231 8.88 ± 0 .0 2 4 5 2 3 3 4 .6  ±  13554 62 .48  ± 2 .1 2
Ci6:l 3 7 5 5 ± 101 0.09  ± 0 .0 1 0 0
Ci8;0 192910.6  ±  11320 4 .58  ± 0 .1 5 2 1 9 0 0 8 .8  ± 2 0 1 7 2 30 .25  ± 1 .2 6
trans C i8:i(n-9) 48708 .13  ± 1 1 2 0 1 1.16 ±  0.13 5 2 6 1 6 .7 5  ± 5 1 5 4 7 .27  ± 3 .0 4
cis Ci8;i (total isom ers) 8 3 9057  ± 1 1 2 4 6 19.92 ± 0 .2 7 0 0
Ci 8:2 (total isom ers) 2 3 7 0 3 6 9  ±  32278 56.28  ± 0 .0 2 0 0
C i8;3 (total isom ers) 33 9 7 0 8 .4  ±  3 9947 8.07 ± 0 .8 4 0 0
C20:0 18242.63 ±  12188 0.43 ± 0 .0 1 0 0
C20:l 6398 .875  ± 6 2 1 4 7 0 .16  ± 0 .0 1 0 0
C22:0 18305.25  ± 4 5 9 3 6 0.43 ±  0 .02 0 0
Total 4 2 1 1 4 6 0  ± 3 6 2 0 8 5 100 723960 .1  ± 3 9 4 8 1 100
*(Data represent the m ean ±  SD  o f  triplicate analyses)
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Table 2.8 Determination o f  TFA content o f  FAME sample containing ca. 5 % methyl
elaidate by GLC analysis pre and post Ag+-TLC.*
FAM E Area (counts) 
Pre-TLC
Area (%) 
Pre-TLC
Area (counts) 
Post-TL C
Area (%) 
Post-TL C
Ci6:0 3 4 6 0 1 3 .4  ±  15039 8.51 ±  1.02 2 9 4 7 1 7 .5  ± 2 1 9 4 7 47.61 ± 2 .3 1
Ci6:l 3 322 .75  ±  1021 0.08 ± 1 .1 1 0 0
Ci8:0 181357.7  ±  11592 4 .46  ±  1.03 1 5 8 7 3 0 ± 10711 2 5 .6 4  ± 0 .0 0 2
trans Ci8:i(n -9) 199879.5  ±  12031 4.91 ±  1.54 165618.1 ± 2 0 4 5 26 .75  ±  1.07
cis C i 8:i (total isom ers) 7 7 9103 .8  ±  36251 19.15 ±  1.22 0 0
C is:2 (total isom ers) 2 2 0 2 5 2 1 ± 109921 54.15 ± 0 .0 2 0 0
C i8:3 (total isom ers) 3 1 5805 .8  ± 11251 7 .76  ± 1 .2 5 0 0
C20:0 1 6 1 1 1 ± 1054 0 .40  ± 0 .0 1 0 0
C20.I 6673 ± 2 1 0 3 0 .16  ± 0 .0 5 0 0
C22:0 16936.13 ±  1044 0.41 ±  0 .00 0 0
Total 4067723  ± 3 3 1 2 4 5 100 6 1 9 0 6 5 .6  ± 3 2 5 7 9 100
*(Data represent the m ean ±  S D  o f  triplicate analyses)
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F ig u re  2 .4  Chromatograms o f  FAM E spiked w ith  5 % m ethyl elaidate (a) pre TLC and 
(b) post TLC.
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Sim ilarly the soya  o il sam ple spiked w ith  approxim ately 25  % m ethyl elaidate w as  
m easured by GLC, pre- and p ost-A g+-TLC and the com position  o f  the o il is  presented in  
Table 2.9. The TFA  present in  the o il w as found to be 2 3 .4  % and 2 2 .2 6  % for pre- and 
p ost-A g+-TLC analyses, respectively , again representing a 95 % recovery  o f  T FA  in the 
sam ple. Figures 2 .5a  and b sh ow  pre and post TLC chrom atogram s respectively , for the 
FA M E sam ple spiked w ith  25 % elaidate.
In addition the analysis o f  soya  o il spiked w ith  1 %, 5 % and 30  % trielaidin w ere 
analysed by GLC, pre and post-T L C  and the results are presented in  T ables 2 .1 0 -2 .1 2 . 
The purpose o f  this w ork w as to com pare the precision  o f  an alyses o f  the preform ed  
FA M E  above w ith  that o f  o il sam ples that w ere m ethylated in the laboratory prior to  
analysis u sing  equation 1 in section  2 .3 .3 . The fatty acid  com p osition  o f  the soya o il 
sam ple spiked w ith approxim ately 1 % trielaidin as m easured b y  G LC , pre- and post- 
A g+-TLC is presented in  Table 2 .10 . U sin g  this data the quantity o f  T FA  present in the  
o il w as calculated relative to C ig;o and w as found to be 1.21 % and 1.13 % for pre- and  
p ost-A g+-TLC analysis, respectively . This represents a 93 % recovery rate o f  TFA  and  
therefore fu lfills  the perform ance criteria. It is  slightly  low er than seen  previously  and  
m ay be a result o f  experim ental error, arising from  loss occurring during scraping o f  the  
trans band from  the TLC plate.
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Table 2.9 Determination o f  TFA content o f  FAME sample containing ca. 25 % methyl
elaidate by GLC analysis pre and post Ag+-TLC.*
FA M E A rea (counts) 
Pre-TLC
Area (%) 
Pre-TLC
A rea (counts) 
Post-TLC
A rea (%) 
Post-TLC
Ci6:0 172898.3  ±  102214 7 .08  ± 0 .1 8 3 7 7 3 1 0 .8  ± 5 5 4 6 9 1 2 1 .4 4  ± 1 .2 3
Ci6:l 20 8 0 .7 5  ±  328 0 .09  ± 0 .0 1 0 0
p 00 o 9 1 418 .88  ± 5 0 4 1 3 .74  ± 0 .2 1 195151 .8  ± 3 0 9 4 4 11.09 ± 5 .0 7
trans Ci8:i(n-9) 5 7 1 7 2 4  ± 4 3 7 9 2 3 .40  ± 0 .7 1 1187132  ± 4 8 7 1 5 6 7 .47  ± 2 .0 1
cis C i 8:i (total isom ers) 3 8 1 7 9 9 .8  ±  10874 15.63 ± 0 .5 8 0 0
Ci 8:2 (total isom ers) 1051908  ± 4 5 6 9 2 4 3 .0 6  ± 2 .3 5 0 0
C i8:3 (total isom ers) 150007 .6  ± 4 1 8 2 6 .14  ±  1.08 0 0
C20:0 8153 .75  ±  1023 0 .34  ±  1.11 0 0
C20:l 4 0 1 5 .7 5  ± 5 4 6 0 .16  ± 0 .0 2 0 0
C22:0 9001 .25  ± 9 6 4 0 .37  ± 0 .0 1 0 0
Total 2 4 4 3 0 0 8  ± 5 1 9 7 2 100 1 759595  ±  129011 100
*(D ata represent the m ean ±  S D  o f  triplicate analyses)
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F ig u re  2 .5  Chromatograms o f  FA M E spiked w ith 25 % m ethyl elaidate (a) pre TLC and 
(b) post TLC.
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Table 2.10 Determination of TFA content of FAME sample containing ca. 1 % trielaidin
by GLC analysis pre and post Ag+-TLC.*
FAM E Area (counts) 
Pre-TLC
A rea (%) 
Pre-TLC
Area (counts) 
Post-TLC
Area (%) 
Post-TLC
Ci6:0 3 7 4133 .3  ± 3 6 2 0 1 4 9 .03  ±  2.01 2 8 9 9 6 6 .8  ±  34561 67.71 ± 2 .1 1
Ci6:l 43 2 6 .7 5  ± 1 0 2 3 0 .10  ± 0 .0 2 0 0
Ci8:0 192658 .6  ± 3 7 2 5 1 4 .65  ±  1.02 111247.5  ±  11021 25 .98  ±  1.03
trans C ig:i(n-9) 50351 .13  ± 4 1 2 3 9 1.21 ± 0 .0 1 27 0 3 1 .2 5  ± 1 2 0 5 6.31 ± 0 .0 2
cis Ci8:i (total isom ers) 827941 .5  ± 4 1 2 3 6 19.98 ± 0 .1 1 0 0
Ci 8:2 (total isom ers) 2 3 2 1 0 0 6  ± 8 1 2 0 5 4 55 .99  ± 0 .1 2 0 0
C i8:3 (total isom ers) 3 2 9 4 3 3 .4  ± 3 5 4 7 1 2 7 .95  ±  0 .23 0 0
C20.0 19484.63  ±  102531 0 .4 7  ± 0 .1 7 0 0
C20:l 6520 .5  ±  1024 0.16  ± 0 .0 1 0 0
C22:0 18947.75  ± 1 1 0 5 4 0 .46  ± 0 .1 2 0 0
Total 414 4 8 0 3  ± 5 4 2 1 8 2 100 4 2 8 2 4 5 .5  ±  142897 100
*(D ata represent the m ean ±  S D  o f  triplicate analyses)
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The fatty acid com position  o f  the soya o il sam ple sp iked w ith  approxim ately 5 % 
trielaidin as m easured by G LC, pre- and p ost-A g+-TLC is  presented  in  Table 2 .11 . U sin g  
these data the quantity o f  TFA  present in the o il w as calcu lated  relative to  C ig:o (using  
equation 1 in section  2 .3 .3 ) and w as found to be 5 .25 % and 5 .1 2  % for pre- and post- 
A g+-TLC analysis, respectively. This represented a 97  % recovery o f  T FA  and therefore 
fu lfills  the perform ance criteria. Figures 2 .6 a  and b represent chrom atogram s o f  this 
sam ple pre and p ost-A g+-TLC.
Sim ilarly the soya  o il sam ple spiked w ith  approxim ately 30  % trielaidin  w as m easured by  
GLC, pre and post A g +-TLC and the com position  o f  the o il is  presented in  Table 2 .12 . 
The TFA  present in the o il w as found to be 30.71 % and 2 7 .3 4  % for pre- and p ost-A g+- 
TLC analysis, respectively, representing a 90 % recovery o f  T F A  in  the sam ple. Figures 
2 .7a  and b represent the pre and p ost-A g+-TLC chrom atogram s for the FA M E  sam ple  
spiked w ith 30 % trielaidin. The criteria for precision  analysis w as fu lfilled  for all the 
sam ples w ith in  this section, and the repeatability and reproducibility o f  the m ethod w as  
verified  by the lo w  SD  values for triplicate analysis on  three separate days for each  
sample.
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Table 2.11 Determination of TFA content of FAME sample containing ca. 5 % trielaidin
by GLC analysis pre and post Ag+-TLC.*
FAM E Area (counts) 
Pre-TLC
A rea (%) 
Pre-TLC
A rea (counts) 
Post-TL C
A rea (%) 
Post-TLC
Ci6:0 3 1 8 2 8 2 .4  ± 2 1 3 0 1 8 .59  ± 0 .1 2 2 6 9 1 7 8 ± 11203 4 7 .9 6  ± 4 .1 2
Ci6:l 3650 .5  ± 1 3 2 0 .1 0  ± 0 .0 1 0 0
Ci8:0 164543.8  ±  1049 4 .4 4  ±  0 .04 13 5640 .4  ± 5 2 1 3 6 24 .17  ± 3 .7 0
tram Cig:i(n -9) 194350.8  ± 3 0 1 2 4 5 .25  ± 2 .0 6 156446.1 ± 2 3 8 8 2 2 7 .87  ± 0 .1 2
cis Ci 8:i (total isom ers) 707686.1  ± 4 1 0 2 19.10 ±  1.20 0 0
Ci 8:2 (total isom ers) 1990910 ± 5 2 1 4 3 53.75  ±  1.39 0 0
C i8:3 (total isom ers) 2 8 3267 .3  ±  15764 7.65 ±  1.22 0 0
C20:0 17903.63 ±  10244 0.48  ± 0 .04 0 0
C20:l 5969 .375  ±  112 0.16  ± 0 .0 1 0 0
C22:0 17719.13 ± 1 5 4 2 0 .48  ± 0 .0 1 0 0
Total 3704293  ± 5 0 1 6 2 100 5 6 1264 .5  ± 2 6 3 1 4 100
*(D ata represent the m ean ±  S D  o f  triplicate analyses)
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Table 2.12 Determination of TFA content of FAME sample containing ca. 30 %
trielaidin by GLC analysis pre and post Ag+-TLC.*
FAM E A rea (counts) 
Pre-TLC
Area (%) 
Pre-TLC
A rea (counts) 
Post-T L C
Area (%) 
Post-TLC
Ci6:0 113467.5  ±  1157 6 .47  ±  0 .75 2 4 5 4 5 2 .8  ± 3 0 4 1 7 17.65 ±  1.47
Ci6:l 1662.125 +  102 0 .0 9  ± 0 .0 0 0 0
Cl8:0 58299.5  ±  1064 3 .32  ±  0.11 107902 .5  ± 11012 7 .76  ±  0 .94
trans Cig:i(n -9) 538761.3  ±  2 1 3 4 4 30.71 ± 0 .0 2 1037611 ± 7 1 1 2 1 74 .60  ±  2 .69
cis Ci g;i (total isom ers) 247164.1  ±  26311 14.09 ±  1.22 0 0
C i8.-2 (total isom ers) 6 8 1634 .9  ±  52413 3 8 .86  ±  2.11 0 0
C i 8:3 (total isom ers) 97250 .38  ±  1152 5 .54  ± 0 .3 1 0 0
C20:0 6380.5  ±  1024 0 .36  ±  0 .02 0 0
O Si p 2699  ±  374 0.15 ± 0 .0 4 0 0
C22:0 6804 .75  ±  125 0 .3 9  ± 0 .0 3 0 0
Total 1754124 ±  10821 100 1390966  ± 2 1 3 6 5 100
*(Data represent the m ean ±  SD  o f  triplicate analyses)
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F igu re 2 .7  Chrom atogram s o f  FAM E spiked with 30  % trielaidin (a) pre T L C  and (b) 
post TLC.
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A n intercom parison study w as perform ed to analyse a  num ber o f  sam ples using the 
m ethodology and conditions described above. O ils contain ing 1 % and 1.5 % T FA  w ere  
analysed by GLC on ly , w h ile  o ils  containing 5 % and 25 % T F A  w ere analysed  pre-and  
post A g+-TLC b y  GLC. A  series o f  perform ance criteria outlined  in  section  2 .3 .9  w ere  
m et prior to analysis o f  each sam ple. M inor trans isom ers o f  C ig:2 and Cis:3, in  addition  
to Ci8:i w ere analysed  as described in section  2 .3 .9  and the results for each  o il, analysed  
in triplicate on  tw o  separate days, are sum m arised and presented as a  series o f  tables 
(2 .13-2 .20).
The sam ple containing 1 % TFA , a physica lly  refined soya  o il, w as analysed  by  GLC for 
TFA content and the results are presented in  Table 2 .13 . The trans content o f  C is i w as  
found to be 0.11 % o f  total TFA, w ith  trans C i8:2 content ranging b etw een  0 .5 6  and 0.62  
% of total TFA w h ich  consisted  m ainly o f  the individual com ponents c, t and t, c C i8:2 
(Table 2 .13). T he trans C is:3 w as found to  be 1 % o f  total T FA , w h ich  con sisted  m ainly  
o f  t , t ,c  + c, c, t and t, c, c C is:3 and the total T FA  for this sam ple w as found to  be 1.7 % 
(Table 2 .13). Certain perform ance criteria (as described in  2 .3 .9 ) w ere fu lfilled  prior to 
analysis o f  the sam ple, the average concentration o f  individual FA M E  in C R M  162 
(Table 2 .1 4 ) fo llo w in g  analysis w as w ith in  the range outlined in  B C R  gu id elin es (Table  
2 .1).
2.4.5 Intercomparison testing
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Table 2.13 TFA analysis of a physically refined soya oil containing approximately 1 %
TFA.*
TFA Day I Day II
Area (%) Area (%)
trans Cig:i (total isom ers) 0.11 ± 0 .0 3 3 0 .10  ± 0 .0 2 1
t,t C18:2 0.01 ± 0 .0 1 2 0.01 ± 0 .0 0 1
c9, t 13 C l8:2 0 .00 0 .00
c, t Cj 8:2 0 .30  ± 0 .0 1 5 0 .34  ± 0 .0 1 9
t, C Ci8;2 0 .24  ±  0 .002 0 .26  ± 0 .0 1 0
other Ci 8:2 isom ers 0.01 ± 0 .0 0 3 0.01 ± 0 .0 0 1
t,t,t Ci8:3 0 .00 0 .00
C,t,t + t,C,t Ci8:3 0 .04  ±  0 .003 0 .04  ±  0 .007
t,t,C + C,C,t Ci8:3 0.48 ±  0 .005 0 .49  ±  0 .004
C,t,C Ci8:3 0 .00 0 .00
t,C,C Ci8:3 0 .42  ±  0.001 0.42 ±  0 .004
other C i8:3 isom ers 0 .04  ± 0 .0 1 1 0 .06  ±  0 .002
trans Cig:i (total isom ers) 0.11 ± 0 .0 3 3 0 .10  ± 0 .0 2 1
trans C i8:2 (total isom ers) 0 .56  ±  0 .030 0 .62  ±  0 .029
trans C i8:3 (total isom ers) 0 .98  ± 0 .0 1 8 1.01 ± 0 .0 1 8
total trans isom ers 1.65 ± 0 .0 0 1 1.73 ± 0 .0 0 2
*(Data represent the mean ± SD of triplicate analyses performed on separate days)
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T a b le  2 .1 4  Perform ance criteria for intercom parison study. A n a lysis  o f  C R M  162 and 
trans-\3/cis-9 Ci8:i and a\\-cis C u j/c w -I  1 C20:i for 1 % and 1.5 % T F A  sam ples.*
CRM 162 
(Individual FAME)
Day I 
% total fatty acids
Day II 
% total fatty acids
Mean
Cl 6:0 10.21 ± 0 .1 2 10.05 ±  0 .04 10.13 ± 0 .1 1 3
Cl 8:0 2.95 ± 0 .1 2 2 .8 7  ± 0 .1 4 2.91 ± 0 .0 5 6 9
Ci8:l 24 .9  ±  0 .02 2 4 .7 2  ± 0 .1 1 24 .81  ± 0 .1 2 7
Ci8:2 56.5 ± 0 .1 7 56.61 ± 0 .1 2 5 6 .5 6  ±  0 .0 7 7
Ci8:3 4 .17  ± 0 .1 2 4 .18  ± 0 .1 7 4 .1 8  ± 0 .0 0 5 6
RESOLUTION (R) Retention time Peak base width
(min) (mm)
Cis:i trans 13 18.93 ± 0 .0 0 3 .1 2  ± 0 .0 1
Cl8:1 cis 9 19.04 ± 0 .0 1 3 .2 0  ±  0 .02
R 1.02 ± 0 .0 1
all CÌS Cl8:3 2 2 .6 4  ±  0 .00 5 .3 0  ± 0 .0 1
C20:1 CÌS 11 2 2 .3 4  ±  0 .00 5 .1 0  ± 0 .0 0
R 1.42 ± 0 .0 1
*(D ata represent the m ean ±  SD  o f  triplicate analyses perform ed on  separate days)
143
A n  R  value ranging from  1.02 to 1.42 (Table 2 .1 4 ) betw een  critical pairs trans-Yilcis-9 
Cis:i and dXl-cis C i8:3 Ids- 11 C20:1 w as achieved fu lfillin g  the perform ance criteria.
The sam ple containing 1.5 % T FA , a physica lly  refined rapeseed  o il, w as analysed by  
GLC for T F A  content and the results are presented in T able 2 .15 . T he trans content o f  
C 18:1 w as found to be 0 .0 8 -0 .1 0  % o f  total TFA , w ith  trans C i8:2 content ranging betw een  
0 .16  and 0 .20  % o f  total T FA  w h ich  consisted  m ain ly  o f  the ind ividual com ponents c, t 
and t, c C i8:2 (Table 2 .15). The trans Cig;3 w as found to be 0 .6 4 -0 .6 7  % o f  total TFA, 
w hich  consisted  m ainly o f  t , t ,c  + c, c, t and t, c, c C i8:3 and the total T F A  for this sam ple  
w as found to range from  0 .8 8 -0 .9 7  % (Table 2 .15). The perform ance criteria (as 
described in  section  2 .3 .9 ) w ere fu lfilled  prior to analysis o f  the sam ple, as this sam ple  
w as analysed on  the sam e day as the sam ple spiked w ith  1 % T FA  the perform ance 
criteria for both sam ples w as the sam e (Table 2 .14).
The sam ple containing 5 % T FA , an o il as used  for m anufacturing m argarine (primarily 
palm  o il), w as analysed pre and post TLC by GLC in triplicate on  tw o  separate days 
(Table 2 .16 ). The trans content pre-TLC o f  C i8:i w as found to be 4 .2 -4 .3  % o f  total TFA, 
w ith trans C i8:2 content ranging betw een  2.41 and 2 .68  % o f  total T F A  w h ich  consisted  
m ainly o f  the individual com ponents c, t and t, c C ig:2 (Table 2 .16).
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Table 2.15 TFA analysis of a physically refined rapeseed oil containing approximately
1.5 % TFA.*
TFA D ay I D ay  II
A rea (%) A rea (%)
trans Ci8:i (total isom ers) 0 .10  ± 0 .0 0 2 0 .08  ±  0 .0 0 2
t,t Ci 8;2 0 .04  ±  0.001 0.01 ± 0 .0 0 1
c9, /1 3  C 18.2 0 .00 0 .0 0
C, t  Ci8:2 0 .08  ± 0 .0 0 1 0 .0 9  ±  0 .003
U C C j  8:2 0 .06  ±  0 .000 0.05 ±  0.001
other C i8:2 isom ers 0 .02  ±  0.001 0.01 ±  0 .0 0 0
t,t,t C i 8.3 0 .00 0 .00
C,t,t + t,C,t Ci8:3 0.01 ±  0 .002 0.01 ± 0 .0 0 4
t,t,C + C,C,t Ci8:3 0.31 ± 0 .0 3 2 0.31 ± 0 .0 1 0
C,t,C C i8 :3 0 .00 0 .00
t,C,C Ci8:3 0.25 ± 0 .0 1 2 0.25  ± 0 .0 2 1
other C i8:3 isom ers 0 .10  ± 0 .0 0 1 0 .0 7  ±  0 .0 0 2
trans Ci8:i (total isom ers) 0 .10  ± 0 .0 0 0 0.08  ± 0 .0 0 1
trans C i8:2 (total isom ers) 0 .20  ±  0.001 0 .1 6  ± 0 .0 3 1
trans C i8:3 (total isom ers) 0 .67  ± 0 .0 1 1 0.64  ± 0 .0 1 2
total trans isom ers 0 .97  ± 0 .0 1 1 0.88  ± 0 .0 2 1
*(Data represent the mean ± SD of triplicate analyses performed on separate days)
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Table 2.16 TFA analysis of manufacturing margarine (primarily palm oil) containing 5
% TFA pre-TLC. *
TFA D ay I D ay  II
A rea (%) A rea (%)
tram  Cig:i (total isom ers) 4 .32  +  0.21 4 .25  ±  1.05
t,t C j8:2 0 .17  ± 0 .0 1 0.13 ± 0 .0 1
c9, t 13 C i8:2 0.00 0 .0 0
c, t C l8.2 1.00 ± 0 .0 1 0 .9 0  ± 0 .3 1
t, c C i8:2 0.97  ±  0 .07 0 .8 7  ±  0 .24
other Ci 8:2 isom ers 0 .54  ± 0 .0 3 0.51 ± 0 .0 5
t,t,t C i8 :3 0 .00 0 .0 0
C,t,t +  t,C,tC  18:3 0.02  ±  0 .00 0 .02  ±  0 .00
t,t,C +  C,C,t C ]8 :3 0.11 ± 0 .0 1 0.11 ± 0 .0 1
C,t,C Ci8:3 0 .00 0 .00
t,C,C C i8 :3 0 .08  ±  0 .00 0 .07  ±  0 .00
other C i8:3 isom ers 0 .04  ±  0 .00 0.00
tram  C is:i (total isom ers) 4 .32  ± 0 .2 1 4 .25  ± 0 .0 1
tram  C is:2 (total isom ers) 2 .68  ± 0 .1 5 2.41 ±  0 .04
tram  Ci8:3 (total isom ers) 0 .25 ± 0 .0 1 0 .2 0  ± 0 .0 1
total tram  isom ers 7.25 ± 0 .3 0 6 .8 6  ±  1.02
*(Data represent the mean ± SD of triplicate analyses performed on separate days)
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The trans C ig;3 content pre-TLC w as found to range b etw een  0 .2 0  and 0 .25  % o f  total 
TFA, w hich  consisted  m ainly o f  t , t , c  + c, c, t and t, c, c C i8:3 and the total T FA  for this 
sam ple w as found to be 6 .8 -7 .2  % (Table 2 .16). The TLC bands corresponding to  Cig:o 
and trans Ci8:i w ere analysed by  GLC in triplicate on  tw o  separate days, and the data 
presented in  Table 2 .17 . U sin g  values from  table 2 .17 , the trans m on oen e content found  
by A g +-TLC and GLC w as calculated as described in section  2 .3 .3 . The trans C is:i 
content post-TLC w as 4 .21 -4 .53  % (Table 2 .1 7 ) w h ich  w as sim ilar to the pre-TLC trans 
Ci8:i content w hich  w as 4 .2 -4 .3  % (Table 2 .16). The perform ance criteria (as described  
in 2 .3 .9 ) w ere again fu lfilled  prior to analysis o f  the sam ple on each  day (Table 2 .18).
The sam ple containing 25 % T FA  w as a partially hydrogenated sunflow er o il and w as 
analysed  pre- and p ost-A g+-TLC by GLC. The trans content pre-TLC o f  Ci8:i w as found  
to be 11-12 % o f  total TFA, w ith  trans C i8:2 content ranging b etw een  5 .54  and 6 .22  % o f  
total T FA  w hich  consisted  m ain ly  o f  the individual com ponents c, t and t, c C ig:2 and 
other unidentified trans C i8:2 (Table 2 .19 ). The trans C i8;3 pre-TLC w as found to be 0 .07  
% o f  total TFA, w h ich  consisted  o f  unidentified trans C i8:3 and w as m uch  low er than  
seen  for the other o ils  analysed. The total TFA  for th is sam ple w as found to range 
b etw een  16.25 and 18.29 % (Table 2 .19 ). The TLC bands corresponding to C i8:0 and 
trans Cig:i from  the hydrogenated sunflow er oil w ere analysed  b y  G LC in  triplicate on  
tw o separate days, and are presented in  Table 2 .20 . The % area o f  C ig:o obtained prior to 
A g+-TLC analysis w as found to be 9 .2 8 -1 0 .3 6  % o f  TFA , and u sing  these values (Table 
2 .2 0 ) the trans m onoene content found by A g +-TLC and GLC w as calculated. The trans 
Ci8:i post-TLC content w as found to b e 11 .15-12 .02  % (Table 2 .2 0 ) w h ich  w as sim ilar to 
the pre-TLC trans Cig:i content (Table 2 .19 ). Certain perform ance criteria (as described  
in  2 .3 .9 ) were fu lfilled  prior to analysis o f  the sam ple on  each  day (Table 2 .18).
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Table 2.17 TFA analysis of manufacturing margarine (primarily palm oil) containing 5
% TFA post TLC. *
FAM E D ay I Day II
Area (counts) Area (counts)
Cl8:0(pOSt-TLC) 2 7 1 6 8 6 1  10234 3 8 5 4 7 8 1 2 0 9 1 5
tram Cigii (total isom ers post- 
TLC)
1 9 3 6 6 8 1  10227 262691  1  10477
Ci8:o by area (%) (pre-TLC) 6 .3 6 1 0 .0 3 6 .32  1  0 .0 4
% tram m onoenes found by  
com bined A g +-TLC and GLC
4 .5 3 1 0 .2 1 4.21 1 0 .0 1
*(D ata represent the m ean ±  S D  o f  triplicate analyses perform ed on  separate days)
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T a b le  2 .1 8  Perform ance criteria for intercom parison study. A n a ly sis  o f  C R M  162 and 
trans-\3/cis-9 Cig-.i and all-cis Cm/cis-l 1 C2o:i for 5 % and 3 0  % T FA  sam ples.
D ata represent the m ean and standard deviation  o f  triplicate an alysis carried out on  tw o  
separate days.
CRM 162 
(Individual FAME)
Day I 
% total fatty acids
Day II 
% total fatty acids
Mean
Ci6:0 10.15 ±0.01 10.17 ±0.01 10.16 ±0.01
Cl8:0 2.91 ± 0.02 2.87 ±0.02 2.89 ± 0.02
Ci 8:i 24.77 + 0.12 24.79 ±0.01 24.78 ± 0.01
Cl 8:2 56.64 + 0.01 56.67 ±0.01 56.66 ± 0.02
Cl8:3 4.17 ± 0.02 4.23 ± 0.05 4.20 ± 0.04
RESOLUTION Retention time Peak base width
(min) (mm)
Cis:i trans 13 18.92 ±0.01 3.10 ±0.00
Ci8:l cis 9 19.07 ±0.01 3.20 ±0.01
R 1.11 ±0.00
all CÌS Cj 8:3 22.64 ± 0.24 5.04 ± 0.04
C20:1 CÌS 11 22.34 ±0.12 5.01 ±0.12
R 1.21 ±0.01
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Table 2.19 TFA analysis of a partially hydrogenated sunflower oil containing 25 % TFA
Pre-TLC. *
TFA D ay I D ay  II
Area (%) A rea (%)
trans Cis.i (total isom ers) 10.64 +  0.01 12.00 ±  0 .44
t,t Ci 8;2 0.31 ± 0 .0 1 0 .3 4  ±  0.01
c9, t  13 C i8:2 0.00 0 .00
c, t C i8:2 2 .00  ± 0 .0 1 2 .2 4  ± 0 .1 2
t, c C i8:2 1.95 ± 0 .0 1 2 .2 0  ±  0.01
other C i8:2 isom ers 1.28 ± 0 .0 2 1.44 ± 0 .0 4
t,t,t Ci8:3 0 .00 0 .00
C,t,t + t,C,t Ci8:3 0 .00 0 .0 0
t,t,C + C,C,t Cig:3 0.00 0 .00
C,t,C C i8.3 0 .00 0 .00
t,C,C Ci8:3 0 .00 0 .0 0
other C i8:3 isom ers 0 .07  ± 0 .0 1 0 .0 7  ±  0 .00
trans C i8:i (total isom ers) 10.64 ± 0 .0 1 12.00 ±  0 .44
trans C is:2 (total isom ers) 5 .54  ± 0 .1 1 6 .22  ± 0 .4 1
trans C is:3 (total isom ers) 0 .07  ± 0 .0 1 0 .07  ±  0 .00
total trans isom ers 16.25 ± 0 .1 2 18.29 ± 0 .4 7
*(Data represent the mean ± SD of triplicate analyses performed on separate days)
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post TLC. *
Table 2.20 TFA analysis of a partially hydrogenated sunflower oil containing 25 % TFA
FAM E D ay I D ay II
Area (counts) Area (counts)
Cig:o(post-TLC) 515737  ± 2 0 4 8 4 8 2 2 5 9 +  10332
trans C is i (total isom ers post- 
TLC)
619693 ± 6 1 2 4 1 5 6 0 8 2 7 ± 10662
C i8;0by area (%) (pre-TLC) 9.28  ±  0 .84 10.36 ± 0 .3 3
% trans m onoenes found by  
com bined A g +-TLC and GLC
11.15 ± 1 .6 9 12.02 ±  0 .24
*(D ata represent the m ean ±  S D  o f  triplicate analyses perform ed on  separate days)
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In v iew  o f  the p ossib le harmful effects o f  dietary T FA , accurate analysis o f  these fatty 
acids is necessary to m onitor their leve ls  in foods. Estim ates o f  intakes (8 -1 2  g/day) are 
approxim ations based on  lim ited  data and problem atic analytical techniques (A S C N /A IN , 
1996). Previous analytical to o ls  w ere inadequate for com plete analysis o f  TFA , m ainly  
due to the unavailability o f  suitable reference m aterial, particularly those o f  minor, 
unusual cis and trans isom ers (Ratnayake and B eare-R ogers, 1990). Therefore a study to 
validate m ethodology w as waranted.
This study validated com bined  A g +-TLC and GLC m eth odology  for the quantification o f  
TFA  in vegetab le o ils. Initially the accuracy and separation pow er o f  the m ethod w as  
established and the effects o f  FA M E  preparation on  the lev e l o f  trans w as investigated. 
Furthermore data from  the analysis o f  com m on sam ples am ong d ifferent laboratories w as  
intercompared w hich  led to critical assessm ent and validation  o f  the m eth odology  for 
TFA  analysis used in this study.
U sing  a test m ixture com posed  o f  C i4:o, C ^ o , Cig:o and C i8:i (1 0  m g/m l) accuracy o f  the 
GLC w as assessed  by com paring the know n m ass w ith  the % peak  areas post GLC  
analysis. The % peak areas for individual FA M E  (T able 2 .2 ) corresponded c lo se ly  w ith  
the know n % m ass o f  the fatty acids, suggesting that d ecom position  and irreversible 
adsorption did not occur, w h ich  w as supported by the relative RF values (relative to 
Cis:i), w hich  did not differ by  m ore than 0 .05 from  1.0. T herefore the relevant 
performance criteria w ere m et, w hether self-prepared sam ples w ere analysed  and the RF
2.5 Discussion
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values calculated w ith in  the laboratory or unknow n test m ixtures w ere analysed  and the 
RF values com pared w ith  data from sim ilar analysis in  other laboratories (see  A ppendix
The effect o f  derivative form ation on  glyceride bound unsaturated fatty acids w as 
assessed  by the m éthylation and analysis o f  three triglyceride sam ples o f  know n  
com position  (C i6:o, Cig:o, C i&i, C i8:2 and C i8:3) and com parison o f  the data w ith  those  
obtained from  an identical preform ed FA M E sam ple. T his acceptance criterion w as not 
fu lfilled , as the difference betw een  the % area values obtained for C i6:o, for preform ed  
FAM E (Table 2 .5 ) and the sam ples m ethylated in the laboratory (T able 2 .4 ) w as greater 
than 0.2 %. H ow ever, criteria w ere fu lfilled  for the other fatty acids analysed  Cis.o, C is:i, 
C j8:2 and C i8:3 as the % area values for preform ed FA M E  (Table 2 .5 ) and the sam ples 
m ethylated in the laboratory did not differ by  m ore than 0 .2  % (T able 2 .4 ). A  sim ilar 
result w as seen  by  other laboratories w hen  results w ere com piled  and the 0 .2  % target 
w as m issed  (A ppendix  2). The rRF (relative response factor) for pre-form ed Cig.3 m ethyl 
ester, the fatty acid  sp ecies m ost likely  to autoxid ise, w as >  1.05 in every  other lab. The 
sam e w as true for glyceride bound C i8:3, regardless o f  type o f  derivative form ation  
(m ethanolic K O H , sodium  m ethoxide, B F3). In order to find sources for the deviations 
observed w ith in  the analysis from  all laboratories several critical parameters in the ester 
preparation step and the subsequent GLC process w ere tested (i.e . com m ercial sources o f  
test m ixtures, instrum entation (different capillary colum ns and d ifferent GLC  
equipm ent), injection  technique, storage stability and type o f  derivative form ation (HCL, 
BF3, N a-m ethoxide as catalysts)). On exam ination neither equipm ent related factors such
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as type o f  capillary colum n, GLC instrum ent, injection  technique nor derivative  
form ation procedures influenced the response factor o f  Cig:3 to a  m easurable extent. It 
has been observed previously  that trans C i8:3 fatty acids co-elu te  w ith  C20 fatty acids 
w hich m ay also be a possib le source o f  error (C hristie et al., 1989).
Poor storage stability and /  or purity o f  com m ercially  available C is:3 standards prepared 
from m ono-acid ic triglycerides m ay be a lik e ly  error source. Poor stability m ay be due to 
the fact that P U F A s are prone to autoxidise very rapidly (Christie el al., 1989). Stability  
studies typ ically  m easure peroxide values (PV ) and p -A nisid ine va lues (P A V ) (Christie et 
al., 1989). Other potential error sources (pre-form ed FA M E ) included  the p ossib ility  o f  a 
w eigh ing error, and oxidative deterioration o f  bound P U F A s. For triglyceride bound  
fatty acids it w as found to  be problem atic to recover P U F A s quantitatively and stability  
problem s w ere observed w ith  glyceride bound P U F A s. A  natural o il w ith  a certified  fatty 
acid profile such as C RM  162, proved to be the m ost effec tive  m eans to dem onstrate 
fitness for purpose o f  the GLC technique used  for trans analysis in  th is case. It 
demonstrated that use o f  a proven m ethylation  m ethod in conjunction  w ith  a very long  
and h igh ly  polar capillary colum n is an e ffec tiv e  process for the quantification o f  even  
highly unsaturated FAM E.
The GLC program used  w as h igh ly  e ffec tiv e  for the separation o f  critical pairs o f  
geom etrical and positional isom ers o f  unsaturated fatty acids (e .g . trans- 13 /  cis-9 Ci8:i 
and all cis Cx^/cis-l 1 C2o:i). The acceptance criterion w as a chrom atographic resolution  
o f  at least 1.00. T he fractionation o f  cis and trans isom ers o f  C i8:i by A g +-TLC according
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to the geom etry o f  the double bond w as also  h igh ly  effec tiv e , as there w as no cross 
contam ination in  either fraction (i.e. no cis peak in  the tram fraction or v ice  versa) and 
recovered fractions w ere not contam inated w ith  other FAM E.
Precision o f  TFA  m eth odology w as dem onstrated by  the su ccessfu l recovery o f  >  90  % 
o f  added m ethyl elaidate or trielaidin contained in  soya  oil FA M E  or so y a  o il using a 
com bination o f  A g +-TLC and GLC. In the overall analysis in vo lv in g  all laboratories, the 
standard deviation  (S D ) for reproducibility varied betw een  2 .1 8  % and 4 .4 7  % for 
sam ples spiked w ith  2 3 .0 9  g  and 1.09 g  m ethyl elaidate /1 0 0  g  fatty acid  m ethyl esters 
and betw een 3 .28 % and 6 .19  % for sam ples spiked w ith  30.21 g  and 1.08 g  trielaidin  
/1 00  g  soya  oil (A ppendix 3). Therefore the m ethods em ployed  i.e . A g +-TLC and GLC  
in  this section  produced accurate and precise data for TFA  analysis and the m ethod w as  
deem ed suitable for use in a certification  exercise for o ils  o f  know n  quantities o f  TFA. 
Precision o f  the A g +-TLC and GLC w as deem ed com parable to data published  in the 
certification report o f  CRM  162 regarding the lo w  and m edium  T FA  lev e ls  (ISO  Guide 
30, 1981), and som ew hat poorer regarding h igh  T FA  levels . H ow ever the m easuring  
principal used  in these experim ents w as far m ore sophisticated com pared w ith  the sim ple  
GLC analysis o f  the fatty acid spectrum  used  in  the certification exercise  o f  C R M  162 
(ISO G uide 30, 1981). Furthermore, R S D  (R ) (R esidual Standard D ev ia tion ) figures 
were w ell w ith in  the expected  range o f  reproducibility (R SD  (R ) b etw een  10 % and 40  
%) (F. U lberth) (A ppendix 4).
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The intercom parison study involved  the analysis o f  prelim inary test m aterials (refined  
soya oil w ith  approxim ately 1 %, 1.5 % 5 %, 25 % T F A ) all o f  w h ich  had undergone 
hom ogenicity  and stability tests based on  B C R  guidelines. S in ce the R S D (R ) (A ppendix  
5) did not range betw een  10 and 40  % for the com bined  an alysis from  all groups the 
analysis w as repeated. The problem  areas w ith  the first intercom parison w ere the 
quantification o f  ¿raws-monoenes in the 1 % T FA  sam ple and /ra«.v-polyenes in  the 5 % 
and 30 % T FA  sam ples (A ppendix 4). The quantities o f  T F A  w ere lo w  and therefore 
underestimated. In order to correct this in the second  intercom parison, the peak area 
reject value w as decreased and all integrated peaks w ere reported. It has been  show n  
previously that colum n overload or the presence o f  large am ounts o f  cis isom ers 
negatively  affect the resolution o f  trans m on oen es (R atnayake and B eare-R ogers, 1990). 
In addition previous studies found m any C is:2 and C i8:3 trans p o lyen es w ere not correctly  
identified (S iguel, 1993) how ever in this study m any peaks w ere found to overlap. This 
w as corrected by d ilution  o f  the sam ple prior to GLC analysis and better resolution  w as 
obtained enabling identification  o f  all trans p o lyenes present. T his is  in  agreem ent w ith  
Ratnayake and B eare-R ogers (1 9 9 0 ) w ho found that dilution and sm aller sam ple load w as 
found to be effec tive  in im proving resolution b etw een  cis and trans isom ers. This is due 
to the presence o f  large quantities o f  saturated fatty acids lead ing to large peak areas, 
w hich co-elute w ith  the m inor trans p o lyen e peaks. Therefore d ilu tion  to sm aller  
quantities enables separation betw een  these peaks as the peak area for each  fatty acid is 
reduced. W o lff  (1 9 9 4 ) dem onstrated that variation o f  the co lum n temperature causes 
C20:1 to elute in different positions before, after or w ith  C i8:3 on  CP Sil 88 colum n. There 
w as poor resolution  betw een  C20.1 and C 18.3 tee, in  this study; h ow ever fo llo w in g  dilution
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o f  the sam ple prior to GLC analysis, it w as p ossib le to separate th ese peaks, w h ich  w as 
im perative as otherw ise values for total trans C ig:3 w ould  be greatly overestim ated. D ue  
to these m odifications sufficient conform ity o f  results w as ach ieved , b etw een  the various 
laboratories. T he R S D (R ) for total T F A  ranged betw een  10 and 4 0  % for the com bined  
analysis from  all laboratories; therefore the analysis w as d eem ed  su ccessfu l and fu lfilled  
the predefined criteria (A ppendix 6).
The m ethodology used  for T FA  analysis in  this study w as validated  and found to be 
useful for the accurate analysis o f  T FA  in foods. In addition, the m ethod in vo lv in g  A g+- 
TLC in com bination w ith  GLC m ay be used  in the certification  o f  reference materials 
containing TFA. T hese w ould  then a llo w  for the accurate quantification  o f  T FA  by all 
analysing laboratories g iven  that such certified  reference m aterial for T FA  are currently 
not available. In addition there is currently inadequate inform ation on  the T FA  content o f  
foods (A S C N /A IN , 1996). The fats and o ils  industry w orld w id e  is  rapidly responding to 
pressure to g ive  consum ers a w id e range o f  ch o ices w ith  respect to household  table fats 
and spreads (H aum ann, 1998). N e w  food  tech nologies, including im provem ents in the 
hydrogenation process (temperature, pressure, tim e, catalyst, m ethods, starting oils), 
interesterification and genetic engineering o f  o il seed plants to  m od ify  the fatty acid  
com position  o f  o ils  have the potential to reduce the TFA  content o f  food s (A S C N /A IN , 
1996). There are m ovem ents in  several countries to m andate the inc lusion  o f  the TFA  
content o f  m argarine and other products on  the food  label (K atan et al., 1994, 1995). 
This is a com plex  area and health claim  issues have b een  raised, but because o f  
inadequate data, m odifications to  labeling m ay be premature. S u ggestion s considered by
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a Task Force (A S C N /A IN , 1996) included the addition or inc lusion  o f  Trans fatty acids 
w ith  saturated fatty acids on  labels. H ow ever, saturated fatty acids are currently defined  
w ithout subtypes (A S C N /A IN , 1996). Including trans fatty acids w ith  saturated fatty 
acids w ould  then change this to a group. S econd ly , trans fatty acid s should  be labeled  as 
a separate class, as currently, trans fatty acids are not included on  the nutrition label in  
the listing  o f  unsaturated fatty acids. Som e trans fatty acids m ay  then be c la ssified  w ith  
cis m onounsaturated fatty acids and som e w ith  polyunsaturated fatty acids. T hey are not 
mandated by  law  to be listed  on  the nutrition label. S om e food  m anufacturers and 
processors have elected  voluntarily to  list unsaturated fatty acids (exclud in g  trans fatty 
acids) on  the nutrition label. H ow ever to reach a decision  on  the labelin g  issue, accurate 
data m ust be acquired, com parable w ith  that for saturated fats concern ing the intake o f  
trans fatty acids, their b io logica l effects and associated  m echanism s o f  action, and their 
relation to d isease (A S C N /A IN , 1996). B ecau se o f  public health  concerns regarding the 
amount o f  fat in  the A m erican diet, the F ood  and D rug A dm inistration  and the U S  
Departm ent o f  Agriculture have em phasized  use o f  the recently reform ed food  label to 
inform  consum ers about the fat and fatty acid  contents o f  food s (Scarbrough, 1997). 
Issues that m ust be addressed to further im prove the com m unication  effec tiven ess o f  the 
food  label include health effects o f  n-3 and n-6  fatty acids; appropriate labeling o f  trans 
fatty acids, Ci8;o, and other non-cholesterol-raising fatty acids; partially absorbed fats; 
and label cla im s, esp ecia lly  health cla im s, for sp ecific  fatty acids and fatty acids o f  
b iotech n ologica lly  altered foods (Scarbrough, 1997).
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Trans fatty acids are form ed during refining and catalytic hydrogenation  o f  vegetab le o ils  
and occur naturally in ruminant fats. In v iew  o f  current interest in  their p hysio logica l 
effects, an accurate analysis o f  these fatty acid isom ers in  the hum an diet and in 
bio logica l sam ples is o f  considerable im portance. S ince no sin g le  routine m ethod ex ists  
for the accurate quantification o f  TFA , the analyst has to ch o o se  am ong different 
m ethods, taking into account what targets have to be m et. In th is study a com bination o f  
A g+-TLC and GLC w as used  for the analysis o f  test m ixtures o f  soya  o il F A M E  and soya  
oil sam ples spiked w ith 1, 5 and 30 % m ethyl elaidate and trielaidin  and four sam ples o f  
edible o ils  containing different lev e ls  o f  T FA  (1, 1.5, 5, 30% ). R esu lts w ere com pared  
w ith data obtained from other laboratories. A  chrom atographic resolution  greater than  
1.00 w as ach ieved  for separation o f  the critical pairs trans- 13 /  cis-9 C is:i and all cis 
C i8:3/c w - l 1. R ecovery o f  T F A  in  all sam ples w as in ex cess  o f  90  % fo llo w in g  A g +-TLC. 
The m eth odology  used for TFA  analysis in  this study w as validated  and found to be 
useful for the accurate analysis o f  T FA  in foods. In addition, the m ethod in vo lv in g  A g +- 
TLC in  com bination w ith  GLC m ay be used  in the certification  o f  reference m aterials 
containing TFA. T hese w ou ld  then a llo w  for the accurate quantification  o f  T F A  by all 
analysing laboratories g iven  that such  certified  reference m aterial for T F A  are currently 
not available.
2.6 Summary
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CHAPTER 3
Enrichment of the conjugated linoleic acid content of 
bovine milk fat by dry fractionation
* Accepted for publication in the International Dairy Journal May 2000
3.1 Introduction
E pidem iological studies have suggested  a  protective e ffec t o f  dietary C LA  against 
breast cancer in hum ans (K nekt et al, 1996, L avillonniere and B ou gou x  1999). 
R elatively rich dietary sources o f  CLA include m ilk  fat-contain ing foods, such as 
butter and cheese, w h ose C L A  contents w ere reported as 9 .4  and 8.4 m g/g  fat, 
respectively (Fritsche and Steinhart, 1998).
One o f  the m echanism s by w hich  C LA  occurs in m ilk  fat is  by m icrobial 
biohydrogenation o f  dietary lin o le ic  acid in the rum en (K epler and T ove, 1967). The 
c9, i l l  C L A  isom er thus form ed in the rumen is rapidly converted  to i l l - C is . i  the 
m ain positional TFA  isom er, w h ich  represents approxim ately 50  % o f  the total trans 
octadecanoic acids in m ilk  fat (K epler et al., 1966). M ilk  fat C L A  m ay also be 
produced endogenously  from  /11-Ci8:i in  mam mary tissue by A9 desaturase (Griinari 
and Baum an, 1999). E laid ic acid (¿9-C iiu) is a m inor com ponent o f  m ilk  fat (W o lff  et 
al., 1998) but is the predom inant trans isom er in partially hydrogenated vegetab le fats. 
A  number o f  studies have dem onstrated that T FA  intake, particularly those o f  
vegetable o il origin, is associated  w ith  alteration o f  p lasm a lip id  and lipoprotein  
concentrations, thereby im plicating these as atherogenic fatty acids (Judd et al., 1994, 
M ensink and Katan, 1990, Z ock  and Katan, 1992). Som e ep idem io log ica l ev idence  
also suggests an association  betw een  T FA  intake and risk o f  coronary heart d isease  
(C H D ) (A scherio et al., 1994, W illett et al., 1993). H ow ever, other studies that have  
estim ated T FA  intake, did not identify an association  w ith  increased risk o f  C H D  (A ro  
et al., 1995, Roberts et al., 1995). M ilk  fat con sists o f  a m ixture o f  triglycerides that 
exhibit a broad and variable m elting range, from  approxim ately - 4 0  °C to + 4 0  °C.
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This a llow s the crystallising out o f  a series o f  triglycerides at tem peratures b e lo w  their 
m elting points by controlled coo lin g  o f  the m elt. S in ce the process d oes not use  
solvents, it is know n as ‘dry fractionation’ and has resulted in  the production o f  food  
grade ingredients for products such as spreadable butters, chocolate and bakery 
products (K aylegian and Lindsay, 1995). The use o f  m ilk  fat fractions w as reported at 
approxim ately 50 ,000  tonnes per year, representing approxim ately 20  % o f  the 
butteroil market (D effense, 1995). The slip-point o f  m ilk  fat ranges b etw een  31 .5  and
32.5  °C (K eogh and H iggins, 1986). The fatty acid com positional changes observed  
in  h igh  m elting fats (35 °C to 25 °C) include a decrease in  C4 to C10 fatty acids, a 
slight increase in  C12 to C15 fatty acids and an increase in Ci6 to Cis saturated fatty 
acids (D im ick  et al, 1996). In the lo w  m elting fractions (25 °C to 10 °C ), the m ain  
com positional changes include an increase in concentrations o f  C4 to C10 and C12 to 
C 15 fatty acids, and a decrease in C i6 to Cig saturated fatty acids com pared w ith  the 
parent fat (D im ick  et al., 1996). The C i8:i/C i8:o ratio is  a lso  generally h igher for lo w  
m elting fractions than for other fractions (K aylegian  and L indsay, 1995). Increased  
utilisation o f  m ilk  fat m ay thus be facilitated by dry fractionation into fractions 
m arkedly different from  one another in com position  and m elting point. F ew  studies 
have exam ined the CLA  content o f  m ilk  fat fractions, although a  recent study reported  
a 2 .5 -fo ld  enrichm ent o f  m ilk  fat in  CLA fo llow in g  urea crystallisation (K im  and Liu, 
1999).
3.2 Objectives
In this study, the effect o f  laboratory scale dry fractionation on  C L A  enrichm ent o f  
m ilk  fat fractions w as investigated, the lev e ls  ach ieved  w ere then com pared w ith  the 
CLA and TFA content o f  a range o f  food  products.
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3.3 Materials and methods
3.3.1 Milk fat fractionation
Anhydrous m ilk  fat (D airygold , M itchelstow n, Co. Cork) w a s fractionated into hard 
and soft fractions by the fo llo w in g  m ethod. Pre-m elted m ilk  fat w as co o led  from  60  
°C to the initial fractionation temperature (33 °C ) in a 5 0 0  m l beaker, p laced  in a 
Lauda program mable water bath (A G B S cien tific, D ublin ) capable o f  a variable 
coo lin g  gradient. Programmed coo lin g  at selected  coo lin g  rates (0 .58 , 0 .74 , 1.17 and 
2 .8  °C /h) w as then initiated until the final fractionation tem peratures (19 , 15 and 10 
°C) w ere reached. A gitation  at 16 rpm w as initiated im m ediately  using a paddle  
stirrer w hich  sw ept w ith in  6  m m  o f  the beaker w all and continued for 2 h  at the final 
fractionation temperature. The fraction containing the crystallised  fat (hard fraction) 
w as then separated from  the soft fraction by centrifugation (Sanyo M SC  M istral 
2000R , G allencam p PLC, Leicester, U K ) at 2 ,5 0 0  g  for 5 m in  at the final fractionation  
temperature.
3.3.2 Fat extraction from selected foods
Fat w as extracted from  a range o f  food  products including spreads, butter, yoghurt and 
ch eese and the C LA, T FA  and total fatty acid com position  analysed by GLC as 
described below . The probiotic ch eese used, w h ich  harboured the strain Enterococcus 
faecium PR 88 strain w as m anufactured as described previously  (Gardiner et al., 1999) 
and analysed fo llo w in g  7 m onths o f  ripening. Fat w as extracted from  the butter and 
spread sam ples according to  the IDF m ethod N o . 593 /E  (ID F, 1992), from  yoghurt by
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the m ethod by Falih et al. (1 9 7 7 ) and from  ch eese  by the m ethod o f  M cN eill and 
C onnolly (1989).
3.3.3 Fatty acid analysis by GLC
For CLA analysis o f  fat sam ples, fatty acid m ethyl esters (FA M E ) w ere prepared 
using acid-catalysed m ethanolysis and analysed by GLC as p reviously  described  
(Stanton et al., 1997a). T he FA M E w ere separated on  a S up elcow ax-10  capillary  
GLC colum n (Supelco Inc, B ellefonte, P A ) (6 0  m  x  0 .3 2  m m  i.d., 0 .25  nm  film  
th ickness), using a Varian 35 0 0  GLC (Varian, Harbor C ity, C A , U S A ) w h ich  w as 
fitted w ith a flam e ionisation  detector (FID). T he c9 , i l l  isom er o f  CLA  w as  
identified  by retention tim e w ith  reference to a C LA  standard m ix  (N u-C heK  Prep 
Inc., Elysian, M N , U S A ). Individual fatty acids ( f l l -C ig ii)  w ere identified  w ith  
reference to  the retention tim es o f  FAM E standards (S igm a C hem ical C o., St. Louis, 
U S A ), and quantified as g/lOOg FA M E, or w ith  reference to the internal standard 
C i3;0, and expressed as m g/g  fat.
For TFA (rl 1-Cis:i) analysis o f  fat extracted from  foods, F A M E s w ere prepared using  
base-catalysed m ethanolysis and TFA w ere separated by  silver ion  thin layer 
chromatography (A g+-TLC ), and subsequently analysed by GLC as previously  
described (Ulberth and H enninger, 1992). Separation o f  T FA  by A g+-TLC is  briefly  
described as fo llo w s. The FA M Es w ere applied to 0 .25  m m  silica  gel p lates 
impregnated w ith 10 % (w /v ) AgNC>3 in acetonitrile (stationary phase) and p laced  in a 
m obile phase o f  hexane : diethyl ether (9  : 1 v /v ) to  d evelop  for approxim ately 3 h. 
The plates w ere then a llow ed  to dry at room  temperature and w ere stained w ith  0.05  
% (w /v) rhodamin B  in ethanol. The trans track, v is ib le  under U V  light, w as eluted
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from the silica  in hexane prior to GLC analysis on  a Chrom pack CP Sil 88 colum n (60  
m m  x  0 .25 m m  i.d ., 0 .02  jam film  th ickness) (Chrom pack, M iddleburg, The 
Netherlands). The injector and detector temperatures w ere 140 and 2 5 0  °C, 
respectively and the N 2 carrier gas w as 20  m l/m in . The co lum n temperature w as  
program med from 140 °C w ith  an initial delay o f  8 m in, fo llo w ed  by an increase to  
200  °C, at a rate o f  8.5 °C /m in and held for 15 m in.
3.4 Results
3.4.1 Effects of dry fractionation on CLA content of the soft fraction 
U sin g  final fractionation temperatures o f  19, 15 or 10 °C  and variable co o lin g  rates, 
increases in C LA  content w ere obtained in the so ft fraction over the parent fat (Table 
3.1). C ooling rate had an influence on  the CLA  content o f  the resulting so ft fraction, 
w ith increased coo lin g  rate generally resulting in reduced C LA  content (Table 3 .1). 
The conditions for m axim um  CLA-enrichm ent w ere found to  be a final fractionation  
temperature o f  10 °C  and a  coo lin g  rate o f  0 .58  °C /h, w h ich  resulted in  an increase 
from  1.36 to 2 .2  g/lOOg FA M E  (63 %) in the C L A  content over the parent A M F. The 
yield  o f  this CLA -enriched fraction w as 30 % o f  the parent A M F (T able 3.1). 
Refractionation o f  th is fraction using the sam e fractionation conditions resulted in a 
reduction in the C LA  content o f  approxim ately 10 % (Table 3 .1 ). T he effec t o f  
agitation on  C LA  yield  w as also investigated, using the soft fraction generated at a 
final temperature o f  19 °C and a coo lin g  rate o f  0 .74  °C/h, w h ich  had a C L A  content 
o f  2 .07  +  0.01 g/lOOg FAM E. A gitation  had a negative im pact on  the C LA  content o f
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this fraction, resulting in reductions o f  8.3 and 12.0 %, after 1 and 2  h agitation, 
respectively.
3.4.2 Fatty acid composition
The fatty acid com positions o f  the parent A M F and the hard and soft fractions 
obtained fo llo w in g  fractionation to a final temperature o f  10 °C, at a co o lin g  rate o f  
0.58 °C/h are g iven  in Table 3.2. The concentration o f  Ci6 - C is saturated fatty acids 
analysed w as higher in the hard fraction and sim ilar or slightly  reduced in the soft 
fraction to the parent A M F. C onversely, the concentration o f  all unsaturated fatty 
acids analysed w ere higher in  the soft fraction and sim ilar or sligh tly  reduced in the 
hard fraction, com pared w ith  the parent A M F. The concentrations o f  Ci6:o and Cig:o 
acids w ere increased by 6 .7  and 2 4 .7  %, respectively, in  the hard fraction. The 
concentrations o f  Cig:i and CLA w ere increased by 2 5 .6  and 63 %, respectively , 
com pared w ith  the parent A M F. Cjg polyunsaturated fatty acids, in  addition to ¿11- 
Ci8:i were also  increased (by ~  30 %) in the so ft fraction, com pared w ith  the parent 
AM F. The concentration o f  C |6 - Cig saturated fatty acids analysed w as h igher in the 
hard fraction and sim ilar or slightly reduced in the soft fraction to the parent A M F.
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T a b le  3.1 The effect o f  different temperature ranges, co o lin g  rates and refractionation  
on  CLA content o f  m ilk  fat
Temperature 
range °C
C ooling Rate 
°C /h
CLA
g /1 0 0 g  F A M E 1
Y ield  o f  so ft fraction  
% ( w /w ) 1
Parent A M F2 1.36 ± 0 .0 2
33 °C - 1 9  °C 2 .8 0 1.91 ± 0 .0 5 37 .8  ±  1.20
33 °C -  19 °C 1.17 2 .06  +  0 .12 40.1  ± 2 .4 0
33 ° C -  19 °C 0.74 2 .07  ± 0 .0 1 3 9 .4  ±  1.60
33 °C -  19 °C 0.58 2 .07  ± 0 .2 1 36.5  ±  0 .52
33 °C - 1 5  °C 0.74 2 .10  ± 0 .0 6 30 .6  ± 0 .1 1
33 °C - 1 5  °C 0.58 2 .12  ± 0 .1 0 31 .2  ± 0 .0 2
33 °C - 1 0  °C 0.74 2 .14  ± 0 .0 8 2 9 .4  ±  1.21
33 ° C - 10 °C 0.58 2 .22  ±  0.01 3 0 .0  ±  1.12
Refractionation
33 °C - 1 0  °C 0.58 2.01 ± 0 .1 0 2 6 .4  ±  1.81
'M ean o f  triplicate analyses ±  standard deviation  
2AM F; anhydrous m ilk  fat
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C onversely, the concentration o f  all unsaturated fatty acids analysed w ere higher in  
the soft fraction and sim ilar or slightly  reduced in  the hard fraction, com pared w ith  the 
parent A M F. The concentrations o f  Ci6:o and Ci8;o acids w ere increased by 6 .7  and  
2 4 .7  %, respectively, in the hard fraction. The concentrations o f  C ig:i and C LA  w ere  
increased by 2 5 .6  and 63 %, respectively, com pared w ith  the parent A M F . C is  
polyunsaturated fatty acids, in  addition to t\ 1-Ci8:i w ere a lso  increased (by ~  30  %) in  
the soft fraction, com pared w ith  the parent AM F.
3.4.3 CLA and TFA content of selected food products
The CLA and T FA  contents o f  a  selection  o f  butter, spreads, yoghurts and ch eeses are 
show n in  Table 3.3. Spreads containing hydrogenated vegetab le fat on ly  as the fat 
source contained n eg lig ib le am ounts o f  C LA (0.3 m g/g  fat), but relatively h igh  TFA  
content, com pared w ith  products containing on ly  m ilk  fat as the fat source. Dairy  
spreads, w hich  contained a blend o f  m ilk  fat and vegetab le o ils, contained  
substantially less CLA (0-3 .3  m g/g  fat) than butter (1 2 .3 -1 4 .2  m g/g  fat) (Table 3 .3). 
Furthermore, the TFA  content o f  butter w as approxim ately 3 -fo ld  less  than dairy 
spreads (Table 3 .3). O f  all the dairy products analysed, butter w as found to be the 
richest source o f  CLA, w h ile  the yoghurt and ch eese sam ples analysed, contained, on  
average, one and tw o-thirds, respectively, o f  the C LA  content o f  butter. It should be  
noted that these sam ples w ere retail products, and as such w ere m ost likely  
manufactured from  different m ilk , obtained at d ifferent stages throughout the season  
and m ost likely  w ith  varying m ilk  fat CLA concentrations. T he C LA  content o f  goats 
m ilk  yoghurt w as found to  be sim ilar to that o f  c o w s’ m ilk  yoghurt. H ow ever goat 
ch eese contained m uch less C LA  than other ch eese sam ples analysed (Table 3 .3).
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T a b le  3 .2: Fatty acid com position  o f  m ilk  fat fractions obtained by dry 
fractionation1
Fatty acid Starting AMF 
g/100g FAME 2
Hard fraction 
g/100g FAME 2
Soft fraction 
g /100g FAME 2
Cl2:0 4.66 ± 0.02 4.20 ±0.01 4.00 ± 0 .12
C|2:l 0.19 ±0.01 0.18 ±0.02 0.24 ±0.01
Cl4:0 15.68 + 0.11 15.52 ±1.02 12.2 ±0.21
Cl4;i 1.18 ± 0.15 0.94 ±0.10 1.28 ± 0 .16
C[5:0 0.83 ± 0.02 0.82 ±0.12 0.98 ± 0.04
Ci6;0 3 0 .6 0 1 0 .1 2 32.65 ±0.01 27.2 ±0.21
Cl6:l 1.89 ±0.02 1.21 ±0.12 2.27 ± 0 .07
Cl 7.0 0.74 ±0.01 0.81 ±0.01 0.82 ±0.01
Ci8:0 14.00 ± 0.42 17.46 ± 1.51 12.83 ±0.05
Ci8:1 22.60 ±0.51 19.68 ±0 .54 28.39 ± 1.62
C )8:1 vaccenic 4.05 ±0 .12 4.10 ± 0.11 5.18 ±0 .08
Cl8:2 0.89 ±0.01 0.71 ±0.01 1.19 ± 0.12
Ci8;2 CLA 1.36 ±0.21 1.31 ±0.01 2.22 ±0.01
C]8:3 0.88 ±0.01 0.41 ± 0.02 1.20 ± 0 .10
fra c tio n a tio n  conditions used  to obtain the fractions w ere a temperature 
range o f  33 to 10 °C and a  coo lin g  rate o f  0 .58  °C h '1 
2 M ean o f  triplicate analyses ±  standard deviation
Table 3.3 CLA and TFA content of selected food products.
Product CLA
m g /g  fat *
T FA
m g/g  fat *
Dairy Spreads (n =  8) 
(vegetable oil: milk fat)
1. 1 0 0 : 0 0 65 .2  ±  11.21
2. 1 0 0 : 0 0.5 ± 0 .0 1 102.4  ± 6 .8 0
3. 99 : 1 < 0 .0 1 112.2 ± 4 .2 1
4. 99 : 1 0 125.2  ±  0 .02
5. 7 0 : 3 0 2 .5  ±  0 .02 133.2 ± 0 .5 7
6. 7 0 : 3 0 1.8 ± 0 .0 4 134.7  ± 3 .4 8
7. 7 0 : 3 0 3.3 ± 0 .1 0 154.3 ± 2 .0 5
8. 70  : 10 1.9 ± 0 .0 1 155.7  ±  1.69
Butter (n = 4)
1. Butter 12.6 ± 0 .1 2 5 0 .7  ±  0 .02
2. Butter 13.4 ± 0 .2 5 50.3  ± 0 .5 1
3. Butter 12.3 ± 0 .3 1 6 0 .9  ± 0 .1 1
4. Butter o il 14.2 ± 0 .0 1 53.3  ± 0 .1 2
Yoghurt (n=4)
1. lo w  fat m ilk  +  live  cultures 4 .2  ± 0 .1 1 50.1 ± 2 .4 0
2. lo w  fat m ilk  +  liv e  cultures 3 .9  ± 0 .0 5 39.5  ± 1 .3 4
3. lo w  fat m ilk  +  liv e  cultures 3.3 ± 0 .3 0 37 .4  ±  0 .02
4. goats’ m ilk  +  live  cultures 4 .6  ± 0 .1 7 34.8  ±  1.05
Cheese (n = 10)
1. probiotic ch eese (Cheddar) 9.3 ± 0 .1 2 57 .4  ±  1.02
2. Cheddar 9.2  ±  1.10 58 .2  ± 0 .4 4
3. Cheddar 16.2 ± 0 .5 1 4 5 .6  ± 3 .2 1
4. Cheddar 6.9  ±  0 .24 36.3  ±  1.45
5. Emmental 6 .6  ± 0 .3 0 2 6 .2  ±  0 .20
6. Camembert 7.2 ± 0 .0 1 2 2 .9  ± 2 .3 7
7. Processed  Cheddar 8.3 ± 0 .1 1 3 3 .2  ± 1 .1 1
8. B lue cheese 4 .0  ± 0 .1 1 32 .7  ± 0 .5 1
9. Gouda 2.3 ± 0 .0 1 2 9 .4  ± 0 .1 2
10. G oat cheese 1.5 ± 0 .0 4 11.5 ±  0.11
* M ean o f  triplicate analyses ±  standard deviation
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3.5 Discussion
This study dem onstrates that fractionation o f  m ilk  fat is a suitable m eans o f  enriching  
the CL A  content over the starting A M F. In v iew  o f  the protective effec t against risk 
o f  mammary cancer developm ent o f  C LA -enriched butter (Ip et ah, 1999a), m ilk  fat 
fractionation m ay offer an alternative m eans by w h ich  a health-beneficia l fo o d  can be 
produced. The m axim um  CLA enrichm ent obtained w as 63 % over the parent fat, 
yield ing a m ilk  fat fraction containing 2 .22  g  CLA  /1 0 0 g  FA M E. A  fe w  approaches 
have already been  investigated to increase the C L A  content o f  m ilk  fat, and in  
particular, anim al feed ing regim es, using dietary o il supplem ents have been  effective  
at elevating m ilk  fat CLA  concentrations (D him an et ah, 1999a,b, K elly  et al., 1998a, 
L aw less et ah, 1998, Stanton et ah, 1997a). A n  enrichm ent o f  m ilk  fat C L A  content 
to 41 m g/g  total fatty acids (Ip et ah, 1999a) w as achieved by feed in g  a selected  herd 
o f  cow s w ith supplem ents o f  sunflow er o il, as described (K elly  et al., 1998a). M ilk  
fat C LA  contents o f  24 .0  and 19.6 m g/g  fat w ere ach ieved  through supplem entation o f  
cow s on  pasture w ith  fu ll fat rapeseeds and fu ll fat soybeans, respectively  (L aw less et 
ah, 1998). A nother approach for production o f  m ilk  fat enriched in C L A  involved  
urea crystallisation, w h ich  resulted in a 25 0  % increase in the C LA  content, to 12.7  
m g/g fat (K im  and Liu, 1999).
In addition to C LA, t\ 1-C is:i, the major tram fatty acid  in m ilk  fat, m ay also  act as a 
beneficial fatty acid, since it is converted to the c9, ¿11-C L A  isom er by  the A9- 
desaturase en zym e (Griinari and Baum an, 1999). F o llo w in g  anim al dietary 
supplem entation, a strong positive correlation has been  observed b etw een  m ilk  fat 
CLA and ill-C i8:iC oncentrations (Jiang e /a / . ,  1996, la w le s s  et al., 1998). F o llow ing
m ilk  fat fractionation in this study, the C LA -enriched m ilk  fat fraction w as increased  
in  /1 1 -Ci8;i content by 28  %, com pared w ith  the parent fat. T he C LA -enriched soft 
fraction w as sim ilar in saturated fatty acid content and higher in  unsaturated fatty 
acids com pared w ith  the parent m ilk  fat. The com positional changes observed  in  the 
CLA-enriched fraction from this study are sim ilar to those in  the C LA -enriched m ilk  
fat fraction obtained by urea fractionation (K im  and Liu, 1999), w h ich  w as higher in  
Ci8:i and low er in C i6;o and Ci8;o, com pared w ith  the parent fat.
A s the final temperature o f  fractionation decreased from  19 to  10 °C , the y ie ld  o f  the 
soft fraction also  decreased, from  38.5  to 30  %, respectively  w h ile  the y ie ld  o f  the 
hard fraction increased. Previously, it has been  show n that the final temperature had a 
significant effect on  the y ield  o f  lin o le ic  acid in  the soft fraction (K eogh  and H iggins, 
1986), w h ile  our study show ed that final temperature had a n eg lig ib le  effect on  CLA  
yield. Furthermore, it w as show n that s lo w  stirring increased the y ield  o f  the soft 
fraction and produced cleaner fractions (K eogh  and H iggins, 1986). In th is study, 
agitation for 2 h o f  the partially crystallised fat post-fractionation further decreased the 
amount o f  CLA  present in the soft fraction and increased the C L A  content o f  the hard 
fraction. This m ay be due to the structure o f  the triglyceride contain ing the conjugated  
double bond, w h ich  has a less kinked structure than that o f  lin o le ic  acid  and therefore 
m ay have been  incorporated m ore easily  to  a crystal structure contain ing Ci6:o and 
Ci8:o- Crystal grow th also occurs during agitation (B lack, 1975) w h ich  p ossib ly  m ay  
entrap the triglycerides into the hard fraction. In previous studies u sing  sim ilar 
procedures for obtaining hard and soft fractions, the hard fractions have found  
applications in various products, including butter, confectionery item s, chocolate and 
soups (K aylegian  and Lindsay, 1995).
The enrichm ent o f  63.2  % in the CLA content represented approxim ately a 3 -fold  
increase in  C LA  over a range o f  m ilk  fat contain ing-food products analysed  in this 
study. Previous studies (Chin et al, 1992, Fritsche and Steinhart, 1998) have reported 
low er CLA  contents o f  butter and ch eese com pared w ith  the va lues reported in this 
study. The d ifferences m ay be due to the higher CLA content o f  the m ilk  fat from  
w hich the food  products w ere manufactured, w h ich  in turn, m ay be due to  d ifferences 
in  the feeding regim es o f  the dairy herds. M ilk  produced in Ireland is  m ostly  from  
cow s on  pasture, and this is associated  w ith  relatively  h igh  m ilk  fat CLA  
concentrations (K elly  et al. 1998b, Stanton et al, 1997b). In addition, the m ilk  may 
have been  obtained at different stages throughout the season, w h ich  m ay also  have 
influenced the C L A  content o f  the m ilk  fat, as w as p reviously  dem onstrated (Stanton  
et al, 1997b). Other factors show n to influence m ilk  fat C L A  concentrations include  
anim al feed ing  regim e and dietary supplem ents (K elly  et al, 1998a, L aw less et al., 
1998). A  large variation w as observed in the CLA content o f  the ch eeses  (1 .5 -1 6 .2  
m g/g fat), w h ich  m ay be due to variations in the CLA content o f  the ch eese  m ilk , an 
effect o f  the different manufacturing p rocesses, or the use o f  d ifferent cultures in  the 
cheese. Studies have dem onstrated that such  parameters as temperature, protein  
quality, ch o ice  o f  starter culture and period o f  ageing can a ffect the C L A  content o f  
dairy and m eat products (Fritsche and Steinhart, 1997, G arcia-Lopez et al, 1994, 
Jiang et al, 1997, L in et al, 1995, Shantha et al., 1994 a,b), although no effect o f  
cheese manufacture w as observed by others (D him an et al., 1999b, W erner et al., 
1992). D ifferences have also been  observed in the C L A  content o f  the m ilk  o f  
different sp ecies w ith  the h ighest level reported in sheep’s m ilk  fo llo w ed  by c o w ’s 
m ilk  and then goat’s m ilk  (Jahreis et al, 1999). This m ay account for the low er CLA
content o f  the goat cheese in this study, but yoghurt m anufactured from  goats’ m ilk  
did not d isp lay low er C LA  content that other sam ples. T he T FA  content o f  the  
products containing hydrogenated vegetab le o ils  w as h igher than th ose containing  
m ilk fat, an observation m ade previously (A ckm an and M ag, 1998).
The fractionation o f  m ilk  fat for C L A-enrichm ent m ay provide an alternative m ethod  
to approaches involv ing  dietary oil supplem ents, w h ich  have led  to elevated  m ilk  fat 
CLA and i l  1-C i8:i- Furthermore, m ilk  fat fractionation had a p ositive  im pact on  the 
t\ 1 -Ci8 i and polyunsaturated fatty acid content o f  the C L A  enriched fraction. 
C onsum ption o f  C LA-enriched butter o il w as associated  w ith  anticancer effects in  
rats, and enhanced accum ulation o f  CLA in  rat tissu e resulted from  the butter 
consum ption, com pared w ith  CLA from  synthetic sources (Ip et al., 1999a). It is  
suspected that the tl  l-Cjgii m ay act as the precursor o f  endogenous C LA  synthesis. 
Thus, m ilk  fat enriched in CLA and tl 1 -C ig :i, by dry fractionation m ay offer a m eans 
to generate a food  ingredient w ith  potential benefits to hum an health.
3.6 Sum m ary
This study investigated the effect o f  fat fractionation on  the C L A  (c9 , /I I -C is :2) 
content o f  bovine m ilk  fat. Anhydrous m ilk  fat w as fractionated into hard and soft 
fractions using controlled coo lin g  and agitation. Fractionation o f  m ilk  fat pre-m elted  
at 60  °C using a temperature program m e o f  33 °C to 10 °C and a  co o lin g  rate o f  0 .58  
°C/h yielded  a  soft fraction containing 63 .2  % m ore C L A  (2 .2 2  g /1 0 0  g  FA M E), 
w hich  w as also  enriched in polyunsaturated fatty acids and trans vaccen ic  acid  ( / l l -  
Ci8:i) com pared w ith  the parent fat. A gitation  fo llow in g  fractionation w as found to
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have a  negative effect on  the C L A  content o f  the so ft fraction. R efractionation  o f  the 
soft fraction d id  not increase the y ie ld  o f  CLA. The C L A  and T F A  content o f  2 6  
selected  food  products ranging in  m ilk  fat content from  0 to  100 % is  reported. CLA  
concentrations ranged from  0  to  16.2  m g/g  fat and w ere generally  low er than the T FA  
content w h ich  ranged from  0 to  155.7  m g/g  fat. Spreads contain ing vegetab le o ils  
contained higher TFA  and low er C LA  contents than m ilk  fat-contain ing products. 
T his study h ighlights that a m ilk  fat fraction enriched in  C L A  m ay b e ach ieved  by  dry 
fractionation.
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CHAPTER 4
Antioxidant enzyme defence responses of human MCF-7 
and SW480 cancer cells to conjugated linoleic acid
* Published in Anticancer Research 19: 1953-1960 (1999)
4.1 INTRODUCTION
A  study o f  the relationship betw een  conjugated polyunsaturated fatty acid-induced  
cytotoxicity  and lipid  peroxidation has revealed the sign ificance o f  the conjugated double  
bond system  in enhancing superoxide radical generation in  cancer ce lls  (C ornelius et al, 
1991). The ability o f  antioxidants to prevent cytotox icity  caused  by  parinaric acid , a 
polyunsaturated fatty acid  w ith  4  conjugated double bonds, is  ev id en ce that lipid  
peroxidation significantly contributes to cytotoxicity . W hether C L A  m ediates a cancer 
cell - sp ecific  prooxidant effect sim ilar to parinaric acid  rem ains to  be determ ined. 
Critical factors influencing in vitro oxidation  o f  C L A  include temperature, presence o f  
m etal ions, extent o f  aeration, hydration, concentration and degree o f  esterification  (Chen  
et al., 1997, V an den B erg et al., 1995, Y uraw ecz et al., 1995). T he oxidative  
susceptib ility  o f  C L A  w as higher than that o f  L A  w hen  tested  in  a  m em brane m odel 
system  com posed  o f  1-palm itoyl -2 -lin o leoy l phosphatidyl ch o lin e under different m etal- 
dependent and independent ox id isin g  conditions (V an den B erg  et al., 1995). Such  
prooxidant inferences m ay n eed  to be interpreted cautiously  in  v iew  o f  other studies  
show ing that C LA  w hen  ox id ised  produces furan fatty acids w h ich  m ay th em selves have  
antioxidant properties (Y uraw ecz et al., 1995). A lthough  ox id isin g  conditions have been  
im plicated in a w ide variety o f  degenerative p rocesses including cancer, the in fluence o f  
the oxidative susceptib ility  o f  C LA  in cancer ce lls  has yet to  be elucidated. A ntioxidant 
activity, as m easured by  the am ount o f  T B A R S in m am m ary tissu e w as reported by Ip et 
al. (1991) in the C L A -fed  D M B A  cancer inducing rat m odel. The antioxidant activity
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w as independent o f  dietary C L A  concentration above 0 .25  % and did not correlate w ith  
the concentration o f  C L A  causing m axim al tumour inhibition.
In another study (Ip et ah, 1996), supplem entation o f  rats fed a 20  % co m  o il d iet w ith  1 
% C LA  for 2 m onths resulted in low er lev e ls  o f  m am m ary tissu e M D A  com pared to 
control rats not receiv ing  C LA, how ever the lev e ls  o f  8 -hydroxydeoxyguanosine (a 
marker o f  oxidatively  dam aged D N A ) w ere unchanged b etw een  the tw o groups. It is 
apparent from  these studies that the ability o f  C L A  to inhib it peroxidation  o f  neutral 
lipids in  mam mary tissue m ay not be effective  at protecting ce ll D N A  against dam age by  
reactive oxygen  sp ecies and that its antioxidant e fficacy  m ay not be im portant in  cancer 
protection.
CLA is  incorporated into rat m am m ary and m ouse forestom ach tum our phospholip ids as 
w ell as neutral lip ids (H a et ah, 1990, Ip et ah, 1991), and therefore the potential o f  CLA  
to m odulate ce ll m em brane-m ediated events and alter fat m etabolism  m akes defin ing its 
role on  cellular ox idative tone o f  great importance. In v iew  o f  findings that gen es for a 
number o f  proteins affecting  ce ll proliferation and various antioxidants are induced in  
response to oxidative stress (Janssen et ah, 1993), a  study o f  the effec ts  o f  C L A  on  the 
antioxidant defence system  o f  cancer ce lls  m ay provide inform ation on  the oxidative  
stress status o f  cancer ce lls  w hen  exp osed  to CLA.
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4.2 Objectives
T o investigate the effects o f  varying dose and tim e responses o f  a m ixture o f  conjugated  
lino leic  acid isom ers on  the grow th o f  M C F-7 breast cancer ce lls  and S W 480  co lon  
cancer ce lls  and to explore the effect o f  CL A  on protein, D N A  and R N A  synthesis. T o  
investigate i f  the grow th suppressive effects o f  C LA  are m ediated  b y  sp ecific  effects on  
lipid peroxidation, by exam ining the effect o f  C L A  on  the antioxidant defence en zym es  
catalase, SO D  and G Px.
4.3 Materials and methods
4.3.1 Cell culture
Hum an breast (M C F-7) and co lon  (S W 480) cancer ce ll lines w ere obtained from  the  
A m erican T ype Culture C ollection , (R ockville , M D , U S A ). Culture m edia and 
supplem ents w ere purchased from  G IBC O BR L (P aisley , Scotland). T he M C F-7 ce lls  
w ere m aintained in  D ulbecco's M inim um  E ssential M edium  supplem ented w ith  5 % v /v  
fetal bovine serum, 0 .2  m M  L-glutam ine, 1 m M  H E PE S, and 1 unit/m l p en icillin  and
streptom ycin. The S W 480 ce lls  w ere m aintained in the sam e m edium  as for M C F-7 ce lls
• 2containing, in  addition, 10 m M  sodium  pyruvate. C ells w ere grow n in F alcon  T -25 cm  
flasks and m aintained at 37  °C in  a hum idified  atm osphere. T he pH  o f  the m edia w as  
m aintained at 7 .2 -7 .4  b y  a required flo w  o f  95 % air and 5 % C O2. U sin g  these  
conditions the effects o f  C L A  (N u-C hek Prep, Inc., E lysian , M N , U S A ) on  the grow th o f
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co lon  and m am m ary cancer ce lls  were determined. In itially  1 x  10 6 ce lls  w ere plated in  
flasks and cultured for 24  hours a llow ing the ce lls  to  attach to  the substratum. The 
m edium  w as then replaced w ith  m edium  alone or m edium  supplem ented w ith  various 
concentrations o f  C LA , 0 (control) 5, 10 and 20  ppm  C L A , d isso lved  in  ethanol. Control 
flasks w ere supplem ented w ith  ethanol to a final concentration o f  0.1 % (v /v ) as in 
experim ental flasks. F o llow in g  incubation, ce lls  w ere harvested u sing  phosphate  
buffered saline (P B S) containing 0.25 % (w /v ) trypsin and counted on  days 4, 8 and 12. 
F ollow ing  each ce ll count, the ce lls  w ere again incubated in  fresh m edium  contain ing the 
appropriate concentration o f  CLA. C ell v iab ility  w as determ ined u sin g  the Trypan blue 
exclu sion  (0.1 % w /v ) m ethod. D ays 4 , 8 and 12 corresponded to the tim es w h en  the 
control flasks w ere at 20  %, 60  %, and 100 % con flu en cy , respectively .
4.3.2 Radiolabelled precursor incorporation into protein, RNA and DNA 
The M CF-7 and S W 480 ce lls  (1 x  106) w ere cultured in appropriate m edium  for 24  hours 
prior to beginning the experim ent. The m edium  w as then replaced w ith  m edium  alone or 
m edium  supplem ented w ith 2 0  ppm CLA. The S W 480  ce lls  w ere incubated w ith  C LA  at 
37 °C for 2  days and the M C F-7 ce lls w ere incubated w ith  C L A  for 6 days, w h en  both  
cultures w ere pulsed  for 6 h w ith  L -[4 ,5 -3H ]leu cin e (163 C i/m m ol, 5 fiC i/flask), [6- 
3H]uridine (17 .8  C i/m m ol, 5|xCi/flask), or [5-3H ]thym idine (163 C i/m m ol, 5|aC i/flask) as 
described by  Shultz et al. (1992a). F o llow in g  incubation w ith  the radioactive precursors, 
the m edium  w as rem oved and ce lls  harvested and centrifuged at 1000 x  g  for 5 m in. 
C ells w ere then w ashed  three tim es in cold  P B S  and the supernatant discarded. O ne m l 
o f  cold  10 % (w /v ) trichloroacetic acid (T C A ) w as added to  the ce ll p e lle t and the
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mixture vortexed for 1 min. The tubes were maintained on ice for 15 m in and 
centrifuged at 750 x g for 10 min. The pellet was washed three tim es in TCA (10 %  w/v) 
and resuspended in 100 fil o f  Protosol tissue solubilizer (Amarsham Pharm acia Biotech, 
Little Chalfont, Buckinhamshire, UK) and digested for 60 m in at 30 °C. The digested 
material was transferred to liquid scintillation vials with 3 ml m ethanol followed by 12 
ml o f  scintillation fluid and counted in a Beckm an LS 6500 scintillation counter. 
Counting efficiency o f tritium  [3H] was 63 %. The amount o f  radioactivity in the TCA- 
insoluble material was a measure o f  the incorporation into protein, RNA and DNA.
4.3.3 Lipid peroxidation analysis
The TBARS test as described previously (Esterbaur and Cheeseman, 1990) was used to 
measure MDA. Cells were seeded as described earlier and after incubation for 24 hours 
the medium was replaced with medium alone or medium supplem ented with varying 
concentrations o f  CLA as described above. A t days 4, 8 and 12, cells w ere harvested and 
disrupted by the addition o f  2 ml o f  10 % (w/v) TCA to precipitate the protein. The 
precipitate was pelleted by centrifugation and an aliquot o f the supernatant was reacted 
with an equal volume o f  0.67 % (w/v) TBA in a boiling waterbath for 20 mins. After 
cooling, absorbance was measured at 535 nm  and the concentration o f  M DA was 
calculated based on an s value o f 153,000. All solutions were freshly prepared on the day 
o f assay.
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4.3.4 Antioxidant enzyme assays
SOD and GPx activity were determined using Ransod and Ransel kits (Randox 
Laboratories Ltd., Armagh, Northern Ireland), respectively. The units o f  G Px activity are 
defined as nmol NADPH oxidised/min at pH 7.4 and 30 °C. 1 unit o f  SOD activity is 
that quantity o f  enzyme that inhibits by 50 %  the conversion o f  xanthine by xanthine 
oxidase to a formazon dye. Catalase activity was determined as described (Aebi, 1984) 
and expressed in milli Bergmeyer units which are defined as nmol [H2O2] decomposed 
m in '1 m l'1 at pH 7 and 25 °C.
4.3.5 Statistical analysis
The experimental design for GPx, TBARS, SOD, catalase and growth curve was a split- 
plot with three replicates. The main plot effects were CLA, cell lines, CLA x cell lines 
and replicates, the sub-plot effects were days, CLA x days, cell lines x days and CLA x 
cell lines x days. In the isotope studies, there was only a  single tim e point and the design 
was a randomised block with effects CLA, cell lines, CLA x cell lines and replicates. 
The data was analysed using GENSTAT and the least significant difference w as used as a 
guide to determine specific differences w ithin the effects.
4.4 RESULTS :
4.4.1 Cell growth experiments
The effect o f incubation with CLA (5-30 ppm) on the viability o f  M CF-7 and SW480 
cancer cell lines is shown in Figure. 4.1. Though SW480 cells displayed more vigorous
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growth than MCF-7 cells, there was a significant decrease (p < 0.001) in cell numbers for 
both cell lines when supplemented with varying concentrations o f  CLA over a period o f 
12 days, with a statistically greater (p < 0.001) cytotoxic influence on M CF-7 cells than 
on SW480 cells. M aximal growth suppression occurred in both cell lines following 
supplementation w ith 15-30 ppm  CLA for 8 to 12 days.
4.4.2 Radiolabelled precursor incorporation studies.
The effects o f  CLA on radiolabeled leucine, uridine and thym idine incorporation into 
protein, RNA and DNA respectively is shown in Table 4.1. Both M CF-7 and SW 480 cell 
lines incorporated 91-93 % less 3H leucine, 56-91 % less 3H uridine and 73-91 % less 3H 
thymidine when supplemented with 7.14 x 10'5 M (20 ppm) CLA than did 
unsupplemented control cells. Though the inhibitory effect o f  CLA on uridine and 
thymidine incorporation was more pronounced in M CF-7 cells (8.6 % and 9.0 % 
respectively, relative to controls) than in SW 480 cells (43.1 % and 27.3 % respectively, 
relative to controls) inhibition o f leucine incorporation was similar in both cell lines.
4.4.3 Lipid peroxidation analysis.
Levels o f  intracellular MDA measured by the TBARS assay increased significantly (p < 
0.001) in a dose and time-dependent manner in both cell lines, the effect being greater in 
the MCF-7 cells (Figure 4.2a) than in SW 480 cells (Figure 4.2b). Follow ing 4 days o f 
supplementation o f  MCF-7 cells with CLA (30 ppm), TBARS increased six-fold 
compared with controls (0.03 nmoles M DA/10 cells).
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Concentration of CLA ppm
■day 4 
□day 8 
■day 12
Figure 4.1 (a)
■  day 4 
□  dayB
■  day 12
Figure 4.1 (b)
Figure 4.1 Growth curve o f  M CF-7 cells (a) and SW 480 cells (b) over a 12 day 
incubation with varying levels o f  CLA. The SEM for these results was 226.98.
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T ab le  4 .1  The effect o f  CLA on uptake o f  tritium radiolabelled uridine and thymidine 
into MCF-7 cell lines
Precursor Medium supplement MCF-7 SW480
level o f  CLA (M)
TCA- % TCA- %
insoluble incorporation insoluble incorporation
fraction relative to control fraction
relative to 
control
(iCi/flask l^iCi/flask
Leucine Control 2.70 6.6% 1.54 8.4%
7.14 x 10'5 0.18 0.13
Uridine Control 1.97 8.6% 1.23 43.1 %
7.14 x 1 O'5 0.17 0.53
Thymidine Control 1.44 9.0% 1.98 27.3%
7.14 x 10’5 0.13 0.54
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Increasing the time period for supplementation to 8 and 12 days increased M DA levels to 
0.1 and 0.105 nmoles M DA/103 cells, respectively. However, w hen cells were 
supplemented w ith lower concentrations o f  CLA (10-20 ppm), the onset o f  lipid 
peroxidation was delayed to between 8 and 12 days (Figure 4.2a). Supplem entation o f  
SW480 cells with 30 ppm CLA resulted in a significant increase in M D A  on day 4 (0.012 
nmoles M DA/103 cells), day 8 (0.062 nmoles M DA/103 cells) and day 12 (0.1 nmoles 
M DA/103 cells) (Figure 4.2b). Lipid peroxidation was induced only w hen these cells 
were supplemented with >_15 ppm  CLA for 8 days or more.
4.4.4 Super oxide dismutase activity.
SOD activity increased in both cell lines with the greatest effect being seen in MCF-7 
cells following supplementation w ith 20 ppm CLA on all days (p < 0.001). Activity 
increased 3-4 fold above control levels on day 4 with 20 ppm  CLA (0.018 mU/103 cells) 
but increased approximately 35-fold above control levels by day 12 (0.05 mU/10 cells) 
(Figure 4.3a). Levels o f  SOD activity in SW480 cells were sim ilar to those o f  control 
cells on days 4 and 8 at all concentrations o f  CLA (Figure 4.3b). A  significant increase 
(p < 0.001) in SOD activity in these cells was observed following 12 days o f  incubation 
with CLA (20 ppm), resulting in similar activity to that obtained in the MCF-7 cell line 
following 12 days o f  incubation w ith 20 ppm CLA (Figure 4.3).
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Figure 4.2 (a)
Concentration of CLA ppm
Concentration of CLA ppm
Figure 4.2 (b)
Figure 4.2 Lipid peroxidation activity in MCF-7 cells (a) and SW 480 cells (b) as 
measured by TBARS. The SEM  for these results was 0.0086.
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Figure 4.3 Superoxide Dismutase activity in M CF-7 cells (a) and SW 480 cells (b). The 
SEM for these results was 0.0056.
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4.4.5 Catalase activity.
In MCF-7 and SW480 cells, catalase activity was not significantly stimulated by 
incubation with CLA, at concentrations o f  0 - 10 ppm  for up to 12 days (Figure 4.4). 
Supplementation o f  M CF-7 cells with 20 ppm CLA induced catalase activity 8-fold over 
controls by day 4 (0.017 mBergmeyer units/103 cells) and 19-fold on day 8 (0.01
-j #
mBergmeyer units/10 cells) (Figure 4.4a). The highest level o f  catalase activity (0.04 
mBergmeyer units/103cells) was observed following 12 days supplem entation w ith 20 
ppm  CLA. By contrast, catalase was maximally expressed in SW 480 cells on day 8 
(0.042 mBergmeyer units/10 cells) when cells were supplem ented w ith 20 ppm  CLA 
(Figure 4.4b). Following 12 days o f  incubation o f  SW 480 cells w ith CLA (20 ppm), 
catalase activity again declined but remained higher than control cells.
4.4.6 Glutathione peroxidase activity.
Supplementation o f MCF-7 cells w ith CLA (5-20 ppm) for 4 days had minim al effect on 
GPx activity (Figure 4.5a). However, incubation for 8 days w ith 20 ppm  CLA resulted in 
a 15-fold increase in GPx activity while lower concentrations o f  CLA had little effect. 
Highest GPx activity (2.2mU GPx/103 cells) was observed following incubation o f  MCF-
7 cells for 12 days with 20 ppm CLA (Figure 4.5a). In the SW 480 cells GPx activity was 
only expressed following 8 days o f  incubation with CLA at concentrations o f  10 and 20 
ppm. Following 8 days o f incubation o f  SW 480 cells w ith 20 ppm CLA, a 60-fold 
increase in GPx activity over control cells was obtained (Figure 4.5b) at 20 ppm  CLA. 
The effect on GPx activity on incubation o f  MCF-7 cells w ith CLA (20 ppm ) was more 
marked than in SW 480 cells, where a 2.07 - fold higher response was obtained following
8 days o f  incubation (Figure 4.5).
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Figure 4.4 (a)
Concentration of CLA ppm
Figure 4.4 (b)
Figure 4.4 Catalase activity in MCF-7 cells (a) and SW 480 cells (b). The SEM  for these 
results was 0.0022.
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Figure 4.5 (a)
Concentration of CLA ppm
Concentration of CLA ppm
Figure 4.5 (b)
Figure 4.5. Glutathione Peroxidase activity in M CF-7 cells (a) and SW 480 
cells (b). The SEM for these results was 0.104156.
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The biochemical mechanism by which CLA exerts its activity has yet to be elucidated, 
despite existing evidence for a number o f  possible mechanisms (Belury and Kempa- 
Stecko, 1997, Belury et a l, 1997, De Voney et a l, 1997, W ong et a l, 1997) e.g. altered 
eicosanoid m etabolism (Cunningham et a l, 1997, Liu and Belury, 1998), conversion to 
potent cytotoxic lipid peroxidation products in hum an tum our cell lines (Schonberg and 
Krokan, 1995) and inhibition o f protein and nucleic acid biosynthesis (Shultz et a l, 
1992a). In this study we have observed a cytotoxic effect o f  CLA, and have provided 
evidence for inhibition o f  protein and nucleic acid biosynthesis by CLA and increased 
peroxidation leading to activation o f the cellular antioxidant defence enzymes.
A  dose and time dependent inhibitory effect o f  CLA on hum an M CF-7 cells is well 
documented (Schultz et a l, 1992a). The results o f  this study confirm  and extend 
previous findings o f  Schonberg and Krokan (1995) indicating that the inhibitory effect o f 
CLA on the growth o f  human tum our cells was accompanied by increased lipid 
peroxidation. We found that CLA exerted a growth inhibitory effect in a dose- and time- 
dependent manner. In this investigation, inhibition o f  the growth o f  m ammary and colon 
cancer cells in vitro following supplementation w ith CLA was characterised by inhibition 
o f  protein and nucleic acid biosynthesis as seen previously by Shultz et al. (1992a) and 
induction o f  lipid peroxidation and cellular antioxidant enzyme defences. In view o f 
findings that lipid peroxides and free radicals can induce enzyme, protein, and DNA 
damage (Roubal and Tappel, 1996, Reiss and Tappel, 1973) it is probable that 
suppression o f growth o f  both cell lines could have been mediated at least in part by an
4.5 Discussion
192
increased susceptibility o f  CLA to undergo lipid peroxidation. Cellular prooxidant states 
promote lipid peroxidation, and is a mechanism by which polyunsaturated fatty acids 
may exert their inhibitory effects on cancer cell proliferation. It has been proposed that a 
conjugated double bond system may allow for more efficient trapping o f  electrons 
resulting in the likelihood o f  superoxide anion generation (Belury and Kempa-Steczo,
1997). Thus, addition o f  CLA to cancer cells m ay stimulate the initiation o f  its own 
oxidation by increasing the amount o f  0 2‘ radicals and by increasing the substrate 
concentration available for lipid peroxidation.
The occurrence o f  lipid peroxidation in both cell lines exposed to CLA is indicative o f  an 
overloading o f the endogenous defence system and the generation o f  severe cellular 
oxidative stress. SOD represents the first line o f  antioxidant defence dismuting 
superoxide radicals to hydrogen peroxide and water. In this study, SOD w as increased in 
both cell lines exposed to CLA indicating the presence o f  O2 ' species, the m ajor initiator 
o f  the oxygen radical cascade that feeds into the lipid peroxidation chain reaction. As 
hydrogen peroxide, the end product o f  SOD activity, is also causative o f  oxidative stress, 
a second enzyme either catalase or GPx is required to remove the hydrogen peroxide 
formed. Lipid peroxidation in the MCF-7 cells suggest that CLA at a concentration o f  20 
ppm may act as a prooxidant generating potential reactive oxygen species as a result o f 
its conjugated diene double bond structure. The onset o f  lipid peroxidation after day 8 
supplementation o f  the more vigorously growing SW 480 cells is also suggestive o f  the 
presence o f  reactive species. The absence o f  SOD activity in SW 480 cells following 
supplementation for 4 and 8 days suggests a possible role for non-enzym atic 0 2 ’
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scavenging molecules. Since lipid peroxidation was maximally induced by day 8 it is 
apparent that as with M CF-7 cells, adding CLA to SW 480 cells rendered them 
susceptible to lipid peroxidation. Activation o f  all enzymes in  the antioxidant defence 
system supports the onset o f  an oxidatively stressed cellular m ilieu w hen cells are 
supplemented w ith CLA. We conclude that the antioxidant defence enzymes failed to 
protect cancer cells from the cytotoxic effects o f  lipid peroxidation products.
4.6 Summary
The relationship between antioxidant-enzyme defence responses and cellular growth 
suppression in human MCF-7 and SW480 cancer cells, exposed to CLA in culture was 
studied. MCF-7 and SW480 cells (1 x 106/flask) were cultured in appropriate medium 
for 4, 8 and 12 days w ith varying levels o f  CLA (0-30 ppm). A  dose-dependent decrease 
in cell numbers and increase in lipid peroxidation, as determined by TBARS was 
observed in both cell lines following incubation with CLA. Exposure o f  both cell lines to 
20 ppm CLA for 2 - 6 days produced a reduction (91-93 %) in 3H leucine incorporation 
into protein while 3H uridine and 3H thymidine incorporation into RNA and DNA were 
reduced by 56-91 % and 73-91 %, respectively, compared with untreated control cells. 
The activities o f  SOD, catalase and GPx were induced in both cell lines exposed to CLA 
(20 ppm) over a period o f  12 days, although to a greater extent in M CF-7 cells than in 
SW480 cells. The data indicate that CLA-induced cytotoxicity against M CF-7 and 
SW480 cancer cell lines is related to the extent o f  lipid peroxidation o f  CLA treated cells 
and affirm that the CLA-induced antioxidant enzymes failed to protect these cells from 
cytotoxic lipid peroxidation products.
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CHAPTER 5
Milk fat conjugated linoleic acid (CLA) inhibits prowth of 
human mammary MCF-7 cancer cells.
* Accepted for publication to Anticancer Research May 2000
5.1 Introduction
CLA is a potent anticarcinogen in animal models (Ip et al., 1994), and has been shown 
to inhibit skin papillomas, mammary tumours and colon aberrant crypt foci (Belury et 
al., 1996, Ip et al., 1996, Liew et al., 1998). A n epidemiological study showing an 
inverse association between risk o f  breast cancer and intake o f  dairy products provides 
indirect evidence that dietary CLA is a  biologically active anticarcinogenic fatty acid 
(Knekt et al., 1996). Furthermore, a study by Lavillonniere and Bougoux (1999) 
showing that CLA content was higher in adipose tissue from benign breast tum ours than 
from m alignant breast tumours, suggests a  protective effect o f  dietary CLA against 
breast cancer in humans. In addition, feeding CLA-enriched butterfat to rats during the 
time o f  pubescent mammary gland development, led to alterations in m am m ary gland 
morphogenesis and a reduction in mammary cancer risk (Ip et al., 1999a).
Potent anticarcinogenic effects o f  CLA have until recently been attributed to a synthetic 
mixture o f CLA at levels as low as 1 % in the diet containing similar amounts o f  c9, t\  1 
(29.5 %) and ¿10, c l2  CLA isomers (29 %) (Ha et al., 1990, Ip et al., 1991, Pariza and 
Hargraves, 1985, Schut et al., 1997). The c9, t i l  CLA isom er was preferentially 
incorporated into phospholipids o f  rat mammary tumour extracts (Ip et al., 1991) and 
studies have shown that this isomer inhibited the growth o f  normal rat mammary 
epithelial cell organoids (Ip et al., 1999b). CLA and its m etabolites have also been 
shown to accumulate in mammary tissue in  a dose-dependent manner, while LA 
metabolites decreased (Cis:3, C20:3 and C20A) (Banni et al., 1999). The c9, t l  1 form is the
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predominant (92 %) CLA isomer found in m ilk fat triglyceride form  (Chin et a l, 1992). 
CLA has been identified in cholesteryl esters, triglycerides, phospholipids and free fatty 
acid extracts o f  hum an serum (Cawood et a l, 1983, Iversen et al., 1984). Studies have 
shown that increasing dietary CLA led to increases in the CLA content o f  plasm a (Britton 
et al., 1992, Huang et al., 1994, Salminen et al., 1998), adipose tissue (Jiang et a l, 1999) 
and milk fat in humans (Park et al., 1999a). The concentration range o f  CLA (0-20 ppm) 
used in cell culture studies (Cunningham et al., 1997, D urgam  and Fernandes, 1997, 
Shultz et al., 1992a,b) spans the concentration o f CLA reported in hum an plasm a (Herbel 
et al., 1998, Huang et al., 1994, Iversen et al., 1985).
5.2 Objectives
A number o f studies have shown that CLA content o f  m ilk m ay be increased by 
modifying the dietary regime o f  the dairy cow (Dhiman et al., 1999a, Lawless et a l, 
1998, Kelly et al., 1998a). W e have previously shown that the m am m ary M CF-7 cancer 
cell line is susceptible to the cytotoxic effects o f  synthetic CLA (Chapter 4) and in this 
chapter, similar parameters were exam ined using CLA-enriched m ilk fat. The present 
chapter reports on the effects o f  incubation o f  CLA-enriched m ilk fat, obtained from 
cows on pasture, supplemented with full fat soybeans (FFS) or full fat rapeseeds (FFR), 
on the growth and antioxidant enzyme defence responses o f  M CF-7 cancer cells. These 
effects were compared with those o f  a control milk fat, not enriched in CLA, and with a 
CLA-enriched milk fat fraction obtained by dry fractionation using a temperature 
programme o f 33 °C to 10 °C and a cooling rate o f 0.58 °C h '1 (Chapter 3). The uptake o f 
CLA by the MCF-7 cells from m ilk fat and synthetic CLA isomers was also examined.
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5.3 Materials and methods
5.3.1 Culture o f  MCF-7 cells.
The human breast cancer cell line (MCF-7) was cultured exactly as outlined in chapter 4.
5.3.2 Preparation o f milk fa t samples.
The milk fat used in this study was obtained following supplem entation o f  lactating dairy 
cows on pasture with full fat rapeseeds (FFR) and full fat soybeans (FFS) for 33 and 34 
days, respectively. The level o f  supplementation and trial conditions were exactly as 
previously described (Lawless et ah, 1998). Composite m ilk  samples for each herd, 
consisting o f  the morning and evening m ilk o f  each individual cow (based on the 
morning and evening m ilk yields) were taken on day 32 for anim als fed pasture only 
(control), day 33 for FFS-fed animals and day 34 for FFR-fed animals. The fat was 
extracted from whole m ilk by centrifugation, as described previously (M urphy et ah, 
1990) and stored at -  20 °C prior to GLC analysis. In addition, a soft m ilk fat fraction 
was obtained by dry fractionation o f  milk fat using a temperature range o f 33 to 10 °C 
and a cooling rate o f 0.58 °C/h (Chapter 3).
5.3.3 Treatment o f  MCF-7 cells.
Initially, 1 x 106 cells were seeded in flasks and cultured for 24 h  allowing the cells to 
attach to the substratum. The medium was then replaced with m edium  containing ethanol 
to a final concentration o f  0.1 % (v/v) (control) or medium supplem ented with CLA
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isomers, LA or various concentrations o f  milk fat dissolved in ethanol and incubated for 
8 days prior to harvest. Three synthetic sources o f  CLA were used in this study, 
including a mixture o f CLA isomers obtained from N u-Chek Prep (Inc., Elysian, M N), 
containing 29.5 % c9, i l l  and 29 % 110, c l2  CLA isomers (in addition to minor 
components o f  other isomers (Sehat et al„ 1998)), and pure c9, /11-CLA and ilO, c l2  
CLA isomers (Matreya, Pleasant Gap, PA). Cells were harvested in the presence o f  
phosphate buffered saline (PBS) containing 0.25 % (w/v) trypsin and viability assessed 
using the trypan blue exclusion assay prior to analysis o f  lipid peroxidation and 
antioxidant enzyme defence activities.
5.3.4 Lipid peroxidation and antioxidant enzyme assays.
Cells obtained from incubation w ith varying concentrations o f  CLA, LA and milk fat 
were monitored for lipid peroxidation using the TBARS test, as described previously 
(Chapter 4). SOD and GPx activities were determined using Ransod and Ransel kits 
(Randox Laboratories Ltd., Armagh, Northern Ireland), respectively. The units o f  GPx 
activity are defined as nmol NADPH oxidised / m in at pH  7.4 and 30 °C. A  unit o f  SOD 
activity is described by the quantity o f  enzyme that inhibits by 50 % xanthine oxidase 
mediated conversion o f  xanthine to a formazon dye. Catalase activity was determined as 
described previously (Chapter 4) and expressed in Bergm eyer units, nmol [H2O2] 
decomposed m in '1 m l'1 at pH 7 and 25 °C.
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5.3.5 Uptake o f l4C-CLA
The lipids o f  MCF-7 cells, incubated w ith 14C-CLA were separated into neutral lipid, 
phospholipid and monoglyceride fractions and analysed for uptake o f  radiolabelled CLA 
(Hamilton and Comai, 1988). M edia containing 0.025, 0.05, or 0.1 jo-Ci 14C-CLA 
(American Radiolabeled Chemical Inc., St. Louis, MO, specific activity 55 mCi/mmol) 
was added to confluent MCF-7 cells for 24 h prior to harvest. Cells were harvested and 
total lipids extracted from the cell pellets obtained from each flask (n=3 per treatment) 
using the method o f Folch et al. (1957) and resuspended in 1 m l o f  chloroform. Cellular 
lipids were fractionated into neutral lipids, monoglycerides and phospholipids using the 
procedure described by Hamilton and Comai (1988). A n aliquot (200 jj.1) o f  each fraction 
was counted by liquid scintillation (LS6500 Beckmann) to determine the levels o f  14C- 
CLA present in each lipid fraction.
5.3.6 Uptake o f CLA into MCF-7 cell membranes
The ability o f  MCF-7 cells to incorporate CLA from different sources was examined. 
Cells were seeded in T-75 cm2 flasks at a density o f  5 x 106 per flask and grown to 90 % 
confluency. Cells were then incubated for 24 hours w ith m edium  containing ethanol to a 
final concentration o f  0.1 % (v/v) (control), medium supplem ented w ith 20 ppm  c9, i l l  
CLA (Matreya), or with medium supplemented with control m ilk fat or FFR m ilk fat 
dissolved in ethanol, each o f which were included to yield a final c9, i l l  CLA 
concentration o f  20 ppm. Subsequently, total cellular lipids were extracted from the cells 
using the method o f Folch et al. (1957), resuspended in 1 ml o f  chloroform  and stored at 
-  20 °C prior to GLC analysis.
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supplemented with full fat rapeseed, respectively. The fatty acid com position o f  the milk 
fat samples was variable between treatments, the most abundant fatty acid Ci6:o, varied in 
content from 21.05 ± 0.08 to 27.2 ± 0 .1 1  g/100 g FAM E for the FFR and soft fraction 
milk fat samples, respectively. The C is:i content ranged between 20.28 ±  0.187 to 28.39 
±  1.62 g/100 g FAM E for the control milk fat and soft fraction, respectively. The ratio o f  
LA/CLA varied between samples from 0.74 ± 0.001 (control m ilk fat) to 2.34 ±  0.004 
(FFS); the LA (Cig:2) content o f  the FFS m ilk fat was at least 2.5-fold higher than the 
other milk fat samples. t\  1-Ci8:i content also varied between samples w ith the control 
milk fat containing 3.14 ± 0.173 g/100 g FAME and the soft fraction containing the 
highest level at 5.18 ±  0.082 g/100 g FAM E (Table 5.1).
5.4.2 The effects on cell viability o f  CLA enriched milk fat.
The effects o f incubation o f  a mixture o f  CLA isomers (N u-Chek Prep), LA, c9, i l l  
CLA, ilO, c l 2 CLA (Matreya) and milk fat on the growth o f  M CF-7 cells during 8 days 
were determined. The m ilk fat content o f  the medium varied between 0.8 to 1.2 mg/ml to 
yield a final CLA concentration o f  20 ppm. All m ilk fat samples significantly lowered (p 
< 0.05) cell numbers to approximately 7-9 % o f untreated control cells, following 8 days 
o f  incubation (Figure 5.1a). However there was no significant difference between the 
final cell numbers (8.3-11.7 x 104 cells) for all m ilk fat treatments. Subsequently MCF-7 
cells (1 x 106 cells/flask) were incubated for 8 days in the presence o f  1 mg /ml milk fat 
to yield CLA concentrations from 16.9 to 22.6 ppm. This perm itted an exam ination o f 
the effect o f  increasing the milk fat CLA concentration, while the m ilk fat content was 
kept constant.
Table 5.1. Fatty acid com position o f  the milk fat samples.
Milk Fatty Acids (g /100 g  FAME)
Fatty Acid Control m ilk f a t 1 FFS milk f a t 1 FFR m ilk f a t 1 Soft fraction milk
(n=2) (n=2) (n=2) (n=3)
C 12:0 4.15 ± 0 .004 3.19 ±0.003* 2.74 ±  0.009* 4.00 ± 0 .120
C i2 :l 0.10 ±0.001 0.07 ±0 .001* 0.07 ± 0.003* 0.24 ± 0 .010
C i4:0 12.00 ± 0.005 9.58 ±0 .001* 9.53 ±0 .061* 12.20 ± 0 .212
C i4 :l 1.15 ±0 .003 0.89 ±  0.002* 1.03 ±0 .006* 1.28 ± 0 .016
Cl 5:0 1.43 ±0 .015 1.08 + 0.009 1.22 ±0.022* 0.98 ± 0.042
C l  6:0 25.93 ±0 .018 21.23 ±0.023* 21.05 ±0.079* 27.2 ± 0 .210
C16:1 1.70 ± 0 .007 1.51 ±0 .003* 1.82 ±0.008* 2.27 ± 0.071
Cl 7:0 0.62 ± 0.005 0.53 ±0 .001* 0.52 ±0.003* 0.82 ±0.011
C i8:0 10.20 ± 0 .010 12.42 ±0.016* 11.07 ±0 .037* 12.83 ± 0 .050
C 18:1 20.28 ± 0 .187 23.37 ±0 .605 26.92 ± 0.579* 28.39 ± 1.621
Ci 8:i vaccenic 3.14 ±0 .173 4.41 ± 0 .604 4.64 ±  0.465 5.18 ± 0 .082
Cl8:2 1.25 ± 0 .045 4.28 ± 0.020* 1.69 ± 0 .353 1.19 ± 0 .120
C l8:3 0.80 ± 0.006 1.07 ±0.001* 0.71 ±  0.007 1.20 ± 0 .100
C i 8:2 CL A 1.69 ± 0 .004 1.83 ±0.005* 2.26 ± 0.005* 2.22 ± 0 .010
S am ples obtained through manipulation o f the dietary regim e o f  dairy cows (Lawless et 
ah, 1998). *Denotes values that are significantly different to the control m ilk fat (p < 
0.05). 2Sample obtained by dry fractionation o f  milk fat (Chapter 3).
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The cell numbers obtained following incubation w ith all m ilk fat samples were 
significantly (p < 0.05) less than the untreated control cells following 8 days o f 
incubation and a dose-dependent decrease in cell num ber was observed with increasing 
milk fat CLA content (Figure 5.1b). M aximal growth inhibition o f  91 % occurred at the 
highest CLA concentration.
Synthetic mixtures were prepared, containing CLA (20 ppm) and LA at concentrations 
similar to those found in the m ilk fat samples (15, 47 and 16 ppm  LA, for control (sample 
1), FFS (sample 2) and FFR (sample 3), respectively). These w ere incubated w ith MCF- 
7 cells for 8 days and the effect on cell viability was assessed (Figure 5.2a). A  significant 
(p < 0.05) inhibitory effect on cell numbers was obtained following incubation w ith all o f 
the CLA/LA mixtures, compared with untreated control cells. Samples 1, 2 and 3 
representing the CLA/LA mixtures were as effective in growth suppression as the milk 
fat treatments resulting in 89 %, 97 % and 92 % decrease in cell numbers, respectively, 
compared with control cells. There were no significant differences in cell numbers 
between the synthetic CLA/LA mixtures (Figure 5.2a).
Two individual isomers o f  CLA (c9, t\  1 CLA and flO, c l2  CLA, M atreya) and a mixture 
o f  CLA isomers (Nu-Chek Prep) were incubated w ith M CF-7 cells (1 x 106 cells) at a 
concentration o f  20 ppm for 8 days. In addition, the effects on cell growth o f  LA alone 
(20 ppm) and a mixture containing 20 ppm CLA (Nu-Chek Prep) and 20 ppm  LA were 
compared with untreated controls (Figure 5.2b).
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F igure 5.1. Growth curve o f MCF-7 cells incubated w ith milk fat samples each 
containing 20 ppm CLA for 8 days (a) and m ilk fat samples containing varying 
concentrations o f  CLA (16.9-22.6 ppm) over 8 days (b). * Denotes results which are 
significantly (p < 0.05) reduced compared with controls.
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F igure 5.2. Growth curve o f  M CF-7 cells incubated w ith a synthetic m ix o f  LA and 
CLA in similar concentrations to that found in the m ilk fat samples for 8 days (a) and 20 
ppm c9, t \  1 CLA, tlO, c l 2 CLA, Nu-Chek CLA and LA for 8 days (b). * Denotes results 
which are significantly (p < 0.05) different com pared w ith controls.
206
Cell numbers obtained following incubation in the presence o f  the pure c9, t \ \  CLA 
isomer and the N u-Chek Prep mixture were significantly (p < 0.01) reduced compared 
with untreated controls and the degree o f  inhibition o f  growth was not significantly 
different between the two CLA preparations (Figure 5.2b). It should be noted that the c9, 
t\ 1 CLA concentration in the medium containing the N u-Chek Prep m ixture was only 6 
ppm. Furthermore, there was also a reduction (p < 0.03) in cell numbers following 
incubation in the presence o f  the mixture containing 20 ppm  CLA (Nu-Chek Prep) and 20 
ppm LA (CLA/LA) compared with untreated controls (Figure 5.2b). This was not 
significantly different to the effect seen with CLA (Nu-Chek Prep) alone, suggesting that 
the presence o f  LA in combination with CLA did not have a significant effect on the 
growth suppressive potency o f  CLA on M CF-7 cells. However, the ¿10, c l 2 CLA isomer 
(20 ppm) had no effect on the growth o f  M CF-7 cells following incubation for 8 days 
compared with untreated controls. Finally, incubation o f  MCF-7 cells with LA alone (20 
ppm) for 8 days resulted in an increase (p < 0.05) in cell numbers com pared with 
untreated controls (Figure 5.2b).
5.4.3 Lipid peroxidation analysis.
LA (20 ppm) had a  negligible effect on lipid peroxidation in M CF-7 cells (Figure 5.3a). 
However, when the cells were incubated w ith the three m ilk fat samples (0.8 -  1.2 
mg/ml) M DA levels were significantly (p < 0.01) increased (> 9-fold) com pared with 
untreated controls (Figure 5.3a). No significant differences were obtained between the 
MDA levels from cells incubated with the different milk fat samples. W hen cells were 
incubated in the presence o f  1 mg /ml milk fat to yield CLA concentrations from 16.9 to
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22.6 ppm, a 2.7 fold increase in M DA levels was observed (Figure 5.3b). An increase in 
MDA levels was obtained following incubation for 8 days w ith m ixtures containing 20 
ppm CLA and LA at concentrations corresponding to those found in  the m ilk fat samples 
(Figure 5.3c). There was no significant difference in M DA levels from  cells treated w ith 
these synthetic CLA/LA samples (Figure 5.3c). There w as a 2-3 fold increase (p < 0.05) 
in MDA levels when cells were incubated with the c9, t l  1 CLA isomer, t 10, c l2  CLA 
isomer and the Nu-Chek Prep CLA mixture o f  isomers at 20 ppm  for 8 days (Figure 
5.3d). Incubation with 20 ppm  LA  for 8 days reduced M DA levels compared with 
CLA/LA treated cells (Figure 5.3d).
5.4.4 Super oxide dismutase activity.
SOD activity increased to 0.006 ± 0.002 mU SOD/IO3 cells in M CF-7 cells following 
supplementation with 20 ppm  LA on day 8 (Figure 5.4a). The M CF-7 cells incubated 
with 1 mg /ml o f  each m ilk fat sample (control, FFS and FFR) to yield CLA 
concentrations from 16.9 to 22.6 ppm for 8 days showed an increase in SOD activity 
compared with control cells. SOD activity in cells was proportional to CLA 
concentration and was 6-fold higher (p <  0.05) in cells treated w ith 22.6 ppm CLA (0.06 
± 0.01 mU SOD/IO3 cells) compared with untreated controls (Figure 5.4b).
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5.4.5 Catalase activity.
Catalase activity was increased (p < 0.05) upon incubation with 20 ppm LA for 8 days 
(0.005 ±  0.002 mBergmeyer units/103 cells (n = 3)) (Figure 5.5a). Catalase activity was 
increased in MCF-7 cells incubated in the presence o f  m ilk fat samples (1 mg /ml) 
containing between 16.9 to 22.6 ppm CLA for 8 days. A  12-fold increase in  catalase 
activity was observed in cells incubated with FFR m ilk fat after 8 days (0.13 ±  0.01 
mBergmeyer units/103 cells) compared with untreated controls (0 .011± 0.001 
mBergmeyer units/103 cells (n = 3). An increase in catalase activity was also observed in 
MCF-7 cells incubated w ith the FFS m ilk fat containing 18.3 ppm  CLA for 8 days, this 
was 17-fold higher (0.08 ± 0.02 mBergmeyer units/103 cells (n =  3)) (Figure 5.5b) than 
that observed in cells treated w ith 20 ppm LA (0.005 ±  0.002 m Bergm eyer units/103 cells 
(n=3)) (Figure 5.5a).
5.4.6 Glutathione peroxidase activity.
GPx activity was 0.08 ± 0.06 mU GPx/103 in MCF-7 cells treated w ith 20 ppm LA for 8 
days (Figure 5.6a). A n increase in GPx activity was obtained when the cells were 
incubated with each m ilk fat sample (1 mg /ml) to yield CLA concentrations from 16.9 to
22.6 ppm for 8 days (Figure 5.6b). M aximum activity (0.62 ± 0 .1 5  m U  GPx/103) was 
observed with the FFR milk fat sample (Figure 5.6b). This represented an approximate 
3-fold increase in GPx activity over similar cells incubated w ith the same concentration 
o f  LA.
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5.4.7 Uptake o f 14C-CLA.
14C-CLA was preferentially incorporated into the phospholipid fraction in a dose- 
dependent manner over a 24-hour incubation period in M CF-7 cells (Figure 5.7a). 
Incubation with 0.025 |iC i 14C-CLA resulted in 40 % o f radiolabelled CLA being 
incorporated in the neutral lipids, 7.5 % in the m onoglycerides and 52 % in the 
phospholipids. W hen the dose was increased to 0.1 jj.Ci 14C-CLA, 6.5 % o f radiolabelled 
CLA was found in the neutral lipids w ith 93.5 % in the phospholipid fraction.
5.4.8 Uptake o f  milk fat-CLA.
There was a 4-fold higher uptake (1.57 g/100 g FAM E) o f  CLA in the lipids extracted 
from cells treated with milk fat compared with untreated controls (Table 5.2). Uptake o f  
CLA from cells treated w ith the pure c9, t\  1 CLA isomer was negligible (0.28 g/100 g 
FAME) and similar to untreated controls (0.26 g/100 g FAM E). C i4;o Ci6:i and t \  1-Ci8:i 
fatty acids were notably increased in the lipids obtained from  m ilk fat treated cells. In 
addition, Cig:o and LA contents in lipids from the FFR m ilk fat-treated cells were 
increased compared with untreated controls.
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F igure  5.5. Catalase activity in MCF-7 cells treated w ith LA (0 - 20 ppm) (a) and milk 
fat CLA (16.9 -  22.6 ppm) (b). * Denotes results which are significantly (p < 0.05) 
increased compared with controls.
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F igure  5.6. Glutathione Peroxidase activity in M CF-7 cells treated w ith LA (0 - 20 ppm) 
(a) and milk fat CLA (16.9 -  22.6 ppm) (b). * Denotes results which are significantly (p < 
0.05) increased compared w ith controls.
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Figure 5.7
F igure  5.7. Incorporation o f 14C-CLA into MCF-7 cellular lipid classes. * Denotes 
results which are significantly (p < 0.05) increased compared w ith controls.
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T able 5.2. Fatty acid composition o f  total cell lipids o f  M CF-7 cells, incubated in the 
presence o f  the pure c9, t\ 1 CLA isomer (Matreya) (20 ppm) and w ith control and FFR 
milk fat samples containing 20 ppm CLA.
MCF-7 Fatty Acids (g /100g FAM E)
Fatty Acid Untreated Controls M atreya c9, t\  1 Control M ilk FFR M ilk Fat
CLA Fat *P < 0.05
C i4:0 2.62 ± 0 .1 8 2.65 ± 0 .1 5 8.85 ±0 .041* 7.26 ±0.05*
Cl 6:0 26.25 ± 0 .13 29.16 ± 0 .12* 28.75 ±  0.22* 26.90 ± 0.61
Ci6:l 1.45 ± 0 .0 4 0 2.12 ± 0 .02* 1.6 ± 0 .03*
Cl8:0 16.74 ±  1.36 18.39 ± 0 .9 9 18.60 ± 0 .61 21.71 ± 0 .94*
C 18:1 20.78 ± 0.62 27.43 ±  0.7* 18.70 ± 0 .66* 21.10 ± 0.59
Ci 8:i vaccenic 0 0 1.32 ± 0 .03* 1.5 ±0 .14*
Cl8:2 1.87 ± 0 .3 2 1.57 ± 0 .0 3 1.49 ± 0 .02* 2.21 ± 0 .3 2
C l  8:3 0.06 ±  0.02 0.68 ±  0.04* 0.43 ±  0.02* 0.54 ± 0.06*
C l8:2 CLA 0.26 ± 0.03 0.28 ±  0.03 1.10 ± 0 .06* 1.57 ±0 .32*
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5.5 Discussion
We have previously reported a cytotoxic effect o f  synthetic CLA isomers (N u Chek Prep) 
in human MCF-7 and SW480 cell lines, and provided evidence for inhibition o f  protein 
and nucleic acid biosynthesis by CLA and increased peroxidation leading to activation o f  
the cellular antioxidant defence enzymes (Chapter 4). In this chapter we have 
demonstrated similar effects to those previously reported, using m ilk fat enriched with 
CLA and a pure c9, t\  1 CLA isomer (M atreya). Thus, m ilk fat CLA is as effective an 
anticancer agent as the synthetic N u Chek prep mixture o f  isomers. A n opposite 
proliferative effect o f  LA was shown, which supports previous studies (Cunningham et 
ah, 1997, Shultz et ah, 1992a,b) showing LA can stimulate cancer cell growth. The 
cytotoxic effects o f  CLA are well documented (Cunningham et ah, 1997, Ip et ah, 1999a, 
Shultz et ah, 1992a,b), with the effects on lipid peroxidation also previously noted 
(Shonberg and Krokan, 1995). The increase in lipid peroxidation observed in CLA- 
treated cells suggests that CLA may reverse the resistance to oxidative stress 
characteristic o f  cancer cells (M eyer et ah, 1998, M uller et ah, 1993, Santillo et ah,
1996).
The data reported suggests that m ilk fat CLA when present in a  food m atrix is as 
effective as the synthetic CLA used in culture and animal studies to  date (Belury et ah, 
1996, Ip et ah, 1994, 1996, Liew et ah, 1995). W hen the concentration o f  m ilk fat in 
these treatments varied from 0.8 to 1.2 m g /m l to yield a final CLA concentration o f 20 
ppm, similar growth effects were observed for all treatments, suggesting that CLA alone
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may be responsible for the effect. This supports the findings o f  Ip et al. (1996) where 
CLA was shown to act independently o f  the level or type o f  fat present in  the diet. When 
the fat concentration o f  each sample was maintained at 1 mg /m l to yield varying levels 
o f  CLA (16.9 -  22.6 ppm) cell numbers decreased as CLA concentration increased and 
peroxidation was stimulated as observed previously (Chapter 4). The cells incubated 
with a synthetic m ix (CLA/LA) that represented the CLA/LA concentration o f  the three 
milk fat samples showed similar effects to those obtained with m ilk fat CLA or synthetic 
CLA.
The c9, t\ 1 -CLA isomer (Matreya) was as effective as the mixture o f  CLA isomers (Nu 
Chek Prep) and both were significantly m ore effective than the /10, c l 2 CLA, suggesting 
that the c9, tl  1 CLA is the active isomer in terms o f  anticarcinogenic activity in these 
cells. The mixture o f  CLA isomers at 20 ppm, yielded only 6 ppm  c9, t l  1 CLA but 
showed a similar effect to the pure c9, / I I  CLA at 20 ppm, suggesting that the 
concentration o f  the c 9 ,111 isomer required for optimal activity was < 6 ppm, and/or that 
other isomers, which are present in the mixture were also exhibiting anticarcinogenic 
activity towards MCF-7 cells. A growth stimulatory effect was obtained, upon 
incubation o f  MCF-7 cells with LA (20 ppm), but co-incubation w ith equim olar amounts 
o f CLA caused a  significant growth inhibitory effect compared w ith LA alone. M ilk fat 
CLA also induced the activities o f  SOD, catalase and GPx to a similar extent as observed 
previously with the synthetic CLA mixture (Nu Chek Prep) (Chapter 4).
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The effects o f  incubation o f  MCF-7 cells with LA in this study displayed very different 
effects to those seen previously with CLA (Chapter 4). Incubation o f  M CF-7 cells with 
LA (20 ppm) had a  negligible effect on M DA levels following 8 days o f  incubation. 
Similarly, both SOD and catalase activities were 5-fold less in LA-treated cells compared 
with CLA-treated cells, while GPx was reduced 10-fold in the LA-treated cells compared 
to the CLA-treated cells. These results suggest a prooxidant effect in m ilk fat treated 
cells as observed previously with the mixture o f  isomers (Nu Chek Prep) (Chapter 4), and 
growth stimulation in LA treated cells was associated w ith negligible peroxidation.
CLA was preferentially incorporated into the phospholipid fraction o f  the M CF-7 cell 
lipids. CLA uptake was more proficient from milk fat than from  synthetic sources, 
supporting previous work by Ip et al. (1999a). This may suggest the possible formation 
o f CLA from /11-Ci8:i present in m ilk fat by the action o f  A-9 desaturase as previously 
suggested (Griinari and Bauman, 1999). The incorporation o f  CLA was 1.4-fold higher 
in FFR treated cell lipids compared w ith those treated with control m ilk fat. This 
increase is comparable to the difference in CLA levels o f  both m ilk fat samples, 
suggesting that CLA incorporation from m ilk fat may be dose-dependent. The tl  l-Cis.i 
content o f  the FFR milk fat sample was 1.4 fold higher than in the control m ilk fat 
sample, which may be relevant in term s o f  endogenous synthesis o f  CLA.
Other anticarcinogens are also present in m ilk fat and these m ay act in conjunction with 
CLA, such as butyric acid, sphingomyelin, ether lipids and m etabolites o f  tumour 
supressor lipids (Parodi et a l, 1997). The m ilk fat samples used in this study (FFR, FFS,
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control (Lawless et al., 1998) and soft fraction (Chapter 3)) dem onstrate sim ilar effects to 
the synthetic CLA mixture o f  isomers. It is envisaged that the practice used to produce 
these CLA-enriched milk fats may be applied at a larger scale to produce CLA-enriched 
products, such as milk, butter, cheese and yoghurt. Consumption o f  such products may 
afford a chemoprotective effect- w ithout the additional cost o f  oral supplem ents or the 
need for dietary changes.
5.6 Summary
The relationship between growth and the antioxidant enzyme defence system in human 
MCF-7 cancer cells treated with bovine m ilk fat enriched w ith CLA was studied. M ilk 
enriched in CLA was obtained from cows on pasture supplem ented with full fat 
rapeseeds and full fat soyabeans. Cell number decreased up to 90 %  (p < 0.05) and lipid 
peroxidation increased 15- fold (p < 0.05) following incubation o f  M CF-7 cells for 8 days 
with increasing levels o f milk fat yielding CLA concentrations between 16.9 and 22.6 
ppm. Growth suppression and prooxidant effects o f  m ilk fat CLA were independent o f 
the variable composition o f the milk fat samples, suggesting that CLA was the active 
ingredient in milk fat responsible for the cytotoxic effect. M ixtures containing isomers o f 
CLA (c9, i l l - ,  ¿10, c l 2-, c l 1, ¿13- and m inor amounts o f  other isomers) and LA at 
similar concentrations to the m ilk fat samples were as effective at inhibiting growth and 
stimulating peroxidation o f MCF-7 cells as the milk fatty acids. Incubation o f  the cells 
with the c9, t\  1 CLA isomer (20 ppm) or the mixture o f  CLA isomers (20 ppm) for 8 
days resulted in a 60 % decrease (p < 0.05) in viability compared w ith untreated controls 
and was significantly (p < 0.05) more effective than incubation w ith the ¿10, c l 2 CLA
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isomer (20 ppm), which caused only a 15 % decrease in cell numbers under similar 
conditions. A  25 % increase (p < 0.05) in cell proliferation occurred when LA (20 ppm) 
alone was incubated with MCF-7 cells for 8 days. 14C-CLA was preferentially 
incorporated into the phospholipid fraction o f  the M CF-7 cell m em branes in a dose- 
dependent manner and CLA accumulated in cell membranes m ore efficiently when the 
cells were incubated in the presence o f  m ilk fat than the c9, t \  1 synthetic CLA isomer. 
SOD, catalase and GPx activities were induced in MCF-7 cells exposed to milk fat 
(containing 16.9-22.6 ppm CLA) over 8 days. The data indicate that m ilk fat 
triglyceride-bound CLA, consisting prim arily o f  the c9, 111 isomer, w as cytotoxic 
towards MCF-7 cells.
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CHAPTER 6
Differential effects of conjugated linoleic acid isomers 
on Ras farnesylation in human mammary MCF-7 and 
colon SW480 cancer cell lines.
6.1. Introduction
Chemopreventive agents act by inhibiting either the acquisition o f  mutations or the 
neoplastic processes that occur subsequent to mutagenesis (Clarke and Shankel, 1975, 
Ferguson, 1994, Hayes et al., 1997) and exert anticarcinogenic effects by mediating 
diverse oxidant-induced signal transduction pathways that culminate in cell 
differentiation, inhibition o f  oncogene activation, inhibition o f  proliferation in initiated 
cells and enhancement o f  apoptosis (Clarke and Shankel, 1975, Ferguson, 1994, Hayes et 
al., 1997). We have previously observed a dose- and time-dependent growth suppressive 
effect and an induction o f  antioxidant enzymes in CLA-treated m ammary and colon 
cancer cells as an adaptive response to induction o f  lipid peroxidation by synthetic CLA 
(Chapter 4) and milk fat CLA (Chapter 5).
M utations in the dominant oncogene ras represent the m ost commonly found gene 
mutations in human cancer cells. This is mainly due to the central role played by the ras 
encoded protein in membrane-to-nucleus signal transduction (Ames et al., 1995). Ras 
oncoprotein is a membrane-bound GTPase required for a variety o f  signal transduction 
pathways involved in cellular proliferation and differentiation. M ore than 50 low 
molecular weight proteins categorised into the Ras-related superfamily act positively to 
stimulate a  cascade o f  kinase-driven phosphorylation events that culminate in the 
activation o f  nuclear transcription (Ames et al., 1995). Because o f  its central role in 
membrane-to-nucleus signal transduction, it has been proposed that modulation o f  the
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Ras superfamily o f  proteins may provide a novel means by w hich growth o f  cancer cells 
may be inhibited (Gibbs et al., 1994).
One o f  the strategies being devised to impair the dom inant activity o f  ras is to inhibit 
famesylation o f  Ras oncoprotein (Gibbs et al., 1994). Fam esylation o f  Ras proteins by 
famesyl protein transferase (PFTase) is an essential step for their binding to internal 
plasm a membranes and for activation o f  events downstream o f  Ras (i.e. activation o f  R af 
kinase, M APK kinase, MAP kinase and phosphorylation o f  fo s  and juri) leading to cell 
proliferation (Stacey et al., 1991). N on-famesylated m utants o f  oncogenic Ras that 
cannot appropriately localise into the plasm a membrane rem ain no longer transforming 
and have been shown to display a dominant inhibitory phenotype to antagonise the 
activity o f membrane-bound oncogenic Ras (Stacey et al., 1991).
Components o f dietary fat have been shown to exert differential effects on oncogenic ras 
p21 expression. In an experimental model o f  colon carcinogenesis, rats fed a high fat diet 
composed o f  com  oil (59 % omega-6 and 1.2 % omega-3 fatty acids) had higher levels o f  
ras p21 in colonic mucosa than rats fed a high fat fish oil diet (8 % omega-6 and 31 % 
omega-3 fatty acids) (Singh et al., 1997). H igher expression o f  ras correlated w ith 
increased incidence and multiplicity o f  grossly visible colon tum ours. By contrast, lower 
expression o f ras in those animals fed the high fish oil diet correlated w ith decreased 
incidence and a lower m ultiplicity o f  colon tumours (Singh et al., 1997). Analysis o f  Ras 
p21 levels in cytosol and plasm a membrane revealed that the dietary fish oil resulted in 
increased accumulation o f  Ras p21 in cytoplasm with a concom itant decrease in
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membrane-bound ras p21 levels. The type and am ount o f  dietary fat w as a potent 
modifier o f  famesylation o f  Ras during the prom otion and progression stages o f  colon 
cancer (Singh et al., 1998). PFTase activity in the azom ethane-induced rat colon cancer 
model was enhanced by a  diet high in com  oil but reduced by a  diet containing fish oil. It 
is therefore apparent that individual components o f  fat, in particular n-3 polyunsaturated 
fatty acids, may inhibit cancer cell growth by interfering w ith posttranslational 
modifications and membrane localisation o f Ras p21 (Singh et al., 1997, 1998). A 
previous study revealed that dietary CLA did not alter the proportion o f  m utant ras versus 
wild-type ras in mammary carcinogenesis (Ip et al., 1997), suggesting that CLA did not 
affect events upstream o f famesylation.
6.2 Objectives
The aim  o f this study was to determine if  CLA as a collection o f  isomers, shown to be 
anticarcinogenic (Ip et al., 1999a, Shonberg and Krokan 1995, Shultz et al., 1992ab), or 
in the pure form o f  c9,111 and 110, c l2 , inhibited cell growth via m odulation o f  PFTase 
activity in MCF-7 mammary and SW 480 colon cancer cell lines.
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6.3. Materials and methods
Human breast (MCF-7) and colon (SW480) cancer cell lines were obtained from the 
American Type Culture Collection, (Rockville, MD). Culture m edia and supplements 
were purchased from GIBCOBRL (Paisley, Scotland). The M CF-7 cells were 
maintained in Dulbecco's M inim um Essential M edium supplem ented with 5 % v/v fetal 
bovine serum, 0.2 mM L-glutamine, 1 mM HEPES, and 1 unit/m l penicillin and 
streptomycin. The SW480 cells were maintained in the same m edium  as for MCF-7 cells 
containing, in addition, 10 mM  sodium pyruvate. [3H] Fam esyl pyrophosphate ([3H] 
FPP; 15|j.Ci/mmol), famesyl pyrophosphate (FPP), H-Ras (recombinant: expressed in 
E.coli), Triton X  100, linoleic acid (LA), and docosahexanoic acid (DHA), (99 % purity) 
were all purchased from Sigma (Chemical Co., St. Louis, USA). W hatman 
phosphocellulose p81 paper was purchased from W hatm an (W hatm an Int., M aidstone, 
England). A mixture o f CLA isomers was obtained from N u Chek Prep (Inc., Elysian, 
MN), and individual c9, i l l  and ¿10, c l2  CLA isomers were obtained from  M atreya 
(Matreya, Pleasant Gap, PA).
6.3.1 Cell culture
The MCF-7 and SW480 cells were cultured and m aintained as previously described 
(Chapter 4). The effects o f  incubation o f Nu Chek Prep CLA, LA, DHA, pure c9, t\  1 and 
pure ¿10, c l2  CLA isomers for 4 days on the growth and PFTase activity o f  cell lines 
were compared. Initially, 1 x 106 cells were plated in flasks and cultured for 24 h in 5 ml 
o f m edia allowing the cells to attach to the substratum. The m edium  was then replaced
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with medium alone containing ethanol to a  final concentration o f  0.1 % (v/v) or medium 
supplemented with 20 ppm  CLA, LA, DHA, c9, ¿11 and ¿10, c l2  CLA dissolved in 
ethanol. Following 4 days o f  incubation, cells were harvested as described previously 
(Chapter 4).
6.3.2 Preparation o f cell extracts
Cell pellets o f harvested cells from each flask were washed by resuspension in 3 ml o f 
PBS (phosphate buffered saline), centrifuged at 800 g for 5 m in and the supernatant was 
removed by aspiration. Cells were resuspended in 100 \x\ o f  PBS and lysed by sonication 
to release cytosolic extracts and 10 pi o f  the cell extract was used for determination o f 
protein content using the Bradford assay (Bradford, 1976), and 10 jj.1 o f  the cell extract 
was used for the PFTase assay, as described below.
6.3.3 PFTase assay
Using cytosolic extracts o f  MCF-7 and SW480 cells as the source o f  PFTase, H-ras as the 
source o f famesyl acceptor protein and [*’3H] fam esyl pyrophosphate (FPP) as the 
famesyl donor, the PFTase activity o f  cells was determined, using methods described by 
Harwood (1995) and Roskosi et al. (1994). A  solution containing 50 m M  Tris-HCL, 5 
mM dithiothreitol and 20 |xM ZnCh was used as the PFTase assay buffer and a PFTase 
cofactor substrate solution was prepared using 2x PFTase assay buffer (400 pi) 
containing 50 (al o f  20 pM  [3H] FPP, 100 (¿1 o f  100 m M  M gC k and 250 pi o f  water to a 
final volume o f 800 jjl. The PFTase reaction was initiated by the addition o f  5 (J.1 o f  20
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|aM solution o f  H-Ras in PFTase assay buffer and 10 jj .1 o f  PFTase cofactor substrate 
solution to 10 |xl o f  each o f  the sonicated cell solutions or 10 jj .1 o f  PFT assay buffer as 
controls and incubated for 60 min at 37 °C. The PFTase catalysed reaction reaction was 
terminated by addition o f  200 jxl o f  10 % (v/v) HCL in ethanol for 15 m in at 37 °C. 
Following incubation 300 jj .1 o f ethanol (HPLC grade) was then added to each sample and 
the entire sample (525^1) was immediately applied to 4 x 4 cm  W hatman 
phosphocellulose paper strips. The samples were air dried for 30 min, then cut into 1 cm 
squares and immersed in 50 ml ethanol/phosphoric acid solution (37.5 mM ) prepared by 
mixing equal volumes o f  95 % ethanol and 75mM  phosphoric acid. The samples were 
then vortexted for 10 m in and, the ethanol/phosphoric acid solution was aspirated and 
replaced with 50 ml o f  fresh 37.5 mM ethanol/ phosphoric acid solution. This washing 
procedure was repeated 4 times as described above. The phosphocellulose squares were 
then air dried for 45 m in and placed in 10 ml o f  scintillation fluid and counted in a 
Beckman LS 6500 scintillation counter. PFTase activity was converted to m olar 
concentrations using the specific activity o f  [3H] FPP (11034 dpm/pmol) and was 
expressed as picomoles o f  H-Ras famesylated mg"1 m in '1 protein.
6.3.4 Statistical analysis.
All analyses were carried out in triplicate except for m ilk fatty acid com position analyses, 
which were carried out in duplicate. The Student’s t test was used to determine 
significance between treatments.
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6.4. Results
6.4.1 Growth ofMCF-7 cells
We have previously shown a  dose dependent growth inhibitory effect o f  CLA in the 
MCF-7 cancer cell line (Chapter 4). High fat fish oil diets are known to inhibit tum our 
growth (Singh et ah, 1997, 1998, Bartsch et ah, 1999) and fam esylation (Singh et al.,
1998) in animal models o f  breast and colon carcinogenesis. The relative potency o f  
DHA, a single n-3 fatty acid component o f  fish oil to inhibit growth and PFTase activity 
when present at an amount equivalent to CLA and LA in the culture m edium  o f two 
cancer cell lines, M CF-7 (breast) and (SW 480) colon was examined in this study. CLA 
significantly (p < 0.05) inhibited growth in MCF-7 cells following 4 days incubation at 
20 ppm compared with control cells (Figure 6.1). The c9, i l l  and ¿10, c 12 isomers o f 
CLA were significantly (p < 0.05) more effective than the CLA mixture o f  isomers at 
reducing cell numbers following incubation for 4 days. Incubation o fM C F -7  cells with 
DHA (20 ppm) for 4 days also resulted in decreased cell numbers (p < 0.02) compared 
with untreated controls and was as effective a growth inhibitory agent as c9, ¿11 -CLA 
and ¿10, c 12-CLA isomers. Cell numbers following incubation in the presence o f  LA (20 
ppm) were similar to untreated control cells following 4 days (Figure 6.1).
6.4.2 PFTase activity in MCF-7 cells
MCF-7 cells were incubated in the presence o f  N u Chek Prep CLA, c9, ¿11- and ¿10, c l2 - 
CLA (Matreya), LA and DHA at 20 ppm  for 4 days following which the effect on
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cytosolic PFTase activity was assessed (Figure 6.2). Incubation with both the c9, ¿1 1 
CLA and the mixture o f  CLA isomers reduced (p < 0.05) PFTase activity in  M CF-7 cells 
compared with untreated controls but the c9, ¿1 1 CLA isomer was significantly (p <  0.03) 
more effective than the N u Chek Prep mixture (P < 0.05) in this regard. Incubation o f 
MCF-7 cells with the ¿10, c l 2 CLA isomer at similar concentrations (20 ppm ) caused an 
increase o f  15 % (p < 0.05) in PFTase activity in M CF-7 cells while LA also resulted in a 
stimulatory effect (Figure 6.2) yielding a 47 % increase in PFTase activity com pared with 
untreated controls. Although, incubation o f  M CF-7 cells w ith DHA reduced PFTase 
activity by 10.5 %, this was not significant compared to control cells (Figure 6.2).
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F igure 6.1. Cell viability for MCF-7 cells incubated w ith 20 ppm  N u-Chek Prep CLA, 
c9, ¿11 and ¿10, c l 2 pure CLA isomers (Matreya), LA and DHA for 4 days. * Denotes 
values that are significantly different (p < 0.05) compared w ith controls, values that are 
significantly different (p < 0.02) compared w ith controls.
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Figure 6.2. PFTase activity for MCF-7 cells incubated with 20 ppm  Nu-Chek Prep CLA, 
c9, / I I  and ¿10, c l2  pure CLA isomers (Matreya), LA and D HA for 4 days. * Denotes 
values that are significantly different (p < 0.05) compared w ith controls, ** Denotes 
values that are significantly different (p < 0.03) com pared w ith controls.
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6.4.3 Growth ofSW480 cells
As observed previously (Chapter 4) the N u Chek Prep mixture o f  CLA isomers and the 
pure c9, i l l -  and ¿10, cl2-C L A  (Matreya) isomers significantly inhibited growth in 
SW480 cells following 4 days incubation at 20 ppm compared w ith control cells (Figure 
6.3). The individual c9, ¿11-CLA isomer and the m ixture o f  isomers were significantly (p 
< 0.05) more effective at reducing cell numbers than the ¿10, c 12-CLA isomer. LA (20 
ppm) had a negligible effect on growth o f  SW 480 cells following 4 days. As observed in 
MCF-7 cells there was a significant (p < 0.05) decrease in cell num bers o f  DHA-treated 
SW480 cells compared w ith controls.
6.4.4 PFTase activity in SW480 cells
An investigation o f  PFTase activity o f  SW 480 cells incubated in the presence o f  N u Chek 
Prep CLA, c9, ¿11- and ¿10, c 12-CLA (M atreya), LA and D HA at 20 ppm  for 4 days 
showed a trend that was similar to that described in MCF-7 cells. However increased 
levels o f  PFTase activity were obtained in the SW480 cells and this m ay be a 
consequence o f  the more vigorous growth observed previously w ith these cells (Chapter 
4) (Figure 6.3). The c9, ¿11-CLA and the N u Chek Prep mixture o f  CLA isomers 
significantly reduced (p < 0.05) PFTase activity by 27 % and 30.7 % respectively, 
compared w ith control cells following 4 days o f  incubation. Incubation o f  M CF-7 cells 
with the ¿10, c l 2 CLA isomer at similar concentrations (20 ppm) caused an increase o f 60 
% (p < 0.01) in PFTase activity in SW480 cells while LA also resulted in a  similar effect 
(Figure 2) yielding an 85 % increase (p < 0.01) in PFTase activity compared with
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controls. Although, incubation o f  SW 480 cells with 20 ppm  DHA  resulted in reduced 
PFTase activity following 4 days incubation this was not significantly different from 
control cells.
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Figure 6.3. Cell viability for SW 480 cells incubated with 20 ppm  N u-Chek Prep CLA, 
c9, i l l  and ¿10, c l 2 pure CLA isomers (Matreya), LA and D HA  for 4 days. * Denotes 
values that are significantly different (p < 0.05) compared with controls.
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F igure 6.4. PFTase activity for SW480 cells incubated w ith 20 ppm  Nu-Chek Prep 
CLA, c9, ¿11 and ¿10, c l2  pure CLA isomers (Matreya), LA  and DHA for 4 days. * 
Denotes values that are significantly different (p < 0.05) com pared w ith controls, ** 
Denotes values that are significantly different (p < 0.01) com pared w ith controls.
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6.5 Discussion
There have been m any possible mechanisms o f action suggested for the anticarcinogenic 
effect o f  CLA, including a prooxidant effect (Schonberg and Krokan, 1995), inhibition o f 
mutagen activation (Liew et al., 1995) and modulation o f  eicosanoid production (Belury 
et al., 1997, Li and W atkins, 1998). In addition, it has been proposed that growth 
regulatory genes such as c-myc and c-jun, may be influenced by binding o f  CLA to 
peroxisomal proliferator activated receptors (M oya-Camarena et al., 1999b). We have 
previously observed that CLA was incorporated into phospholipids and neutral lipids o f 
MCF-7 cells (Chapter 5). As a result o f  incorporation into phospholipids CLA may 
modulate subsequent signal transduction pathways which depend on the proper 
membrane localisation o f oncogene encoded proteins, for exam ple Ras. As observed 
previously a  high fat fish oil diet containing 31 % n-3 fatty acids has been shown to 
inhibit PFTase activity (Singh et al., 1998). In this study we com pared the effects o f 
equal amounts (20 ppm) o f  DHA, CLA and LA on PFTase activity o f  M CF-7 and SW480 
cell lines.
Data from this study suggest that specific isomers o f CLA differentially modulate the 
action o f  Ras oncoprotein. A n association between decreased fam esylation and growth 
suppression was observed in the M CF-7 and SW480 cells treated w ith the CLA mixture 
o f  isomers and with c9, i l l  CLA. Diminished famesylation suggests that the Ras 
remained in its biologically inactive form and prevented growth signals from reaching 
proliferation genes in the nucleus. Incubation with DHA caused a decrease in cell
236
numbers for both cell lines, however PFTase activity was negligible in these cells. This 
may be a consequence o f  the DHA concentration (20 ppm) used, as it has been reported 
that tumourigenic inhibition by fish oil is expressed at levels close to 100 tim es the level 
o f  CLA (Scimeca et al., 1994). In addition, modulatory effects on tumourigenic 
inhibition and Ras famesylation o f  fish oils were manifested by diets that contained a 
mixture n-3 fatty acids; therefore DHA m ay not be the sole m odulator o f  fam esylation 
kinetics (Singh et al., 1997, 1998). A 47 % increase in PFTase activity w as observed in 
the LA treated MCF-7 cells, which may be responsible for the proliferative effect 
displayed by LA when incubated with these two cancer cell lines. The relationship 
between growth and famesylation was more notable in SW 480 cells treated with 20 ppm 
LA, where a 100 % increase in PFTase activity was associated w ith 14 % increase in 
growth. The proliferative effect o f  LA in this study supports previous studies (Shultz et 
al., 1992ab, Cunningham et al., 1997) showing LA can stimulate cancer cell growth. 
Inhibitory effects o f  CLA and c9, t\  1 CLA, on PFTase and stimulatory effects o f  the ¿10, 
c l2  CLA isomer suggest that growth is only partly controlled by fam esylation
Incubation w ith the ¿10, c l 2 CLA isomer caused a 15 % increase in the activity o f 
PFTase in MCF-7 cells and a  66 % increase in SW480 cells, yet was anti-proliferative in 
both cell lines. Stimulation o f the fam esylation reaction in ¿10, c l 2 CLA and LA treated 
cells may have initiated different phosphorylation signaling cascades resulting in 
proliferation in LA-treated cells and growth suppression in ¿10, c l 2 CLA treated cells. 
However the differential effects o f  individual fatty acid treatments suggest that 
famesylation is only partly responsible for growth modulatory effects observed in these
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cells. This is evident from the observation that the large increase (100 %) in PFTase 
activity observed in LA treated SW 480 cells was associated w ith only a marginal 
increase in growth (15 %). The ¿10, c l  2 CL A isomer m ay also target events downstream 
o f  Ras famesylation and thereby inhibit proliferation. The c9, ¿1 1 CLA isom er at 20 ppm 
had a similar effect as a  CLA mixture o f  isomers which contained only 6 ppm  c9, ¿1 1 
CLA. The m ixture also contained approximately 6 ppm  ¿10, c l2  CLA, which in the pure 
form (20 ppm) was found to be stimulatory towards PFTase activity. This suggests that 6 
ppm c9, ¿11 CLA may be sufficient to reduce PFTase activity, and that the c9, ¿11 isomer 
has a  dominant effect over the ¿10, c l2  isomer. However other isomers present in the 
mixture may also have an effect.
Famesyl-pyrophosphate the substrate for Ras famesylation by PFTase is formed as an 
intermediate in the mevalonate pathway responsible for cholesterol biosynthesis (Singh et 
ah, 1997, 1998). n-6 and n-3 fatty acids have been shown to differentially modulate the 
activity o f 3-hydroxymethylglutaryl Co-enzyme A (HM G-CoA) reductase, the rate 
limiting enzyme in the mevalonate pathway (ElSohemy and Archer, 1997). Further 
studies examining the effects o f  CLA on HM G-CoA-reductase in  cancer cells are 
warranted.
W e have previously shown a 90 % inhibition o f  growth in  cancer cells treated w ith milk 
fat to yield a CLA concentration o f  20 ppm (Chapter 5). The c9, ¿11 form is the 
predominant (92 %) CLA isomer found in milk fat triglycerides (Chin et ah, 1992) and in 
view o f the inhibitory effect o f  this CLA isomer on PFTase activity, it is possible that
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milk fat CLA in its triglyceride bound form may also modulate cell growth in these cells 
by inhibition o f ras famesylation. Further studies to investigate the effects o f  milk fat 
CLA and individual CLA isomers on events downstream o f  Ras are warranted.
6.6 Summary
Ras oncoproteins have been implicated in a phosphorylation cascade w hich results in the 
activation o f  proliferation genes. The aim o f this study w as to determine if  the 
anticarcinogenic fatty acid CLA inhibited the activity o f  PFTase, the rate limiting enzyme 
in the famesylation o f  Ras in M CF-7 and SW480 cancer cell lines. A  mixture o f  CLA 
isomers (c9, t i l - ,  ¿10, c 12-, e l l ,  ¿13- and minor amounts o f  other isomers), c9, t i l  CLA, 
¿10, c l2  CLA and DHA (all at 20 ppm) significantly (p < 0.05) suppressed growth o f 
both cell lines following 4 days o f  incubation com pared w ith untreated controls. 
Incubation o f  MCF-7 and SW 480 cells with LA (20 ppm) had negligible effects on cell 
numbers after 4 days. Incubation o f  both cell lines w ith 20 ppm  CLA (mixture o f 
isomers) or 20 ppm c9, ¿11 CLA for 4 days resulted in significantly (p < 0.05) reduced 
PFTase activity compared with untreated controls. A lthough the pure c9, ¿11 CLA 
isomer was a more potent inhibitor (p < 0.03) than the m ixture o f  CLA isomers (p < 0.05) 
o f  MCF-7 cell PFTase activity, there was no significant difference between these two 
treatments on the activity in SW 480 cells. On the other hand PFTase activity was 
increased (p < 0.05) in both MCF-7 and SW 480 cells incubated w ith similar 
concentrations (20 ppm) o f  pure ¿10, c l2  CLA or LA com pared w ith untreated control 
cells. DHA (20 ppm) had a negligible effect on PFTase activity in both cell lines. The 
results suggest that the m ixture o f  CLA isomers and the pure c9, ¿11 CLA isomer down
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regulate a ras-dependent signaling cascade resulting in  growth suppression. Stimulation 
o f  the fam esylation reaction in the LA treated cells m ay have induced signaling events 
that initiated proliferation. The stimulation o f  PFTase activity due to incubation w ith the 
pure ¿10, c l2  CLA isomer suggests that the two CLA isom ers (¿10, c \2  and c9, ¿11) 
mediate growth suppressive effects in  cancer cells via distinct m echanisms o f  action.
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CHAPTER 7 
Final Discussion and Conclusions
The f ie ld  o f  cancer chem oprevention has experienced a rap id  g ro w th  in  the id e n tif ic a tio n  
and characterisation o f  a vast num ber o f  antica rc inogen ic  substances that are present 
na tu ra lly  in  m any food  sources. Research is u n v e ilin g  m ilk  fa t as a n o ve l source o f  such 
anticarc inogen ic substances; evidence contained w ith in  th is  thesis suggests tha t C L A  in  
pa rticu la r is a potent anticarc inogen ic com ponent o f  m ilk  fat. F o llo w in g  a landm ark  
study show ing  a p o w e rfu l p ro tec tive  e ffect o f  C L A -e n rich e d  bu tte r against r is k  o f  
m am m ary cancer developm ent in  rodents (Ip  et al., 1999a), i t  is im pera tive  tha t foods 
enriched in  th is nove l fa tty  acid are made available. M a n y  hea lth  enhancing com ponents 
o f  m ilk  are cu rren tly  be ing  exp lo ited  fo r  the deve lopm ent o f  added-value ‘ fu n c tio n a l 
fo o d ’ ingredients o r nutraceutica ls, and is an area w here  b io techn o logy  m ay p ro v id e  new  
poss ib ilitie s  fo r  the food  in d u s tiy . B io techno logy  embraces a w id e  range o f  techno log ies 
over and above genetic m an ipu la tio n  and includes fe rm enta tion  technologies, p ro te in  
separation technolog ies and the use o f  enzymes fo r food  processing. These techniques 
o ffe r an o p p o rtu n ity  to the d a iry  indus try  to  p rom ote  da iry  products  and overcom e the 
negative consum er im age tha t exists due to  the presence o f  cholestero l, saturated and 
trans fa tty  acids in  these products. C L A  is a trans fa tty  acid and in  v ie w  o f  the po ten tia l 
ha rm fu l effects o f  T F A  described in  chapter 2 i t  is necessary to m o n ito r the leve ls o f  T F A  
du ring  frac tiona tion  and/or l ip id  m o d ific a tio n  procedures aim ed at enrichm ent o f  
products w ith  C L A . The aims o f  the current study w ere 5-fo ld : ( i)  to va lida te  
m e thodo logy fo r the accurate quan tifica tion  o f  T F A  in  ed ib le  o ils  and fats, ( i i )  to analyse 
the C L A  and T F A  contents o f  a range o f  food  products, ( i i i )  to investiga te  d ry  
frac tiona tion  as a means o f  en rich ing  the C L A  content o f  m ilk  fa t, ( iv )  to investiga te  
spec ific  m echanism s o f  action in  hum an cancer ce ll lines that m ay be responsib le  fo r  the
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anticarc inogen ic e ffec t o f  synthetic C L A  and (v ) to  com pare effects o f  synthe tic  C L  A  
w ith  those o f  m ilk  fa t tr ig ly ce rid e  bound C L A .
A na lys is  o f  T F A  in  the past has been ham pered b y  the u n a v a ila b ility  o f  su itab le  reference 
m ateria ls p a rticu la rly  those o f  m ino r, unusual cis and trans isom ers (Ratnayake, 1990). 
O il samples o f  kn o w n  T F A  content w ere supplied to European laboratories as pa rt o f  an 
in te rna tiona l co llabo ra tive  study fo r the purpose o f  v a lid a tin g  m ethodo logy lead ing  to  the 
accurate q u a n tifica tio n  and deta iled com pos itiona l analysis o f  in d iv id u a l T F A  isomers. 
The analysis o f  s im ila r  samples by d iffe re n t laboratories us ing  d if fe r in g  techniques was 
c r it ic a l in  the deve lopm ent o f  a suitable m ethod. T h is  s tudy va lida ted  a com b ined  A g - 
T L C  and G L C  m e thodo lo gy  fo r  the q u a n tifica tio n  o f  T F A  in  vegetable o ils . In it ia l ly  the 
accuracy and separation pow er o f  the m ethod was established by the successive analysis 
o f  fa tty  acid standards u n t il satisfactory repea tab ility  and re p ro d u c ib ility  was obtained. 
The base catalysed F A M E  procedure was show n to  have no adverse effects on the T F A  
levels. In te rcom parison  o f  data obtained fro m  analyses o f  com m on samples in  d iffe re n t 
laboratories led to c r it ic a l assessment and va lid a tio n  o f  the m e thodo lo gy  fo r  T F A  
analysis. G iven that ce rtif ie d  reference m ate ria l fo r  T F A  are genera lly  no t ava ilab le , th is  
m ethodo logy m ay be used in  the c e rtif ica tio n  o f  reference m ateria ls con ta in in g  T F A . 
Spreads con ta in ing  hydrogenated vegetable fa t o n ly  as the fa t source conta ined re la tiv e ly  
h ig h  amounts o f  T F A  com pared w ith  products con ta in ing  o n ly  m ilk  fa t as the fa t source. 
C L A  analysis o f  d a iry  products in vo lve d  acid catalysed m ethano lys is  (4  %  H C L  in  
m ethano l) o f  samples fo llo w e d  b y  separation o f  F A M E  on a Supelcow ax-10 c a p illa ry  
G LC  co lum n (S tanton et cil., 1997a). O f  a ll the d a ily  products analysed, bu tte r was found
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to  be the richest source o f  C L A  (12.3 -  14.2 m g/g  fa t), w h ile  the yo g h u rt and cheese 
samples, contained, on average, one and tw o -th irds , respective ly , o f  the C L A  content o f  
butter. Evidence n o w  indicates that spec ific  b io lo g ic a l effects m ay be due, in  some cases, 
to the spec ific  ac tion  o f  a s ing le  C L A  isom er and in  o ther cases, to  a m ore general e ffect 
that m ay be produced by  tw o  or m ore C L A  isomers. A c c o rd in g ly , i t  is im pe ra tive  to 
have standardised m ethodo log ies fo r  separating and q u a n tify in g  in d iv id u a l C L A  isom ers 
in  com plex m ix tu res  such as foods, b io lo g ica l m ateria ls  and m anufactu red  products. In  
add ition , as basic research reveals new  in fo rm a tio n  concern ing the b io lo g ica l im portance  
o f  spec ific  C L A  m etabolites, i t  w i l l  be desirable to q u a n tify  th e ir levels in  foods tha t are 
derived fro m  anim als tha t na tu ra lly  produce C L A  (i.e. rum inants) and those fed C L A  in  
e ither a na tu ra l o r synthetic fo rm . A  study s im ila r to that carried ou t in  chapter 2 o f  th is  
thesis w o u ld  p rov ide  a standard m ethod o f  C L A  analysis and a llo w  accurate 
quan tifica tion  o f  in d iv id u a l C L A  isomers in  foods and b io lo g ica l m ateria ls.
N o  studies have ye t been pub lished that docum ent typ ica l C L A  in take  using  the go ld  
standard, food  dup lica te  m ethodology. T h is  approach invo lves co m b in ing  estimates o f  
C L A  leve ls in  dup lica te  po rtions  o f  food  w ith  d ie ta ry  records. In d ire c t m ethodo log ies 
re ly in g  on ava ilab le  C L A  databases have been used. Because C L A  concentrations w ith in  
s im ila r foods can va ry  g rea tly  depending on the in it ia l com pos ition  o f  ra w  food  products, 
the accuracy and adequacy o f  these databases are questionable. R igo rous va lid a tio n  o f  
these n u tr ie n t databases is necessary, and po ten tia l ind ica tors o f  C L A  in take , such as 
fasting  p lasm a leve l o r adipose tissue concentrations o f  C L A  should be evaluated. 
A d d it io n a lly , estim ations o f  d ie ta ry  intakes o f  C L A  isom eric  fo rm s b y  in fan ts , ch ild re n
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and adolescents have not ye t been docum ented. I t  is im portan t that estim ations o f  C L A  
in take in  ch ild ren  be investigated in  v ie w  o f  the fin d in g  that d ie ta ry  C L A  was m ore 
e ffec tive  in  in flu e n c in g  anticarc inogen ic a c tiv ity  w hen consumed du ring  periods o f  active 
m am m ary gland developm ent in  the rodent m odel (Ip  et al., 1995). A ge  and d ie ta ry  C L A  
in take m ay in teract, such that increased C L A  intake du ring  in fa n cy  and adolescence 
m ig h t p re fe re n tia lly  decrease the r is k  o f  cancer in  la ter life . E xa m in a tio n  o f  the 
re la tionsh ips am ong d ie ta ry  in take o f  C L A  isom ers, th e ir  concentrations in  adipose tissue 
and plasma, and r is k  o f  various ch ron ic  degenerative diseases (e.g. cancer, diabetes and 
osteoporosis) is essential fo r  scientists and p u b lic  hea lth  o ff ic ia ls  to d raw  conclusions 
concern ing the im portance o f  d ie ta ry  C L A  isom ers in  hum an health.
D iy  frac tiona tion  was exam ined as a means o f  increasing the C L A  content o f  m ilk  fat. 
The m a x im u m  C L A  enrichm ent obta ined b y  d ry  frac tiona tion  in  th is  study was 63 % 
over the parent fat, y ie ld in g  a m ilk  fa t fra c tio n  con ta in ing  2.22 g C L A  /100g  F A M E . 
Th is  enrichm ent in  the C L A  content represented app rox im a te ly  a 3-fo ld  increase in  the 
am ount o f  C L A  found in  a range o f  m ilk  fa t con ta in in g -food  products. F o llo w in g  m ilk  
fa t frac tiona tion , the C LA -en riched  m ilk  fa t frac tion  w as increased in  i l  1-Ci8:i content b y  
28 % , com pared w ith  the parent fat. I t  has been proposed that tl  1 -C-1h-i the m a jo r trans 
fa tty  acid in  m ilk  fat, m ay  also act as a bene fic ia l fa tty  acid (Ip  et al., 1999), since recent 
studies show tha t i t  is converted in vivo to the c9, tl 1 -C L A  isom er b y  the A9-desaturase 
enzym e (G riin a r i and Baum an, 1999, Santora et al., 2000). T o  establish the im portance 
o f  i l l - C i  8; 1 as a precursor o f  endogenous synthesis o f  C L A , i t  is im pe ra tive  to  conduct 
an im a l and ce llu la r studies to investiga te  c e ll and tissue responses to  i l l - C i8 : i -  B o th
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descriptive data (tissue sites) and quantitative studies (activities of A9-desaturase) should 
be undertaken. Such studies will increase not only our understanding of CLA 
metabolism in humans, but also will contribute to an appreciation of the importance of 
these fatty acids in the diet. Thus, milk fat enriched in CLA and 1^1 -Cj8:i, by dry 
fractionation may offer a means to generate a food ingredient with potential benefits to 
human health. Lipase mediated interesterification reactions to modify the fatty acid 
composition of milk fat triglycerides is a novel biotechnological approach to enriching 
dairy products with CLA (Garcia et cil., 1998). The use of starter cultures (e.g. lactic acid 
cultures) and additives (e.g. lactose and fructose) which promote CLA formation from 
linoleic acid are alternative possibilities leading to the natural production of food grade 
products enriched in CLA.
The anticarcinogenic effects of CLA were examined in this study using two human 
tumour cell lines. Mammary and colon tumour cell lines furnished in vitro models for the 
investigation of the anticarcinogenic effects of CLA. Evidence of CLA-induced 
cytotoxicity, lipid peroxidation and modification of Ras oncoprotein famesylation in 
these two cell lines was provided. CLA-enriched milk fat and the pure c9, t i l  CLA 
isomer (Matreya) exerted similar cytotoxic and prooxidant effects in these cell lines. An 
opposite proliferative effect was demonstrated in these model systems for LA, which 
supported previous studies (Cunningham et al., 1997, Shultz et cil., 1992) showing LA 
can stimulate cancer cell growth. An excess of intracellular reactive oxygen species in 
relation to antioxidative systems is the driving force in several human malignancies. It 
results in an oxidative environment which may modulate gene expression or damage
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cellular molecules via adduct formation. Data suggests that enhanced ability of tumour 
cells in scavenging free radicals by antioxidant enzymes and thiol compounds may, at 
least in part, contribute to the resistance of cancer cell death during chemotherapy 
(Suzuki et al., 2000). High levels of glutathione during chemotherapy can reduce the 
effectiveness of a chemotherapeutic drug due to detoxification (Hercberg, 1992). Efforts 
made to treat cancer with chemotherapeutic agents are often hampered by intrinsic or 
acquired drug resistance of the tumours. Some tumours initially respond favourably to 
chemotherapy, but subsequently develop multi-drug resistance. Enrichment with 
polyunsaturated fatty acids makes leukemia cells more susceptible to lipid peroxidation 
and increases total lipid radical formation in response to oxidative stress. 
Polyunsaturated fatty acids such as DHA, eicosapentaenoic (EPA), gamma linolenic acid 
(GLA) and parinaric acid, have been shown to be cytotoxic to tumour cells by inducing 
oxidative stress and altering the activity of cell membrane bound enzymes such as 
sodium-potassium-ATPase, suggesting that essential fatty acids and their metabolites can 
reverse tumour cell ding resistance at least in vitro (Bums and Spector, 1994, Das et al.,
1997). The prooxidant activity of CLA observed in cancer cells may provide a means to 
reverse this resistance to chemotherapy. Future work must elucidate if the cytotoxic 
effect of CLA in cancer cell lines can be blocked by the addition of antioxidants.
The prooxidant effect observed in cancer cells treated with CLA in this study may not be 
solely responsible for the anticarcinogenic activity of CLA. CLA was preferentially 
incorporated into the phospholipid fraction of the MCF-7 cell membranes. CLA uptake 
was more proficient from milk fat than from synthetic sources, supporting previous work
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by Ip et al. (1999a), suggesting possible enzymatic conversion of t\ 1-C]g:i present in milk 
fat to CLA by a cellular A9-desaturase. The presence of A9-desaturase in humans would 
offer potential for t\ 1-Cis: i -enriched products allowing for endogenous synthesis of CLA. 
Indeed dietary il 1-Ci8;i led to increased levels of CLA in carcass lipids (Santora et al., 
2000). This may be a more effective means of increasing CLA levels in tissues than 
dietary intake of CLA. Through its incorporation into membrane phospholipids CLA 
may modulate signal transduction pathways which depend on the proper membrane 
localisation of oncoproteins, for example Ras. Data from this study suggest that an 
association exists between decreased famesylation and growth suppression in the MCF-7 
and S W480 cells treated with the CLA mixture of isomers and with c9, t\ 1 CLA. The c9, 
111 form is the predominant (92 %) CLA isomer found in milk fat triglycerides (Chin et 
al., 1992) and in view of the inhibitory effect of this CLA isomer on PFTase activity, it is 
possible that milk fat CLA in triglyceride bound form may also modulate cell growth in 
these cells by inhibition of ras famesylation.
CLA may have potential effects on other stages of carcinogenesis yet to be investigated 
such as angiogenesis. Neovascularisation, or angiogenesis, is essential for solid tumour 
growth (Folkman, 1990), and also provides the tumour cells with access to the vascular 
circulatory system, thus establishing the potential for metastatic disease progression. 
Angiogenic activity in primary breast cancers has been associated with metastasis 
(Heimann et al., 1996), benign breast lesions or breast ductal carcinoma with a propensity 
for progression to malignant disease (Guinebreti et a.l., 1994, Heffelfmger et al., 1996). 
The process of neovascularization is promoted by a variety of angiogenic factors, which
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include both prostaglandins (Form et al., 1983) and 12-HETE (Tang et al., 1995). 
Transfection of the MCF-7 human breast cancer cell line so that it stably overexpresses 
eicosanoids (12-LOX and 12-HETE), causes rapid growth with not only reduced 
apoptosis, but also high angiogenic activity (Connolly & Rose, 1998). Dietary CLA, 
because of its suppressive effects on eicosanoid biosynthesis, may prove to be 
antiangiogenic.
Although extensive research has now shown that a family of enzymes known as matrix- 
degrading metalloproteinases are implicated in early and late stages of tumour 
progression (Me Donnell et al., 1999), no study has yet related the antimetastatic effect of 
dietary CLA with these enzymes. Hence studies to examine the influence of CLA on 
metalloprotease secretion, angiogenic capacity and invasion, factors critical in the 
metastatic cascade seem warranted.
The possibility that CLA may be considered as a potential dietary component for use in 
nutritional prevention of breast cancer is an attractive issue. However, to date beneficial 
effects of CLA have been demonstrated in animal experimental models and in vitro 
systems only. Even though there is some epidemiological evidence in the literature 
linking CLA intake and mammary tumour prevention in humans, more studies are 
required to confirm this effect. The amount of dietary CLA required, the duration of 
intervention, as well as the most appropriate stage(s) in life for such an intervention are 
issues that are not yet known. Performing human dietary intervention studies with diets 
enriched in CLA, such as selected dairy products, followed by analysis of adipose tissue
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fatty acids would provide more insight into these issues. The efficacy of CLA 
supplementation to inhibit tumour growth in cancer patients needs to be evaluated. 
Analysis of normal and malignant tissues post surgery would give a novel insight into the 
use of CLA as adjuncts to conventional therapies.
More mechanistic studies are required to tie the multifunctional benefits of CLA together. 
Future work needs to ascertain potential biomarkers of CLA exposure; such work is ideal 
for DNA array analysis. Multi array analysis is a new tool of functional genomics that 
has been developed to visualise changing patterns of gene expression in a more holistic 
fashion than was possible at any other time in biology. This technology will be required 
to give information on the effects of CLA on a large number of genes regulating for 
example differentiation, apoptosis and lipogenesis in CLA treated cells and tissues. 
Technologies such as differential display reverse transcriptase polymerase chain reaction 
(DD RT-PCR) offer a method of rapidly identifying many genes that are expressed in 
different amounts in two or more samples. Unlike subtraction—hybridisation, the DD RT- 
PCR method enables the detection of both up-regulated and down regulated mRNAs in 
the same experiment. The technique involves seven major steps that lead to the 
definition of specific gene(s) that are affected by a treatment. These steps are (1) 
extraction of total and mRNA from a biological sample, (2) cDNA synthesis with distinct 
one base-anchored oligo (dT) primers, (3) amplification of cDNAs with a combination of 
anchored and random primers in the presence of a radiolabeled deoxynucleotide 
triphosphate, (4) separation of the amplified radiolabeled cDNA fragments on 
polyacrylamide gel followed by exposure of the dried gel to an autoradiographic film, (5)
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lane by lane comparison of the cDNA bands displayed on the film followed by 
identification and selection of differentially displayed bands, (6) excision of the selected 
bands from the gel followed by extraction of cDNA, amplification and purification, and 
(7) cloning and sequencing of the gel-purified cDNAs and verification of the specific 
mRNA change by Northern analysis. The possibility of identifying non homologous 
effects between two samples from the comparison of their entire gene sequences will 
allow for the identification of specific functions of individual genes. This technology 
would provide an exciting new approach to studying effects of CLA in conjunction with 
other beneficial fatty acids such as omega-3 fatty acids.
It is becoming increasingly recognised that, at least in the long term, future advances in 
clinical cancer research will come from an emphasis on prevention rather than the 
treatment of metastatic disease. Such research efforts will encompass epidemiological 
studies, laboratory experiments, and the execution of clinical preventive trials 
(Greenwald et al., 1993). This would provide a sound scientific basis for investigating if 
CLA may be considered for use as a nutraceutical in functional foods for maintaining 
health and preventing certain diseases in the human population.
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3 0 7
A ccu racy  Testing
R e la tive  R F  values fo r  the d is tribu ted  test m ix tu re  (mean o f  5 rep lica tes). *  A n a lys is  in  
th is  labo ra to ry
Appendix 1
Lab C|4:0 C16:0 Cl8;0 C,8:l (n-9)
1 1.028 1.014 1.000 1.019
2 0.920 0.966 1.000 1.006
3 1.048 1.020 1.000 1.001
4 0.995 0.989 1.000 0.996
5 1.009 1.001 1.000 1.008
6 1.072 1.034 1.000 1.023
7 0.948 0.977 1.000 1.024
8 1.035 1.008 1.000 1.010
9 0.979 1.004 1.000 1.010
10* 1.082 0.914 1.000 0.971
11 0.995 0.999 1.000 1.018
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Appendix 2
Relative response factors o f the distributed FAME mix (n = ll)
Mean SD Min Max
ClG:0 1.005 0.037 0.936 1.062
C18:0 1.000 0
C|8:| 0.992 0.014 0.962 1.006
C|K:2 1.022 0.023 0.986 1.055
C |8 :3 1.058 0.038 1.001 1.121
Relative response factors o f  the distributed triglyceride mix (n= l 1)
Mean SD Min Max
C16:0 0.985 0.040 0.898 1.029
Ci8:() 1.000
CtB:| 0.989 0.047 0.846 1.023
C|8:2 1.009 0.036 0.927 1.075
C | g-.3 1.060 0.050 0.999 1.174
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Repeatibility (r) and reproducibility (R) o f  Ag-TLC/ GLC for quantification o f  methyl 
elaidate in soya oil FAME (gTFA/100 g FAME),
Appendix 3
FAM E 1 FAM E 2 FAM E 3
RSD (r) 3.61 1.65 2.65
RSD(R) 6.97 3.61 3.37
Repeatibility (r) and reproducibility (R) o f  Ag-TLC/ GLC for quantification oftrieladin  
in soya oil (gTFA /100 g FAME).
Oil 1 Oil 2 Oil 3
RSD (r) 4.47 1.95 2.18
RSD(R) 6. i 9 2.90 3.28
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laboratories
L o w  leve l T F A
Appendix 4
Comparison of precision data between 1st and 2nd intercomparison studies for 11
C 18:1 Cl8;2 C] 8:3 T o ta l
In te rcom parison r 2nd r 2nd r L 2no r 2"d
R S D (r) 247 167 115 62 55 25 53 36
R S D (R ) 247 167 115 62 55 25 53 36
M e d iu m  le ve l T F A
C] 8:1 Cl8:2 C l8 :3 T o ta l
In tercom parison r x 2nd 1« 2nd l Sl 2 "J
1« 2nd
R S D (r) 6 5 8 4 29 15 5 4
R S D (R ) 13 10 15 10 116 32 9 8
H ig h  L e ve l T F A
Cl 8:1 Cl8:2 C l8 :3 T o ta l
In te rcom p ari son r 2 nd l Sk 2nd l Sl 2nd 1 * 2nd
R S D (r) 3 3 5 2 54 136 3 2
R S D (R ) 15 7 13 9 179 245 13 5
311
Intercomparison 2 data from 11 labs 
Soya Oil
Appendix 5
C|R;l C|8:2 C |8 :3 Total
Mean 0.05 0.63 0.97 1.64
Min 0.00 0.51 0.49 1.13
Max 0.18 0.81 1.15 2.13
RSD(r) 84.58 9.82 4.72 5.24
RSD(R) 142.83 16.06 18.96 16.60
Rapseed Oil
C)8:l C|8:2 C |8 :3 Total
Mean 0.06 0.16 0.57 0.79
Min 0.00 0.00 0.30 0.30
Max 0.28 0.31 0.75 1.33
RSD(r) 108.65 36.41 5.77 10.22
RSD(R) 167.36 62.32 25.32 35.61
7 % TFA Sample
C i R : | C 18:2 C 18:3 Total
Mean 4.75 2.51 0.23 7.50
Min 4.23 1.95 0 . 1 1 6.87
Max 5.50 2.85 0.34 8.68
RSD(r) 5.29 4.45 15.13 3.62
RSD(R) 10.46 10.39 31.69 8.37
20 % TFA Sample
C|8:l C|8:2 C | 8 : 3 Total
Mean 13.51 6.24 0.02 19.77
Min 11.76 4.83 0 . 0 0 17.95
Max 14.65 6.94 0 . 1 1 20.92
RSD(r) 2.85 2.08 135.52 2.31
RSD(R) 6.82 8.94 245.26 5.03
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